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Preface
Losses of specific chromosomal regions are frequently reported in different human tumors,
suggesting that these regions may contain important genes associated with tumor develop‐
ment. Cell fusion studies provided the first functional evidence for a class of negatively-act‐
ing tumor suppressor genes (TSGs) harbored on certain human chromosomes. Based on
Knudson’s “two-hit hypothesis", the first TSG, RB was identified. Since 1980s, many TSGs
have been discovered by using different approaches. Accumulated knowledge indicates that
TSGs not limited to tumor suppression play critical roles in various biological activities in
human cells.
In 20132, InTech published a book called “Tumor Suppressor Genes”, which covers the most
important fields, from cell cycle control, signaling pathways, epigenetic regulation, and cur‐
rent challenges to therapeutic applications of known TSGs. Some well-studied TSGs, such as
p53 and p16, and their regulatory mechanisms in tumor development are addressed in this
book. However, TSG research is a fast growing area, and many novel approaches and find‐
ings have been discovered recently. Therefore, it is necessary to publish a new open access
book that may provide future directions for TSG studies.
This book, “Future Aspects of Tumor Suppressor Genes”, contains some important areas that
were not mentioned in the previous book. The majority of known TSGs were identified from
hereditary tumor syndromes. However, more than 90% of human tumors are sporadic cases,
so it is always a challenge to identify tumor susceptibility loci in sporadic tumors. Using ani‐
mal models, authors in this book investigated whether strain-specific allele loss was an im‐
portant clue to identify tumor suppressors involved in tumor susceptibility, which should be
interesting to many researchers. Other basic researches contain investigations of several TSG
signaling pathways from different laboratories: START-GAP/DLC family proteins and their
molecular pathways involved in the control of cell growth, E2F-mediated tumor suppressive
mechanism associated with RB, p53, ARF, p27Kip1 and TAp73 transcription factors, and
TSGs in the regulation of receptor tyrosine kinase signaling via a negative feedback loop.
Understanding these signaling regulatory mechanisms may lead to findings of molecular tar‐
gets for cancer therapy. In recent years, it has been well-accepted that microRNAs are an
abundant class of endogenous small RNA molecules that can regulate tumor development.
To reflect the trends of these novel researches, authors in this book present an extensive re‐
view for current knowledge of microRNAs that play in the control of tumor growth and ther‐
apeutic application.
This book also includes some other fascinating fields and emerging subjects in TSG studies.
For example, the application of Drosophila as a special model for tumor suppression studies
is addressed, and future directions used for the pharmacological screening and therapy
strategies are also proposed. Natural compounds, such as polyphenols, interfere with the
initiation and progression of cancer development via multiple TSG pathways. Recent evi‐
dence, demonstrating that these compounds are able to modulate various cellular activities,
such as cell cycle arrest, anti-angiogenesis, and metastasis suppression, are summarized in
the relevant chapter. Finally, the regulatory role of TSGs, such as p16, p53 and RB, in cell
reprogramming, stemness transition process, and signaling networks of these genes during
these cellular processes are extensively reviewed, which indicates that TSGs are actively in‐
volved in many aspects of stem cell biology and regenerative medicine.
I would like take this opportunity to express my gratitude to all authors and InTech staff for
their contributions in this publication project, and I hope that this book will be helpful for
students, researchers and clinicians.
Yue Cheng, PhD
Department of Clinical Oncology
The University of Hong Kong
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Chapter 1
Strain-Specific Allele Loss: An Important Clue to
Tumor Suppressors Involved in Tumor Susceptibility
Nobuko Mori and Yoshiki Okada
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/55159
1. Introduction
Development of tumors is controlled by multiple genes such as cellular oncogenes and tumor
suppressors activated or inactivated by somatic mutations and/or epigenetic mechanisms.
Tumor development is also controlled by heritable factors as well as environmental factors, i.
e., diet, oxidative stress and sustained inflammation, as reviewed by a large number of recent
reports [1-12]. Both heritable and environmental factors are important targets for clinical
controls and prevention of cancers.
Heritable factors underlying cancer risks have been identified in familial cancer-prone
pedigrees. In the pedigree members, tumors develop in a Mendelian dominant inheritance
fashion. Breast cancer 1, early onset (BRCA1) encoding a nuclear phosphoprotein that plays a
role in maintaining genomic stability is one of the heritable cancer risk factors hitherto
identified. Women bearing a mutated BRCA1 allele are at high risk for both breast and ovarian
cancers through their lifespan. According to the recent estimations, average cumulative risks
in BRCA1-mutation carriers by age 70 years are 65% (95% confidence interval 44%–78%) for
breast cancer and 39% (18%–54%) for ovarian cancer [13]. Thus, disease penetrance is incom‐
plete, albeit rather high, in the mutated-BRCA1 carriers. The BRCA1 gene maps to human
chromosome 17q21, where frequent loss of heterozygosity (LOH) is observed in both familial
and sporadic breast cancers. Although tumors developed in the BRCA1-mutation carriers are
homozygous for the defective BRCA1 allele via LOH mechanisms, sporadic cases rarely show
mutation in the BRCA1 gene [14]. The BRCA1 gene may rather undergo inactivation via
epigenetic mechanisms such as DNA methylation in sporadic tumors.
Unlike the BRCA1 case, tumor susceptibility is expressed in a non-Mendelian inheritance
manner, because multiple genes with incomplete penetrance participate in the phenotype.
Moreover, tumor susceptibility alleles may occasionally express genetic interaction, i. e.,
© 2013 Mori and Okada; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
epistasis that hides or enhances the effect of some alleles at some susceptibility loci with the
effect of other alleles at other susceptibility loci [15]. Despite growing number of association
studies localizing tumor susceptibility loci exploiting SNPs in humans [16, 17], validation of
these loci in human population with miscellaneous variations in the genetic background might
be an intractable task.
Several strains of mice with different susceptibility to lymphomagenesis so far reported might be
useful in the study of tumor susceptibility. Using genetic crosses between BALB/cHeA (refer to
as BALB/c, hereafter) and STS/A (refer to as STS) mice with different tumor susceptibility, and
between the BALB/c and recombinant congenic CcS/Dem strains of mice with 12.5% STS and 87.5%
BALB/c allele in the genome, we mapped three loci controlling susceptibility to radiation-
induced apoptosis of thymocytes to chromosomes 16, 9 and 3 [18, 19], and two loci for susceptibil‐
ity to lymphomagenesis to chromosome 4 [20]. We identified the protein kinase, DNA activated,
catalytic polypeptide (Prkdc) as a candidate for the apoptosis susceptibility gene mapped to
chromosome 16, which was also associated with susceptibility to radiation lymphomagenesis
[21]. As indicated by our studies, susceptibility to apoptosis as well as lymphomagenesis is
controlled by multiple genes. To analyze the effect of one gene involved in such multigenic traits,
congenic animals are ordinarily used. We are currently analyzing the genes controlling suscept‐
ibility to lymphomagenesis on chromosome 4 by the use of congenic animals.
In this chapter, we initially review recent advances in the research of tumor susceptibility, in
particular, susceptibility to radiation lymphomagenesis in mice, and show that two loci
controlling radiation lymphomagenesis map to chromosome 4. Then, we show that two types
of allele loss, i. e., loss common to lymphoma and parental strain-specific loss, occur in
radiation-induced lymphomas from various F1 hybrids between strains with different
lymphoma susceptibility. We show that LOH on chromosome 4 in F1 hybrids between BALB/
c and STS occurs in a strain-specific manner and exhibits a bias towards the STS allele loss. At
the close, by exploiting congenic strains of mice containing different segments of chromosome
4 from the donor strain STS on the BALB/c background, we present a concordance between
the allele loss region and a lymphoma susceptibility locus area on chromosome 4, where the
BALB/c mouse harbors a hypomorphic allele of Cdkn2a. Significance of the strain-specific allele
loss in probing tumor susceptibility loci will be discussed.
2. Mouse strain difference in susceptibility to radiation-induced
lymphomagenesis
In laboratory strains of mice irradiated by ionizing radiation according to a well-established
protocol, development of lymphomas starts around three months after the exposure to
radiation and is terminated around ten months. Radiation-induced lymphomas are mostly of
thymic origin. Several laboratory strains of mice such as BALB/c and C57BL reside in Mus
musculus musculus, and are known to be highly susceptible to radiation-induced lymphoma‐
genesis, while other strains STS and MSM/Ms (refer to as MSM) are not [22, 23]. The BALB/
cHeA and STS/A strains of mice are originally provided by Dr. J. Hilgers at the Netherlands
Future Aspects of Tumor Suppressor Gene2
Cancer Institute [22], and maintained more than twenty generations at the animal facility of
Osaka Prefecture University. The BALB/cHeOpu mouse is the direct descendant of the BALB/
cHeA mouse [20]. The MSM/Ms strain of mice belongs to a subspecies Mus musculus molossi‐
nus. Its progenitor was trapped in Mishima-city, Shizuoka, Japan and established as an inbred
strain at the National Institute of Genetics (Mishima, Japan). Mice were exposed to 4 x 1.7 Gy
of X rays using a well-established protocol for radiation-induced lymphomagenesis. Tumor
development was observed during one year. The results were summarized in Table 1. BALB/
cHeA mice developed lymphomas at high frequency (33/43, 77%), while STS/A mice develop
tumors at less than 10% of frequencies [22]. The onset of tumor development was around three
months in both strains. On the other hand, one of 30 MSM/Ms mice developed lymphoma with
more than ten months of latency. Lymphomas occurred at high frequency (30/35, 86%) in
BALB/cHeOpu mice subjected to X-ray irradiation using the same protocol. Thus, the pattern
of tumor development in BALB/cHeOpu mice showed good concordance with that in their
progenitor BALB/cHeA mice [20].
Strain of mice Number of irradiateda Number of affected (%)b Reference
BALB/cHeA 43 33 (77%) [22]
BALB/cHeOpu 35 30 (86%) [20]
STS/A 60 5 (8%) [22]
MSM/Ms 30 1 (3%) [23]
aOnly females.
bCumulative incidence of lymphomas within one year in BALB/cHeA, STS/A and MSM/Ms, and within ten months in
BALB/cHeOpu.
Table 1. Strain difference in susceptibility to radiation lymphomagenesis
3. Current status of the studies on tumor susceptibility in mice
Numerous tumor susceptibility loci have been mapped by analyzing genetic crosses between
strains of mice exhibiting different tumor susceptibility [17]. Several genes responsible for
tumor susceptibility have been identified, some of which are validated by supporting eviden‐
ces: Pla2g2a encoding phospholipase A2, group IIA (platelets, synovial fluid), for the modifier
of Min1 (APCMin)-induced intestinal tumors (Mom1) identified in the distal portion of chromo‐
some 4 [24–26]; cyclin-dependent kinase inhibitor 2A (Cdkn2a) encoding a tumor suppressor
p16, for pristen-induced plsmacytoma resistance1 (Pctr1) mapped in the middle of chromo‐
some 4 [27, 28]; protein tyrosine phosphatase, receptor type, J, (Ptprj), for susceptibility to colon
cancer 1 (Scc1) on chromosome 2 [29, 30]. LOH occurs at PTPRJ, the human homolog of mouse
Ptprj (Scc1), in the early stage of human colorectal cancer [31]. Hence, PTPRJ may play a role
in tumor suppression in humans. The biological function of Pla2g2a (Mom1) differs from other
tumor susceptibility genes so far identified. Pla2g2a plays a role in physiological processes such
as anti-bacterial defense, inflammation and eicosanoid generation, which are preferable targets
of medical controls for cancer prevention.
Strain-Specific Allele Loss: An Important Clue to Tumor Suppressors Involved in Tumor Susceptibility
http://dx.doi.org/10.5772/55159
3
Despite the availability of strains of mice with obvious difference in susceptibility to radiation
lymphomagenesis, it is much difficult to analyze such traits as to be expressed in a binominal
fashion (tumor-free survivals of animals after exposure to radiation). However, there is one
successful case: a suggestive linkage near D4Mit12 at 57.8 centimorgan (cM) position on
chromosome 4 with susceptibility to radiation lymphomagenesis, which was detected in the
genetic cross between BALB/c and MSM, is confirmed by exploiting congenic mice with the
MSM allele at D4Mit12 on the BALB/c background [32, 33]. Because BALB/c mice had a
hypomorphic allele at the Mtf1 locus, they reported the metal-responsive transcription factor-1
(Mtf1) gene as the candidate gene for the susceptibility locus near D4Mit12 [32, 34]. Mtf1
activates expression of metallothionein I and II genes as well as gamma-glutamylcysteine
synthetase, a key enzyme for glutathione biosynthesis, and metallothionein and glutathione
are involved in detoxification processes, such as scavenging reactive oxygen intermediates
generated by ionizing radiation. Reduced reactivity of Mtf-1 retains an increased level of ROS
in the BALB/c thymus [35].
4. Mapping of lymphoma susceptibility loci on mouse chromosome 4 using
genetic crosses between BALB/c and STS strains of mice
We so far showed that the protein kinase, DNA activated, catalytic polypeptide (Prkdc) gene was
a candidate for the apoptosis susceptibility gene on chromosome 16, and also responsible for
susceptibility to radiation lymphomagenesis [21]. DNA-PK is a key enzyme for DNA double-
stranded-break repair as well as V(D)J recombination of T- and B-cell receptors. Because BALB/c
mice carry a Prkdc variant allele that causes lower DNA-PK activity, resultant hypersensitivity to
radiation may raise frequency of cell death in the thymus and promote lymphomagenesis possibly
via illegitimate recombination mechanisms. However, strain difference between BALB/c and STS
in susceptibility to radiation lymphomagenesis has not been fully explained by the variations in
Prkdc. According to M. Okumoto et al. [22, 23], cumulative incidence of lymphomas in (BALB/c x
STS)F1 exposed to 4 x 1.7 Gy of X-ray irradiation was in between those in parental BALB/c and STS,
while (BALB/c x MSM)F1 developed lymphomas at high frequency similar to BALB/c. The data
suggest that strain difference in tumor susceptibility is controlled by multiple genes that influ‐
ence onset, latency and frequency of tumorigenesis.
Previously, M. Okumoto et al. reported a suggestive linkage of susceptibility to radiation-
induced lymphomagenesis, named lymphoma resistance (Lyr) (Mouse Genome Informatics,
MGI: 96893) in the middle area of chromosome 4 using a series of recombinant inbred (RI) CXS
strains of mice whose genome was constituted of 50% STS and 50% BALB/c genes [36]. It is
worthwhile to test whether the Lyr locus is segregated in a genetic cross using BALB/c and
STS. We performed genome-wide screen for microsatellite markers linked to lymphoma
susceptibility using siblings from (BALB/c x STS)F1 backcrossed to BALB/c or STS. We detected
significant linkage disequilibrium in the middle area of chromosome 4 by the use of 219 siblings
from (BALB/c x STS)F1 backcrossed to BLB/c [20]. No significant linkage was detected by using
another backcross. The primary locus with a conspicuous effect existed in an approximately
10 cM segment spanning D4Mit302 (37.6 cM) and D4Mit255 (48.5 cM) in the middle range of
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chromosome 4 (χ2=19.3, genome-widely corrected p=0.0075). This locus was likely identical to
the Lyr locus localized between tyrosinase-related protein 1 (Tyrp1) (38 cM) and interferon
alpha (Ifna) (42.6 cM) [36]. The secondary locus with a weaker effect was detected near D4Mit17
(χ2=16.0, genome-widely corrected p=0.034), a marker approximately 10 cM proximal to
D4Mit302. The STS allele at these loci was associated with resistance to lymphomagenesis.
Mtf1, a candidate susceptibility gene for radiation lymphomagenesis so far identified by other
investigators, is located near D4Mit12 (57.8 cM), more than 10 cM distal to the critical regions
containing these loci [32, 33]. Effect of Prkdc, which we identified as a lymphoma susceptibility
gene by exploiting congenic mice [21], was not detected in tumor-free survivals in these crosses.
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Figure 1. The Lyr locus exists between D4Mit302 and D4Mit144 on chromosome 4.
To narrow down the tumor susceptibility gene regions, we generated congenic strains of mice
with different portions of STS-derived chromosome 4 on the BALB/c background by back‐
crossing (BALB/c x STS)F1 mice to the BALB/c. Establishment of the congenic lines was
facilitated by positive and negative selections with typing of microsatellite markers on
chromosome 4 and markers distributed in the whole genome [20]. Because the Lyr locus was
so vicinal (10 cM distance, approximately) to the secondary locus, we selected several strains
with or without the STS allele at the critical markers D4Mit17, D4Mit302 and other markers
near these markers, and compared their tumor-free survivals with that of BALB/cHeOpu
exposed to X-ray irradiation (data shown in Table 1). A part of the results in [20] is represented
in Figure 1. In this figure, the strain names of the C.S congenic mice are abbreviated by
hyphened two Arabic numbers that represent STS allele-bearing microsatellite (Mit) markers
at the proximal and distal end of the chromosomal segment. For instance, C.S163–31 represents
a congenic line with the STS allele in the segment spanning D4Mit163 and D4Mit31. The order
and megabase (Mb) positions of the markers are indicated by arrowheads on chromosome 4,
which is represented by a line at the top of the figure. The primary lymphoma susceptibility
Strain-Specific Allele Loss: An Important Clue to Tumor Suppressors Involved in Tumor Susceptibility
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locus Lyr exists between D4Mit302 (85.2 Mb) and D4Mit9 (94.7 Mb). Although the secondary
locus was not detectable by a simple comparison of the tumor-free survival of congenic lines
with that of BALB/c, linkage was reconfirmed by crossing congenic lines (data not shown here).
5. Loss of heterozygosity (LOH) in radiation-induced lymphomas from
various F1 hybrids: common loss and cross-dependant loss
Tumor suppressors frequently undergo loss of heterozygosity (LOH) in a variety of tumors in
humans and mice. We previously reported that frequent LOH (more than 20%) occurred on
chromosomes 4, 12 and 19 in radiation-induced lymphomas from (BALB/c x STS) F1 mice, with
incidences 27% (20 of 74 lymphomas), 57% (42 of 74 lymphomas) and 50% (37 of 74 lymphomas)
on chromosomes 4 (at D4Mit31), 12 (at D12Mit17) and 19 (at D19Mit11), respectively [37] (Table
2). Importantly, STS allele-specific loss occurred on chromosome 4. The bias was confirmed
using reciprocal F1 hybrids between BALB/c and STS [37].
Micea Number of tumors Chr Marker (Mb)b LOH (%) Reference
(CXS)F1 74 4 D4Mit31 (106.8) 20 (27%) [37]
12 D12Mit17c 42 (57%)
19 D19Mit11 (42.5) 37 (50%)
(SXM)F1 20 4 D4Mit54 (137.4) 5 (25%) [39]
12 D12Mit233 (109.5) 12 (60%)
(CXM)F1 d 81 12 D12Mit181 (110.0) 53 (65%) [40]
16 D16Mit122 ( 74.5 ) 38 (45%)
aAbbreviations used are BALB/c, C; MSM, M; STS, S.
bMegabase (Mb) positions of markers are according to Mouse Genome Informatics (MGI) 5.10.03. (http://www.infor‐
matics.jax.org/).
cPhysical position not assigned.
dF1 hybrids between BALB/c and MSM hemizygous for Trp53.
Table 2. LOH in radiation-induced lymphomas from various F1 hybrids.
In these crosses, allele loss involved almost entire chromosomes 4 and 19, without showing
any peaks in LOH frequencies. Cytogenetic analysis showed that allele loss in such large areas
was not caused by chromosomal deletion, but ascribable to mitotic recombination [38]. In
lymphomas from (STS x MSM)F1 mice, LOH occurred on chromosomes 4 and 12 with inci‐
dences 25% (5 of 20 lymphomas) and 60% (12 of 20 lymphomas) on chromosome 4 (at D4Mit54)
and chromosome 12 (at D12Mit233), respectively [39]. In these lymphomas, LOH on chromo‐
some 19 was infrequent (1/20, 5% at D19Mit63). In radiation-induced lymphomas from (BALB/
c x MSM)F1 mice, allele loss frequently occurred on chromosomes 12 (53/81, 65% at D12Mit181)
and 16 (38/81, 45% at D16Mit122) [40].
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Interestingly, LOH on chromosome 12 commonly occurred in radiation-induced lymphomas
from these three F1 hybrids, while LOH frequencies on chromosomes 4 and 19 markedly varied.
Frequent LOH was detected on chromosome 4 in lymphomas from (STS x MSM)F1 mice, but
not (0/20 at D4Mit13) in lymphomas from (BALB/c x MSM)F1 mice [40]. LOH on chromosome
19 was infrequent (0/20 and 1/20, at D19Mit63 and D19Mit123) in lymphomas from (STS x
MSM)F1 mice. In the context of LOH on chromosome 19, results were similar in lymphomas
from the (BALB/c x MSM)F1 hybrid. Thus, LOH on chromosomes 4 and 19 occurred in a cross-
dependent manner. This suggests that LOH frequencies on these chromosomes are controlled
by genetic interaction, possibly between putative tumor suppressors, the locations of which
are indicated by LOH, and by genetic variations in the background. Moreover, the situation
of LOH on chromosome 4 is somewhat different from that on chromosome 19. We present
allele loss frequencies at several markers on chromosome 4 in these lymphomas in Table 3.
Micea Number of tumors Marker (Mb)b LOH (%) References
(CXS)F1 47 D4Mit17 (63.0) 14 (30%) [37]
D4Mit9 (94.7) 14 (30%)
D4Mit13 (142.0) 14 (30%)
(SXM)F1 20 D4Mit9 (94.7) 1 (5%) [39]
D4Mit54 (137.4) 5 (25%)
(CXM)F1 c 20 D4Nds2 (124.4) 0 (0%) [40]
D4Mit13 (142.0) 0 (0%)
(CXM)F1 43 D4Mit9 (94.7) 3 (7%) Unpublished data
51 D4Mit13 (142.0) 4 (8%) [41]
aAbbreviations used are BALB/c, C; MSM, M; STS, S.
bMegabase (Mb) positions of markers are according to Mouse Genome Informatics (MGI) 5.10.03. (http://www.infor‐
matics.jax.org/).
cF1 hybrids between BALB/c and MSM hemizygous for Trp53.
Table 3. Variation of LOH frequencies at microsatellite markers on chromosome 4 in radiation-induced lymphomas
from various F1 hybrids.
Notably, LOH frequency at D4Mit9 was reduced compared to that at D4Mit54, a marker in the
proximity of D4Mit13 and approximately 43 Mb distal to D4Mit9, in lymphomas from (STS x
MSM)F1 hybrid mice. Using lymphomas from (BALB/c x MSM)F1 mice, we reconfirmed that
allele loss at markers D4Mit9 and D4Mit13 on chromosome 4 was very infrequent (3/4 and
4/51 [41], respectively). Because D4Mit9 is located very close to cyclin-dependent kinase
inhibitor 2A (Cdkn2a) encoding tumor suppressors p16 and p19Arf, Cdkn2a is excluded as the
putative tumor suppressor for lymphomagenesis in the (STS x MSM)F1 and (BALB/c x
MSM)F1 backgrounds. Frequent LOH on chromosome 4 and 19 were also reported by other
investigators in lymphomas from (C57BL/6JxBALB/cJ)F1 and (C57BL/6J x RF/J) F1 hybrid mice
[42, 43]. According to the data in [43], strain-specific allele elimination is not found in the LOH
on chromosome 4 from (C57BL/6JxBALB/cJ)F1 mice.
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The LOH frequencies at markers on chromosome 12 formed a sharp peak near telomere [41],
and a putative tumor suppressor B cell leukemia/lymphoma 11B (Bcl11b) was later cloned from
the peak [44]. The BCL11B tumor suppressor is also involved in human T cell acute lympho‐
blastic lymphomas [45]. Some of the lymphomas used for the genome-wide screen of LOH
were generated in Trp53 hemizygous (BALB/c x MSM)F1 mice [40]. Because LOH frequencies
at markers on chromosome 16 were markedly varied depending on the status of Trp53 in (STS
x MSM)F1 mice [39], the high frequency of the LOH on chromosome 16 observed in lymphomas
from (BALB/c x MSM) F1 mice may likewise be explained.
6. The STS allele-specific loss occurred in the Lyr region on chromosome 4
Allele loss on chromosome 4 was significantly biased towards loss of the STS allele in lym‐
phomas from (BALB/c x STS)F1 mice [37]. It is of interest to examine whether putative tumor
susceptibility genes on chromosome 4, which we identified in different regions of chromosome
4, are associated with the strain-specific allele loss on chromosome 4 by using congenic strains
of mice with various regions of chromosome 4 from the donor strain STS on the background
strain BALB/c, namely the C.S congenic series. LOH was studied in lymphomas generated in
(BALB/c x C.S163–31)F1 and (BALB/c x C.S302–9)F1 mice. Both C.S163–31 and C.S302–9 strains
of mice showed resistance to lymphomagenesis as shown in Figure 1. The C.S163–31 strain
harbors the STS allele at two tumor susceptibility loci, one locus near D4Mit17 and the other,
Lyr in the D4Mit302–D4Mit9 segment. The results are shown in Table 4.
Frequent allele loss at markers in the chromosome 4 segments was detected in lymphomas
from (BALB/c x C.S163–31)F1 (cross A) and (BALB/c x C.S302–9)F1 (cross B) with incidences
11/34 (32%) and 10/34 (29%), respectively. The LOH frequencies in these F1 hybrids were
concordant with the original data in (BALB/c x STS)F1 ([37] in Table 3). The STS-allele loss ratios
were 9/11 (D4Mit302) and 10/11 (D4Mit9) in the cross A; 8/10 (D4Mit302) and 9/10 (D4Mit9)
in the cross B. Because the STS-allele loss occurred with similar ratio in both crosses, we
combined the data from crosses A and B (presented as A + B in Table 4). Analysis of the
combined ratios 17/21 (D4Mit302) and 19/21 (D4Mit9) indicate that the distortions are signif‐
icant at both markers D4Mit304 and D4Mit9 (χ2 values were 8.0 and 13.7, p<0.005, degree of
freedom = 1, respectively). The data indicating the STS-allele specific loss (D4Mit31) in
lymphomas from reciprocal (BALB/c x STS)F1 and (STS x BALB/c)F1 hybrids are also presented
([37] in Table 4). Thus, the skewed allele loss that was originally observed in a wide area of
chromosome 4 in (BALB/c x STS)F1 and (STS x BALB/c)F1 hybrids is reproducible in the limited
segments of the STS-derived chromosome 4. Our results suggest that tumor suppressor(s)
associated with susceptibility to lymphomagenesis exist in the limited areas of chromosome
4. Since C.S39–86 mice carry the STS allele in the vicinity of D4Mit17, i. e., the secondary locus
controlling susceptibility to lymphomagenesis, we further examined allele loss at markers
D4Mit7 (67.7 Mb), a marker in the vicinity of D4Mit17, and D4Mit86 using 25 lymphomas from
(BALB/c x C.S39–86)F1 x BALB/c mice [20]. Allele loss at these markers was detected in only
one of 25 tumors (less than 5%). In this case the BALB/c allele was lost. Hence, approximately
40 Mb of the D4Mit39–86 segment, to which the secondary locus for tumor susceptibility was
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localized, was excluded from the skewed loss region. Analysis on congenic strains strongly
suggest that the STS-strain specific loss is ascribable to the D4Mit302–D4Mit9 segment of
chromosome 4, which harbors a putative tumor susceptibility gene Lyr.
Micea Number of tumors Marker (Mb)b LOH (%) S loss C loss
A. (C x C.S163–31)F1 34 D4Mit17 (63.0) 11 (32%) 9 2 c
D4Mit302 (85.2) 11 (32%) 9 2 c
D4Mit9 (94.7) 11 (32%) 10 1 c
D4Mit31 (106.8) 11 (32%) 10 1 c
B. (C x C.S302–9)F1 34 D4Mit302 (85.2) 10 (29%) 8 2 d
D4Mit9 (94.7) 10 (29%) 9 1 d
A + B 68 D4Mit302 (85.2) 21 (31%) 17 4
D4Mit9 (94.7) 21 (31%) 19 2
(C x S)F1 39 D4Mit31 (106.8) 11 (28%) 10 1 e
(S x C)F1 35 D4Mit31 (106.8) 9 (26%) 7 2 e
(C x S)F1 + (S x C)F1 74 D4Mit31 (106.8) 20 (27%) 17 3 e
aBALB/c and STS mice are abbreviated as C and S.
bMegabase (Mb) positions of markers are according to Mouse Genome Informatics (MGI) 5.10.03. (http://www.infor‐
matics.jax.org/)
cUnpublished data.
d Data in [20].
eData in [37].
Table 4. LOH at markers on chromosome 4 in lymphomas induced by radiation in F1 hybrids between BALB/c and STS
or C.S congenic lines.
In the Lyr region between D4Mit302 and D4Mit144, three known tumor suppressors Cdkn2a,
cyclin-dependent kinase inhibitor 2B (Cdkn2b) encoding p15INK4B and methylthioadenosine
phosphorylase (Mtap) exist (Figure 2). Involvement of Cdkn2a and Cdkn2b, specifically in acute
lymphoblastic lymphomas (ALL) in humans and thymic lymphomas in mice has been reported
[46–49]. Mtap is a key enzyme in purine and polyamine metabolism and regulation of
transmethylation reactions and frequently inactivated in human tumors such as lymphomas
by large homozygous deletion of the 9p21 region [50]. Since these deletions inactivate
CDKN2A/ARF and CDKN2B as well as MTAP [51], it has been hypothesized that loss of MTAP
in tumors is a result of co-deletion. However, a recent study showed that mice heterozygous
for the targeted Mtap gene were affected with T-lymphocyte hyperproliferation followed by
T-cell lymphomas late in their lives [52]. In these lymphomas, as shown by the study, expres‐
sion of Mtap was markedly reduced, while expression of Cdkn2a was not. The results suffice
the criteria for tumor suppressors, indicating that Mtap is a candidate tumor suppressor
distinct from Cdkn2a. It has also been reported that the Cdkn2b gene is particularly inactivated
by allele loss and hypermethylation of the remainder allele in radiation-induced lymphomas
in mice [53]. BALB/c mice carry a hypomorphic variant allele at Cdkn2a, which is shown to be
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causative in the sensitivity to plasmacytomagenesis [28]. STS mice and most of strains other
than BALB/c have the wild-type allele at the Cdkn2a locus ([28], DNA sequences we confirmed).
Although Cdkn2a is a potential candidate for tumor susceptibility gene Lyr, Cdkn2b and Mtap
are at present not ruled out as candidates for the tumor susceptibility gene. Analysis for allele
loss, sequences and expression levels of these tumor susceptibility genes in BALB/c and
C.S302–9 congenic mice is currently underway.
Figure 2. Locations of tumor suppressors in the lymphoma susceptibility Lyr gene region.
7. Conclusion
Frequent LOH occurs on chromosomes 4, 12 and 19 in radiation-induced lymphomas from
various F1 hybrid mice. These allele losses are classified into two groups: common loss and
cross-dependent loss. The putative tumor suppressor harbored in common loss on chromo‐
some 12 might be a key player in radiation-induced lymphomgenesis. Cross-dependent allele
loss such as those on chromosomes 4 and 19 reflects genetic interaction between tumor
suppressors harbored in the LOH region and the genetic background. BALB/c and STS strains
of mice are susceptible and resistant to radiation-induced lymphomagenesis, respectively.
Allele loss occurs on chromosome 4 in approximately 30% of lymphomas induced by radiation
in (BALB/c x STS)F1 mice and shows preferential loss of the STS allele. Our analysis of congenic
lines with various portions of STS-derived chromosome 4 on the BALB/c background shows
a link between the skewed LOH and the tumor susceptibility Lyr locus, where tumor sup‐
pressors p16Ink4a/Arf, p15Ink4b and Mtap genes are localized. Although the Lyr gene is as yet
unidentified, p16Ink4a/Arf may be one of the potential candidates. Studying cross-specific LOH
and distorted allele loss may lead to better understanding of variable pathways of radiation
lymphomagenesis.
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To Grow, Stop or Die? – Novel Tumor-Suppressive
Mechanism Regulated by the Transcription Factor E2F
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1. Introduction
Proliferation of mammalian cells is strictly regulated by growth stimulation. Cell prolifera‐
tion is stimulated not only by normal growth stimulation but also by abnormal growth stim‐
ulation originated from oncogenic changes. Such abnormal growth stimulation leads to
tumorigenesis, if not properly guarded by appropriate cellular response. Cells are endowed
with intrinsic tumor suppressor pathways to protect cells from tumorigenesis upon such on‐
cogenic threat [1]. The tumor suppressor pathways halt cell proliferation either by restrain‐
ing cell cycle progression or by inducing apoptosis (programmed cell death) in case of being
unable to stop aberrant cell cycle progression. Consequently, the cell-fate, whether to grow,
stop growing or die, is dependent on the balance between growth-promoting effects origi‐
nated from oncogenic changes and growth-suppressive effects mediated by the tumor sup‐
pressor pathways upon oncogenic changes (Figure 1). When the tumor suppressor
pathways are disabled by further oncogenic changes, the balance of cell-fate determination
shifts from growth suppression to proliferation, and cells start deregulated proliferation,
leading to tumorigenesis. Among the intrinsic tumor suppressor pathways, two major path‐
ways are the RB pathway and the p53 pathway. Both pathways are important for induction
of cell cycle arrest or apoptosis [2]. In addition, accumulating evidence indicates that the tu‐
mor suppressor TAp73, a member of the p53 family, also plays crucial roles in tumor sup‐
pression by inducing apoptosis independent of p53 [3, 4].
The transcription factor E2F, the main target of the RB pathway, plays crucial roles in cell cycle
progression by activating growth-promoting genes [5]. In this regard, E2F is thought to mediate
growth-promoting effects originating from normal growth stimulation and oncogenic changes.
Supporting this notion, E2F could be an oncoprotein [6]. On the other hand, recent studies indi‐
cate that E2F also plays crucial roles in activation of the major intrinsic tumor suppressor path‐
© 2013 Ozono et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
ways by sensing oncogenic changes, halting cell proliferation by inducing cell cycle arrest or
apoptosis. Supporting this notion, E2F could also be a tumor suppressor [7]. Taken together,
these observations indicate that E2F is located at the center of the balance between cell prolifera‐
tion and cell cycle arrest or apoptosis, determining the cell-fate upon oncogenic changes (Figure
1). E2F can be regarded as a double-edged sword in cell growth control. In this chapter, we will
describe the major intrinsic tumor suppressor pathways and activation of the tumor suppressor
pathways by E2F upon oncogenic changes. We will focus on how E2F differentially regulates
expression of target genes upon normal growth stimulation and oncogenic changes that have
completely opposite roles in cell-fate determination, to grow, stop or die.
Figure 1. To grow, stop or die? The balance between the activity of growth-promoting pathways and tumor suppressor
pathways determines the cell fate upon oncogenic changes. E2F is located at the center of the balance (see also Figure 6).
2. Major tumor-suppressor pathways
2.1. The RB pathway (CDK inhibitor–Cyc/CDK–RB)
The retinoblastoma gene (RB1) is the first identified tumor suppressor gene [8]. Individuals
with heterozygous deletion or mutation of the RB1 gene are susceptible to retinoblastoma in
early life by additional deletion or mutation of the other allele. The RB1 gene product pRB, to‐
gether with its relatives, p107 and p130, comprises a family of pocket proteins [9, 10] (Hereafter
we refer all pocket proteins to RB, and the RB1 gene product to pRB). The main target of RB is the
transcription factor E2F, which plays central role in cell proliferation by activating growth-pro‐
moting genes including those required for DNA replication and cell cycle progression [9]. In
quiescent phase, RB binds to E2F and suppresses transcriptional activity of E2F. Moreover, RB
recruits various chromatin-modifying factors, such as histone deacetylases (HDACs) [11] and
histone methyl transferase SUV39H1 [12] to actively suppress expression of E2F target genes.
Hence the main role of RB in tumor suppression is thought to be suppression of cell prolifera‐
tion through suppression of E2F target gene expression. Growth stimulation induces expres‐
sion of cyclins and activates cyclin dependent kinases (CDKs), which are called accelerators and
engines in cell cycle progression, respectively. CDKs, in turn, inactivate RB by phosphorylation,
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leading to expression of E2F target genes by releasing them from suppression by RB during G1
to S phase cell cycle progression (Figure 2) [13]. In contrast, growth-suppressive signals such as
contact inhibition and DNA damage induce expression of CDK inhibitors, which are called
brakes in cell cycle progression owing to their ability to inhibit activity of CDKs. Suppression of
CDKs keeps RB in hypo-phosphorylated form, which binds to and inhibits E2F. Consequently,
the activity of E2F to activate growth-promoting genes is controlled by the activity of RB, which
is regulated by CDKs and CDK inhibitors. The pathway converging to RB, including CDKs and
CDK inhibitors, is referred to the RB pathway.
Whether a cell progresses one round of the cell cycle or not is determined at the restriction
point, which is located at late G1 phase of the cell cycle. Once a cell passed through the re‐
striction point, it is programmed that the cell cycle automatically proceeds to the end of M
phase. Thus, whether a cell proliferates or not is determined by whether the cell passes
through the restriction point or not. Two major determinants whether a cell passes through
the restriction point or not are E2F activity and cyclin dependent kinase activity, which is
induced by E2F through activation of the Cyclin E (CycE) gene [14]. Since E2F plays essential
roles in passing through the restriction point, RB can be regarded as a gatekeeper in cell cy‐
cle progression by controlling E2F activity. Hence disruption of the RB pathway and conse‐
quent activation of E2F is thought to be an essential event for tumorigenesis [2]. Actually,
deletion or mutation of the RB1 gene is observed in about 30% of cancers. Moreover, defects
in the RB pathway upstream of RB such as overexpression of CycD and dysfunction of CDK
inhibitors such as p16INK4a are frequently observed in other cancers retaining RB1 [2]. It is
predicted that all cancers have at least some defect in the RB pathway.
The RB pathway plays essential roles in tumor suppression by inducing cell cycle arrest or
cellular senescence through suppression of the activity of E2F. As described below, disrup‐
tion of the RB pathway reinforces cell cycle arrest by induction of CDK inhibitor p21Cip1 ex‐
pression through the p53 pathway or p27Kip1 expression. When cells failed to induce cell
cycle arrest, apoptosis is triggered through the p53 pathway or TAp73, a p53 family mem‐
ber, which activates various pro-apoptotic genes.
Figure 2. The regulatory mechanism of the transcription factor E2F by the RB pathway.
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2.2. The p53 pathway (ARF–p53–cell cycle arrest or apoptosis related effectors)
The tumor suppressor p53 is a transcription factor that is activated by a variety of stress sig‐
nals, including DNA damage, hypoxia and various oncogenic changes including aberrant
activation of E2F [15]. In response to such stress signals, p53 induces either cell cycle arrest
or apoptosis. Cell cycle arrest is mainly mediated through activation of the CDK inhibitor
p21Cip1 gene [16], whose product suppresses wide range of CDKs. Apoptosis is mainly medi‐
ated through activation of the Bax and BH3 only family genes, whose products destabilize
mitochondrial membrane to facilitate cytochrome c release, which triggers apoptotic cas‐
cades of caspase activation.
Since p53 plays crucial roles in induction of cell cycle arrest or apoptosis, the expression
level  of  p53  is  kept  low  by  rapid  ubiquitin/proteasome-dependent  degradation,  mainly
caused  by  Mdm2  (mouse  double  minute  2,  Hdm2  in  humans),  which  is  often  overex‐
pressed in many cancers [15].  Mdm2 is  E3 ubiquitin ligase,  which directly binds to p53
and  promotes  p53  degradation.  Mdm2  also  inhibits  TP53  mRNA  translation  [17].  The
Mdm2  gene  is  a  target  of  p53,  forming a  negative-feedback loop to  control  the  level  of
p53 [18]. Another negative regulator of p53 is MdmX, also known as Mdm4. MdmX has
recently  emerged as  a  discrete  critical  negative  regulator  of  p53 [19].  Though MdmX is
not  a  direct  target  of  p53,  structure  of  MdmX is  significantly  similar  to  that  of  Mdm2.
MdmX is reported to enhance p53 ubiquitination by altering the substrate preference of
the Mdm2, thereby indirectly regulating p53 [20].
Regarding response to oncogenic stresses, a potent activator of p53 is the tumor suppressor
ARF (alternative reading frame, known as p14 in humans and as p19 in rodents) [2]. ARF
directly binds to and sequesters Mdm2 to nucleoli, stabilizing p53 that leads to the expres‐
sion of its target genes [21]. The pathway including upstream and downstream of p53 is re‐
ferred to the p53 pathway. Of note, the ARF gene is a direct target of E2F [22] and this E2F-
ARF interaction connects the RB pathway and the p53 pathway, enabling efficient tumor-
suppressive response. When the RB pathway is disrupted by oncogenic changes, E2F is
activated to induce ARF gene expression, leading to activation of the p53 pathway, which
inhibits oncogenic cell growth by inducing cell cycle arrest or apoptosis (Figure 3). There‐
fore, disruption of both of the tumor suppressor pathways powerfully shifts the cell-fate de‐
termination balance to proliferation (Figure 1) and is thought to be essential to induce
deregulated cell proliferation that leads to tumorigenesis. Indeed, about 50% of cancers car‐
ry TP53 mutations or deletion and most cancers have defects in the p53 pathway including
those in upstream and downstream of p53.
2.3. The TAp73 pathway (E2F–TAp73–pro-apoptotic targets)
The tumor suppressor TAp73 is a homologue of p53 and can induce apoptosis independent‐
ly of p53 [3, 4, 23]. The TP73 gene encodes two isoforms, TAp73 and DNp73, which are driv‐
en by different promoters. DNp73 lacks the transactivation (TA) domain and counteracts
TAp73 and p53 [24]. Thus DNp73 is anti-apoptotic. The TAp73 gene is thought to be a tumor
suppressor gene and is known to be a target of E2F1 [3, 4, 25]. Similarly to p53, TAp73 is
activated by both oncogenic changes and DNA damage [26, 27] and TAp73 target genes
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partly overlap with those of p53, such as the PUMA and NOXA genes [28, 29] that are cru‐
cial for induction of apoptosis. Moreover, TAp73 can induce apoptosis in the absence of p53
[3, 4]. Therefore, TAp73 seems to back-up the important tumor suppressive function of p53.
Figure 3. E2F activates major intrinsic tumor suppressor pathways.
3. The transcription factor E2F
The transcription factor E2F was originally identified as a cellular DNA-binding protein,
which mediate E1A-dependent activation of the adenovirus E2 promoter [30]. Members of
E2F family are downstream targets of the tumor suppressor RB and make repressor com‐
plexes with RB that keep cells in quiescent state [9, 10]. Though E2F plays central roles in
cell proliferation by activating growth-promoting genes, certain members of E2F can induce
apoptosis [15]. In this paragraph, we will describe three points as follows (1) E2F family
members, the role of them in cell cycle progression, cell cycle arrest and apoptosis. (2) Regu‐
latory mechanism of E2F. (3) E2F target genes, to better understand the regulatory mecha‐
nism of cell-fate determination mediated through E2F.
3.1. E2F family members
E2F consists of eight family members (E2F1-E2F8). E2F1-E2F5 are bound by their repressor
RB family proteins through RB binding domain. E2F1-E2F5 activate transcription when free
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from RB and repress transcription when bound by RB. E2F1-E2F3a are induced at G1/S
boundary and activate transcription free from RB. In contrast, E2F3b-E2F5 are expressed all
through the cell cycle and play main roles in transcriptional repression in G0/G1 bound by
RB. E2F6-E2F8 repress transcription independently of RB. Hence E2F family members are
divided into two groups: activator E2Fs (E2F1-E2F3a) and repressor E2Fs (E2F3b-E2F8). Ac‐
tivator E2Fs play major roles in activation of target genes involved in growth promotion,
growth suppression and induction of apoptosis. Repressor E2Fs are roughly divided into
two groups; E2F3b-E2F5, which make repressor complex together with RB, and recently
identified E2F6-E2F8, which function independently of RB.
Figure 4. Structure of E2F family members. E2F1-E2F6 bind to their target promoter with binding partner DP proteins
through dimerization domain. E2F7 and E2F8 have two DNA binding domains and make homodimers or E2F7/E2F8
heterodimer.
A structural characteristic of activator E2Fs (E2F1-E2F3a) is longer N terminal region, which
does not exist in repressor E2Fs (E2F3b-E2F6). Expression of E2F1-E2F3a is induced by E2Fs
themselves [31]. When growth stimulation inactivates p130 by phosphorylation through ac‐
tivation of CycD/Cdk4 or CycD/Cdk6, repressor E2Fs (E2F4 and E2F5) are released from
p130 and activates the E2F1-E2F3a genes. E2F1-E2F3a in turn replace E2F4 and E2F5, and ac‐
tivate growth-promoting genes including E2F1-E2F3a themselves. Each activator E2F has
preferential roles in cell cycle progression and induction of apoptosis. p107 preferentially
make complexes with E2F4-E2F5 in G1/S to S phases.
E2F1 is generally thought to be the most powerful transcriptional activator of pro-apoptotic
genes among activator E2Fs. Overexpression of E2F1 in tissue culture cells alone can induce
cell cycle progression in otherwise quiescent fibroblasts [32]. Overexpression of E2F1 can be
oncogenic in vitro [33, 34] and in vivo [6]. In contrast, E2F1 is dispensable for cell cycle pro‐
gression, since E2F1 knockout mice are viable. On the other hand, over expression of E2F1 in
cancer cell lines leads to apoptosis [35]. E2F1 also plays a key role in induction of cellular
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senescence by activating the ARF-p53 pathway, when overexpressed in human normal fi‐
broblasts [36]. Moreover, E2F1 null mice resulted in tumorigenesis [7]. Taken together, E2F1
seems to play the most important roles in tumor suppression among activator E2Fs by acti‐
vating genes involved in apoptosis and cell cycle arrest.
E2F2 has 46% overall amino acid sequence similarity to E2F1 [37] and is thought to play
roles in both cell proliferation and tumor suppression. E2F2 null mice exhibit increased pro‐
liferation of hematopoietic cells and frequently develop autoimmunity and tumors [38, 39].
In tumor suppression, E2F2 plays major roles in suppression of Myc-induced T cell lympho‐
magenesis. Inactivation of neither E2F1 nor E2F3 had no effect on tumor progression in T
cells, and only loss of E2F2 accelerated lymphomagenesis [40].
E2F3 is thought to be the most important activator E2F in cell proliferation. Although E2F1
or E2F2 null mice are viable and tumor-prone, E2F3 null mice are typically embryonic lethal
in pure background [41] or show partially penetrant embryonic lethality in mixed back‐
ground [42]. Although mouse embryonic fibroblasts (MEFs) with combined knockout of
E2F1 and E2F2 proliferate, those with combined knockout of E2F1, E2F2 and E2F3 fail to
proliferate and can not re-enter the cell cycle [5]. The E2F3 locus encodes two isoforms,
E2F3a and E2F3b, a truncated variant of E2F3 in its N-terminus [43, 44]. Although both
E2F3s partly overlaps their roles in cell cycle progression [45], E2F3a is expressed in G1/S to
S phases and is thought to play crucial roles on cell proliferation, while E2F3b is expressed
equivalently in quiescent and proliferating cells, and associates with pRB, representing the
predominant E2F-pRB complex in quiescent cells [44, 46]. E2F3b also plays roles in myogen‐
ic differentiation by promoting gene expression related to differentiation [47].
Figure 5. Roles of activator E2Fs in cell-fate determination. E2F1 plays crucial roles in induction of apoptosis. E2F3 is
thought be essential for cell proliferation. It is predicted that the character of E2F2 is in the middle of E2F1 and E2F3.
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E2F4 and E2F5 were cloned by their association with p107 and p130, and are significantly
detected in quiescent cells [48, 49]. Knockout mice of either E2F4 or E2F5 are viable [50-52].
E2F4 knockout mice are runted and display defects in late stage of maturation. In addition,
these mice present reduced thickness of the gut epithelium and developmental craniofacial
defects. E2F5 knockout mice develop hydrocephalus after birth apparently due to increased
secretion of cerebrospinal fluid by the choroid plexus. E2F4 and E2F5 double knockout mice
die before birth because of developmental defects, suggesting that E2F4 and E2F5 have some
redundant functions during development [53]. Cells lacking E2F4 and E2F5 are unable to
stop cell cycling upon growth-suppressive signals such as TGF-β treatment, suggesting that
E2F4 and E2F5 are major repressor E2F in restraining cell cycle progression. These two E2Fs
are thought to be important for cell cycle exit and terminal differentiation.
E2F6 does not possess RB binding domain. As predicted from the structure, E2F6 contrib‐
utes gene silencing independent of RB [54] and is predicted to make repressor complex with
polycomb proteins [55]. Consistent with this, E2f6-/- animals display overt homeotic trans‐
formations of the axial skeleton that are strikingly similar to the skeletal transformations ob‐
served in polycomb deficient mice [56]. E2F6 is reported to bind the same E2F-repressor site
as E2F4, suggesting E2F6 may partly overlaps its function as transcriptional repressor with
E2F4 in S phase [57].
E2F7 and E2F8 are thought to function as transcriptional repressors independently of RB
proteins. An important target of E2F7 and E2F8 is the E2F1 gene. E2F7 and E2F8 knockout
mice are embryonic lethal, at least in part, due to apoptosis caused by inability to down reg‐
ulate expression of E2F1, leading to activation of p53 [58]. Recent report showed that E2F7
and E2F8 promote angiogenesis through transcriptional activation of the VEGFA promoter
with hypoxia inducible factor 1 (HIF1) [59].
3.2. Regulatory mechanism of E2F
E2F1 through E2F6 associate with DP family proteins (DP1 or DP2) to form heterodimeric
complexes that bind to DNA in a sequence-specific manner (consensus sequence: TTTC/GG/
CCGC). E2F7 and E2F8 have two DNA binding domains and do not require DP proteins for
binding to DNA. E2F7 and E2F8 make homodimer or E2F7/E2F8 heterodimer to bind to the
target [58].
Transcriptional activity of E2F1 through E2F5 is suppressed by binding of RB family pro‐
teins. pRB preferentially binds E2F1 through E2F3, whereas p107 and p130 preferentially
bind E2F4 and E2F5. However, pRB can also bind E2F4, depending on the cellular circum‐
stances. E2F6 through E2F8 can repress transcription independently of pRB family proteins
[10, 60]. In quiescent phase, E2F3b/pRB, E2F4/p130 and E2F5/p130 repress promoters of E2F
target genes. Upon growth stimulation, activated CycD/Cdk4 and CycD/Cdk6 phosphory‐
late pRB and p130, inhibiting their binding to the E2Fs and allowing accumulation of the
free E2Fs [31]. This release from repression conferred by the pRB family proteins is the pri‐
mary activation step for induction of E2F target genes. In this context, E2F3b, E2F4 and E2F5
mainly act as repressors together with the pRB family proteins during G0/G1 phases. Ex‐
pression of E2F1, E2F2 and E2F3a is induced at the G1/S boundary by E2F itself, and activate
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the growth related genes, including the CycE gene. CycE activates Cdk2, whose activity is
essential for initiating DNA replication, and drive cells into S phase [31]. In late S phase, Cy‐
cA/Cdk2 complex represses the transcriptional activity of E2F/DP complex by phosphoryla‐
tion, which releases the complex from the binding element [61].
3.3. E2F target genes
Classical E2F targets are genes involved in DNA replication and cell cycle progression. In
addition to these, recent studies with DNA microarray and chromatin immunoprecipitation
(ChIP) identified a variety of E2F targets. These include genes involved in DNA repair,
checkpoint, differentiation, development, metabolism, micro RNAs, apoptosis, cell cycle ar‐
rest and others.
DNA replication
E2F regulates expression of most of the genes involved in initiation of DNA replication:
the  ORC1  (origin  recognition  complex1),  CDC6,  MCM  (maintenance  of  minichromosome)  2-7,
ASK  and CDC45  genes.  These factors are assembled into pre-replication complex,  which
is activated by CycE/Cdk2 to initiate DNA replication [31].  Cdt1 also plays crucial  roles
in  initiation  of  DNA replication  and is  negatively  regulated  by  geminin.  The  Cdt1  and
geminin  genes  are  both E2F targets  [62].  Genes,  which code for  machineries  responsible
for  DNA replication,  are  classical  E2F targets.  These  include the  DHFR  (dihydrofolate  re‐
ductase),  DNA polymerase  α,  thymidine  kinase,  thymidylate  synthase  and PCNA (proliferating
cell nuclear antigen) [53].
DNA repair, checkpoint
E2F target genes related to DNA repair are the Rad51, MSH2 and MLH1 genes, which are
involved in homologous recombination repair and mismatch repair [63]. E2F target genes
related to checkpoint are the ATM, Chk1, Mad3, Bub1, Claspin and RanBP1 genes [53, 64-67].
It is expected that E2F regulates these DNA repair and checkpoint genes to prepare machi‐
neries to quickly respond in case of emergency.
Cell cycle progression
E2F induces expression of genes, which play major roles in induction of S phase, such as the
CycE and activator E2F (E2F1-E2F3a) genes themselves [31]. Also, the upstream negative reg‐
ulators of pRB, the Emi1 and Skp2 genes are E2F targets [68, 69]. The genes, which encode
CycA, Cdc2 (CDK1), CycB and B-myb that are important for S and G2/M phase progression,
are also E2F targets [53]. Repressor E2Fs, E2F7 and E2F8 genes are reported to be targets of
E2F1 that promote embryonic development by suppressing E2F1-p53 induced apoptosis,
forming a negative feedback loop. Although c-Myc is reported as a target of E2F [70], E2F
may play a role in suppression of c-Myc expression upon negative growth signals [71].
Development and differentiation
E2F  also  regulates  expression  of  genes  involved  in  development  and  differentiation.
The  Firizzled  homologs1-3,  Homeobox  and  TGF  genes  are  shown  to  be  targets  of  E2F
To Grow, Stop or Die? – Novel Tumor-Suppressive Mechanism Regulated by the Transcription Factor E2F
http://dx.doi.org/10.5772/54510
25
[53].  It  is  reported  that  overexpression  of  E2F1-3  induced  various  genes  involved  in
development  and  differentiation  [72].  Interestingly,  although  E2F7  and  E2F8  are  gener‐
ally  regarded  as  transcriptional  repressors,  a  recent  study  reported  the  roles  of  E2F7
and E2F8 in transcriptional  activation of  genes such as  VEGFA as written before [59].
Cellular metabolism
Recent work reported that E2F1 and pRB are required for repression of genes implicated in
oxidative metabolism [73]. E2F1 repressed key genes that regulated energy homeostasis and
mitochondrial functions in muscle and brown adipose tissue, and E2F1 null mice had a
marked oxidative phenotype. Their work suggests a metabolic switch from oxidative to gly‐
colytic metabolism that responds to stressful conditions.
Micro RNAs
Accumulating evidence indicates that expression of E2F is regulated by microRNAs and
that E2F also induces expression of microRNAs [74]. One of the major microRNAs regulated
by E2F is miR-17~92. miR-17~92 is a negative regulator of E2F1-E2F3 and is also a target of
E2F1-E2F3, constructing a fail-safe mechanism to regulate E2F activity. E2F seems to be rig‐
orously controlled by many miRNAs, suggesting that E2F activity must be strictly control‐
led for appropriate cell cycle progression.
Apoptosis and cell cycle arrest
E2F can activate genes involved in apoptosis and cell cycle arrest, which are inconvenient
for cell proliferation. Regulatory mechanism of these growth-suppressive genes by E2F is
yet to be elucidated, especially regarding regulation of cell growth versus tumor suppres‐
sion in response to normal growth stimulation and oncogenic changes. The caspase3, caspase7
and Apaf1 genes, which code for apoptotic machineries, are direct targets of E2F [53]. Cas‐
pases are expressed as inactive precursors (procaspases), and expression of procaspases and
Apaf-1 alone does not necessarily induce apoptosis. These apoptotic machineries require up‐
stream signals to be activated to induce apoptosis. Expression of these two pro-apoptotic
E2F targets and all E2F targets mentioned above is induced by growth stimulation. Thus, ex‐
pression of the pro-apoptotic machinery by growth stimulation is thought to be fail-safe
mechanism to induce apoptosis in case of emergency. We refer these E2F target genes,
whose expression is induced by growth stimulation, to ‘typical E2F targets’. Typical E2F tar‐
gets are activated by growth stimulation, which physiologically inactivates RB by phosphor‐
ylation and activates E2F by release from repression.
In contrast to typical E2F targets, we identified three E2F targets, which are not activated by
growth stimulation. These include the tumor suppressor ARF, TAp73 and CDK inhibitor
p27Kip1 genes. As described below, these genes are critically important in tumor suppression.
We describe the regulatory mechanism of the tumor suppressor ARF, TAp73 and CDK in‐
hibitor p27Kip1 genes by E2F in next paragraph.
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Figure 6. E2F activates both growth-promoting genes and growth- suppressive genes, including E2F itself. It is pre‐
dicted that the expression levels of E2F targets, related to growth- promotion or growth- suppression, decide the bal‐
ance of cell-fate determination.
4. Deregulated E2F
Since E2F1-E2F3a are activated by growth stimulation, it is generally thought that their tar‐
get genes are all activated by growth stimulation. However, E2F1-E2F3a also activate genes
involved in cell cycle arrest or apoptotic, which are inconvenient for cell growth. It has yet to
be elucidated how E2F regulates genes involved in cell cycle arrest or apoptosis, regarding
normal cell growth and tumor suppression.
Since all E2F targets are thought to be activated by growth stimulation, it is surprising that
our previous work identified three growth suppressive E2F targets, which were not activat‐
ed by growth stimulation at all in human normal fibroblasts [75-77]. In contrast, these E2F
targets were activated by deregulated E2F activity induced by overexpression of E2F1 or
forced inactivation of pRB. Overexpression of E2F1 generates exceeding amount of exoge‐
nously introduced E2F1, which becomes out control by RB proteins. Forced inactivation of
pRB induces endogenous deregulated E2F activity out control by pRB. We refer these
growth suppressive E2F targets, which are not activated by growth stimulation but are acti‐
vated by deregulated E2F, to ‘atypical E2F targets’. These atypical E2F targets include the
tumor suppressor ARF and TAp73 genes and the CDK inhibitor p27Kip1 gene These three
atypical E2F target genes play major roles in tumor suppression. ARF is an upstream activa‐
tor of the tumor suppressor p53. CDK inhibitor p27Kip1 activates the RB pathway by inhibit‐
ing CDKs. TAp73 is the tumor suppressor, which can induce apoptosis in dependently of
p53. Our observations suggest that E2F activity induced by RB dysfunction, one of major on‐
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cogenic changes, has distinct function from that induced by growth stimulation in activating
target genes (Figure 7).
E2F activity induced by RB dysfunction activates both typical and atypical E2F targets. In
contrast, E2F activity induced by growth stimulation activates only typical E2F targets and
interestingly, not atypical E2F targets. Both of the E2Fs are similar in the sense that they are
released from repression by RB. However, it is shown that growth stimulation does not to‐
tally inactivate pRB and some portion of activator E2Fs is still in complex with pRB [78].
Moreover, the RB1 gene is an E2F target [79] and expression of pRB is increased in G1/S to S
phases [80]. Indeed, the amount of activator E2Fs/pRB complex rather increases in G1/S to S
phases, as examined by gel mobility shift assay [78]. This observation indicates that E2F ac‐
tivity induced by growth stimulation is still under control of RB. In contrast, E2F activity in‐
duced by dysfunction of RB is thought to be out of control by RB. Here, we refer E2F
activated by growth stimulation to ‘physiological E2F’ and that by dysfunction of RB to ‘de‐
regulated E2F’. Our findings indicate that deregulated E2F is functionally different from
physiological E2F.
In this paragraph, we describe the regulatory mechanism of atypical E2F targets by deregu‐
lated E2F and discuss about the characteristics of deregulated E2F activity regarding its role
in tumor suppression.
Figure 7. Atypical E2F target genes are specifically activated by deregulated E2F activity through specific E2F respon‐
sive elements.
4.1. Atypical E2F targets
The first atypical E2F target identified was the ARF gene [75]. ARF is the major activator of
p53 pathway and links the RB and p53 tumor suppressor pathways [22], playing crucial
roles in tumor suppression. Consistent with this notion, deletion, mutation or silencing of
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the ARF gene is frequently observed in cancers. Moreover, Arf null mice are highly prone to
tumorigenesis [81]. Various oncogenic signals are able to elicit the activation of the ARF
gene. Overexpression of adenovirus E1a or E2F1 in primary mouse embryonic fibroblasts
(MEFs) rapidly induces ARF gene expression and p53-dependent apoptosis [16]. Myc over‐
expression and oncogenic mutant Ras are also strong activators of the ARF gene and combi‐
nation of absence of Arf in mice severely impaired the tumor suppressive activity of p53
[82]. Arf promoter seems to monitor these oncogenic signals as shown by ARF promoter-
GFP transgenic model, in which GFP expression was observed in tumors induced by Myc or
Ras but not in normal growing tissues [83]. Other studies elucidated that ARF also restrains
cell growth independently of p53, interacting with other factors [84]. Taken together, the
ARF gene plays crucial roles in tumor suppression through p53-dependent and independent
pathways.
The  CDK  inhibitor  p27Kip1  is  an  upstream  regulator  of  the  RB  pathway  and  known  to
contribute to the ability of pRB to induce cell-cycle arrest, differentiation and senescence
[85-87].  There is cross regulation between p27Kip1  and pRB. p27Kip1  enhances pRB growth
suppressive function by inhibiting Cyc/CDK, keeping pRB in hypo-phosphorylated form.
pRB increases the amount of p27Kip1  by sequestrating Skp2, a component of E3 ubiquitin
ligase complex,  which promotes degradation of  p27Kip1  [86].  pRB also known to cooper‐
ate with APC/Ccdh1,  another E3 ubiquitin ligase,  to induces Skp2 degradation, stabilizing
p27Kip1  [88].  Taken together,  pRB and p27Kip1  seem to  keep close  relationship  in  the  RB
pathway  to  efficiently  suppress  aberrant  cell  proliferation.  Indeed,  our  previous  study
showed that inactivation of RB by adenovirus E1a increased BrdU (bromodeoxyuridine)-
positive cells  much earlier  in p27Kip1-/-  MEFs than in wild type MEFs [66].  These results
support the notion that p27Kip1  plays important roles in the RB pathway to suppress cell
cycle progression induced by oncogenic changes.
The  tumor  suppressor  TAp73  gene  had  been  identified  as  a  direct  target  of  E2F  using
cancer  cell  lines  [4].  We  found that  the  TAp73  gene  was  activated  by  deregulated  E2F
but  not  by  physiological  E2F  in  human normal  fibroblasts  [77].  TAp73  is  a  p53  family
member  and plays  important  roles  in  tumor suppression with  its  other  family  member
p53 and p63.  All  of  the three genes express differentially spliced isoforms [89,  90].  Two
major isoforms are TA isoforms, which retain transactivation (TA) domain,  and delta N
(DN) isoforms, which lack TA domain. Since these family members activate their targets
as tetramers and DN isoforms lack transactivation (TA) domain, DN isoforms have dom‐
inant-negative properties  [24].  Although p53 is  deleted or mutated in half  of  all  human
cancers,  deletion or mutations of  p73 and p63 occur rarely [91,  92].  Rather over expres‐
sion of DN form of p73 and p63 are commonly observed in many cancers, such as over
expression of DNp73 isoform in gliomas and carcinomas of the breast and the colon [93,
94],  and that  of  DNp63 isoform in bladder  carcinomas [95].  Each DN isoform can sup‐
press  all  three  types  of  TA forms [92,  96,  97].  Therefore,  it  is  expected that  tumor-sup‐
pressive  TA  isoforms  are  suppressed  by  DN  isoforms  in  many  cancers.  This  could
explain why deletion or  mutations of  the TP73  and TP63  genes are rare.  TAp73  can in‐
duce apoptosis independently of p53. Moreover, TAp73 knockout mice are tumor prone,
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infertile, sensitive for carcinogen-induced tumorigenesis and defective for maintenance of
genomic  stability  [98].  The  TAp73  gene  is  activated  by  various  stress  signals  including
deregulated E2F and DNA damage.  These  observations  suggest  that  TAp73 contributes
to  tumor suppression in  addition to  the  p53 pathway in  response to  various  oncogenic
changes.
Accumulating evidence indicates that the three atypical E2F targets explained above play
crucial roles in tumor suppression, by activating the RB pathway, the p53 pathway and the
p53 independent pathway. Taken together, deregulated E2F seems to be critically important
for activating major intrinsic tumor-suppressor pathways in responding to oncogenic
changes to suppress tumorigenesis (Figure 8).
Figure 8. Deregulated E2F plays important roles in activating major tumor suppressor pathways (RB, p53 and TAp73
pathways) by activating the ARF, p27Kip1 and TAp73 genes.
4.2. Distinct transcriptional regulatory mechanism mediated by deregulated E2F
ARF, p27Kip1 and TAp73 exert its effects when expressed unlike pro-apoptotic targets, which
are expressed as inactive precursors such as pro-caspases. Thus the regulation of expression
of these genes is critically important for tumor suppression. The finding that these genes are
specifically activated by deregulated E2F but not by physiologically activated E2F indicates
that there is a mechanism to specifically respond to oncogenic changes to suppress tumori‐
genesis, while allowing normal cell growth upon normal growth stimulation.
We first identified the tumor suppressor ARF gene as an atypical E2F target [75]. In our
studies, we used human normal fibroblasts (HFFs or WI-38) to examine the responsiveness
of each growth-suppressive E2F target to physiological and deregulated E2F. This is because
most of previous studies used cancer cell lines and were unable to examine responsiveness
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of E2F target genes to normal growth stimulation. To induce physiological E2F, we used se‐
rum stimulation, common growth stimulation for fibroblasts. To induce deregulated E2F ac‐
tivity, we used ectopically expressed E2F1 or forced inactivation of RB either by adenovirus
E1a, which binds to and inactivates all RB family proteins, or shRNA against RB1 (shRB),
which represses the expression of pRB. The latter (adenovirus E1a and shRB) is expected to
induce endogenous deregulated E2F activity.
Ectopically expressed E2F1, adenovirus E1a and shRB induced ARF gene expression in RT-
PCR, and activated ARF promoter in reporter assay. However, serum stimulation, which
physiologically activates E2F, did not induce ARF gene expression or activate ARF promoter
under the condition that CDC6 gene (one of typical E2F targets involved in DNA replica‐
tion) expression was significantly induced and CDC6 promoter was clearly activated. These
results indicate that the ARF gene is specifically activated by deregulated E2F but not by
physiological E2F. Promoter analyses identified the E2F responsive element of ARF promot‐
er (EREA), which specifically responds to deregulated E2F activity. Interestingly, the se‐
quence of EREA was composed of only GC repeat and lacked T stretch. This is in contrast to
that of consensus E2F binding motif, which is composed of T stretch and GC repeat
(TTTG/CC/GCGC) in typical E2F targets. In addition, the location of EREA was far upstream
from transcription start site compared to that of typical E2F sites, which is within 100 bp
from transcription start site in most cases. Moreover, our gel mobility shift assay and ChIP
assay showed that EREA specifically binds ectopically expressed E2F1 but not physiological
E2F1 induced by serum stimulation, both in vitro and in vivo, respectively. Taken together,
these observations suggest that the ARF gene is specifically activated through EREA by de‐
regulated E2F activity, triggered by ectopically expressed E2F1 or forced inactivation of RB,
but not by physiological E2F activity, induced by serum stimulation (Figure 7).
A later study showed that ARF promoter lacking EREA was still activated by overexpression of
E2F1 [99]. Our further analyses of ARF promoter identified multiples of EREA-like elements in
ARF promoter. It seems that, although EREA is the major E2F responsive element in ARF pro‐
moter, it is not the sole responsive element and multiple EREA-like elements co-operate to spe‐
cifically respond to deregulated E2F activity (manuscript in preparation).
Defects in the RB pathway activate E2F out of control by RB, promoting abnormal cell
growth. In response to such oncogenic insults, deregulated E2F activates the ARF gene, lead‐
ing to activation of p53 to protect cell from tumorigenesis. For induction of tumorigenesis,
the p53 pathway must be disabled by further oncogenic changes. Indeed, defects in the p53
pathway are observed in almost all cancers. It is expected that the presence of deregulated
E2F be tolerated in cancer cells by further inactivation of the p53 pathway. We thus exam‐
ined the existence of deregulated E2F activity in RB1 deficient cancer cell lines and in nor‐
mal growing fibroblasts. When we introduced constitutively active form of pRB into RB1
deficient cancer cell lines (5637, Saos-2 and C-33 A) and normal growing fibroblasts (WI-38
and HFF), activity of EREA and ARF promoter were decreased in RB1 deficient cancer cell
lines, but not in normal growing fibroblasts. These results showed that deregulated E2F ac‐
tivity specifically exists in RB1 deficient cancer cell lines but not in normal growing fibro‐
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blasts. The presence of deregulated E2F activity may serve as a useful marker to
discriminate cancer cells from normal growing cells.
Our search for new E2F targets with subtraction method identified the CDK inhibitor p27Kip1
gene as an atypical E2F target [66]. p27Kip1 plays important roles in cell cycle arrest by inhib‐
iting Cyc/CDKs. Using reporter assay, we showed that EREK (E2F responsive element of
p27Kip1) was responsible for specifically sensing deregulated E2F activity in human normal
fibroblasts and that EREK was specifically activated in the RB1 deficient cancer cell lines
[76]. Consistent with EREA, the location of EREK was far upstream compared to typical E2F
binding sites. Interestingly, the sequence of EREK contained T in addition to GC repeat and
is rather similar to that of typical E2F binging site. However, EREK bound deregulated E2F1
but not physiological E2F1 in ChIP assay, showing that its character was similar to EREA.
These results suggest that not only the sequence of E2F responsive elements, but also the se‐
quence around the responsive elements may be important for discriminating deregulated
E2F activity from physiological E2F activity. There is also a possibility that structure of the
whole promoter might also affect the discrimination.
Third atypical E2F target is the tumor suppressor TAp73 gene [77]. TAp73 promoter specifi‐
cally responded to deregulated E2F activity through four ERE73s (E2F responsive elements
of TAp73), which were specifically activated by deregulated E2F activity. The sequences of
ERE73s contained T stretch and were similar to that of typical E2F binding sites. Important‐
ly, our ChIP assay showed that bindings of ectopically expressed ‘exogenous’ E2F1 and de‐
regulated ‘endogenous’ E2F1 induced by adenovirus E1a were detected on ERE73s, but not
that of physiological E2F1 induced by serum stimulation. Thus, although the sequences of
ERE73s were similar to or almost same as that of typical E2F binding sites, the characters of
both were completely different. ERE73s were specifically activated by deregulated E2F ac‐
tivity and specifically bound to both ‘exogenous’ and ‘endogenous’ deregulated E2F1. These
results support the notion that both sequences of the E2F binding site and its flanking region
may be important for discriminating deregulated E2F activity from physiological E2F activi‐
ty. Consistent with EREA and EREK, reporter assay showed that ERE73s were also activated
in the RB1 deficient cancer cell lines and not in normal fibroblasts. Moreover, reintroduction
of the constitutive active from of pRB by recombinant adenovirus reduced the expression of
the TAp73 gene in all the cancer cell lines in RT-PCR, indicating that the cancer cell lines har‐
bor deregulated E2F activity that activates the endogenous TAp73 gene.
Interestingly, our unpublished data suggest that not only the RB1 deficient cancer cell lines
but also cancer cell lines retaining pRB harbor deregulated E2F activity. Activity of ERE73s
and expression of the TAp73 gene were suppressed by introduction of the constitutive active
form of pRB in cancer cell lines retaining pRB. These results suggest the possibility that E2F-
mediated transcriptional program can sense defects in the RB pathway, not only pRB itself
but also upstream regulators of pRB. Taken together, deregulated E2F activity might be‐
come a universal means to discriminate cancer cells (may be regardless of the presence of
pRB) from normal growing cells.
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4.3. Difference between deregulated E2F and physiologically activated E2F
Deregulated E2F and physiologically activated E2F are similar in a sense that both are ‘re‐
leased from RB’. However, there is a functional difference between deregulated E2F and
physiologically activated E2F. Deregulated E2F activates both typical and atypical E2F tar‐
gets. In contrast, physiologically activated E2F activates typical E2F targets but not atypical
E2F targets. Why atypical E2F targets are activated by deregulated E2F and not by physio‐
logically activated E2F? What is the difference between deregulated E2F and physiologically
activated E2F? Deregulated E2F is totally ‘out of control’ by RB due to dysfunction of the RB
pathway. In contrast, physiologically activated E2F is temporarily released from RB, predict‐
ed to be ‘under control’ of RB. During normal cell growth, activator E2Fs are induced at
G1/S boundary of the cell cycle. At the point, it is generally believed that pRB is phosphory‐
lated and inactivated. However, pRB is not totally inactivated at the point. Previous studies
indicate that the RB1 gene is an E2F target [79] and expression of pRB is increased in G1/S to
S phases [80]. Moreover, the amount of activator E2Fs/pRB complex rather increases at G1/S
boundary as shown by gel mobility shift assay [78], indicating that some portion of pRB is
still active and is regulating the activity of activator E2Fs. Thus, physiologically activated
E2F is still under control by pRB. It is likely that activity of activator E2Fs is strictly control‐
led by degree of phosphorylation of pRB dependent on the activity of CDKs, reflecting the
strength of growth stimulation. There must be difference between activation of E2F out of
control by pRB and activation of E2F under control by pRB. Our studies of regulatory mech‐
anism of atypical target promoters by E2F elucidated the four different points between regu‐
lation of typical E2F target promoter and that of atypical E2F target promoter.
1. Although sequences of EREK and ERE73s resemble that of typical E2F binding sites, se‐
quence of EREA is different from that of typical E2F sites. The sequence of consensus
E2F binding motif of typical E2F targets is composed of T stretch and GC repeat
(TTTG/CC/GCGC). EREA is composed of only GC repeat and lacks T stretch. Difference in
binding sequence suggests the possibility that there may be a difference in factors,
which recognize the sequence and bind.
2. In all three cases, location of E2F responsive elements of atypical E2F targets is far from
the transcriptional start site compared to that of typical E2F binding sites in typical E2F
targets. In the case of typical E2F targets, location of E2F binding sites is within 100 bp
from transcriptional start site in most cases. Typical E2F targets are under repression by
E2F/RB complex in quiescent phase and are released from repression upon growth
stimulation. Close proximity of E2F binding sites to transcriptional start site may be re‐
quired for this mode of regulation. In contrast, atypical E2F targets are not under re‐
pression by E2F/RB complex and literally activated by deregulated E2F. E2F responsive
elements of atypical E2F targets behave as enhancer elements, which can function from
distance.
3. Deregulated E2F1 bound to EREA, EREK and ERE73s and physiologically activated
E2F1 did not bind to these elements as shown by ChIP assay. In the case of EREA, it is
also shown that repressor type E2F4 does not bind to EREA. This observation is com‐
patible with the observation that these atypical E2F targets are not under repression by
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E2F/RB. The fact that deregulated E2F bind to atypical E2F targets, while physiological
E2F does not bind to atypical E2F targets, suggest that there is difference in binding be‐
havior between deregulated E2F and physiologically activated E2F.
Figure 9. Differences in E2F regulation of target promoters between deregulated E2F and physiological E2F. (1) Se‐
quence of the atypical E2F responsive elements and surrounding regions are different from that of typical E2F targets.
(2) E2F responsive elements of the atypical E2F targets locate far upstream from transcriptional start sites compared to
that of typical E2F targets. (3) E2F responsive elements of atypical E2F targets specifically bind deregulated E2F and
not physiologically activated E2F. (4) Unlike typical E2F targets, promoters of atypical E2F targets are not under repres‐
sion of RB and are specifically activated by deregulated E2F activity.
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4. Regulatory mechanism of promoters is different between typical E2F targets and atypi‐
cal E2F targets. Promoters of typical E2F targets are repressed by E2F/RB complex.
Growth stimulation inactivates RB and releases promoters from the repression by RB.
Thus, so-called activation of typical E2F targets by physiological E2F is ‘release from re‐
pression by RB’. In contrast, activation of atypical E2F targets by deregulated E2F is lit‐
erally ‘activation’. Mutation of EREA, EREK or ERE73s in corresponding full-length
promoter did not enhance basal promoter activities, indicating that these three promot‐
ers are not under repression through the E2F responsive elements. This is consistent
with the observation that binding of physiological E2F to promoters of atypical E2F tar‐
gets was not observed in ChIP assay, including repressor type E2F4 (Figure 9).
It  is  generally accepted that  the amount of  free E2F is  important for differential  regula‐
tion of E2F targets,  which have opposite roles in cell-fate determination, as proposed as
threshold model [100].  According to this model,  when the amount of free E2F (released
from repression of  RB)  is  below the  threshold,  E2F activates  only  growth-related target
genes.  When  the  amount  of  free  E2F  exceeds  the  threshold,  E2F  activates  not  only
growth-related targets but also pro-apoptotic targets.  However,  molecular mechanism of
how different amount of free E2F differentially regulates target genes is not yet elucidat‐
ed. The ‘quantitative’ difference of free E2F seems not sufficient to explain the four differ‐
ences between deregulated E2F and physiologically activated E2F. The above-mentioned
differences strongly suggest the presence of qualitative difference between physiologically
activated E2F by ‘temporal  release’  from RB and deregulated E2F induced by ‘dysfunc‐
tion’ of the RB pathway [75-77] (Figure 9). The ‘qualitative’ difference between both of the
E2Fs seems to be a useful cue to elucidate how cells discriminate oncogenic growth stim‐
ulation from physiological growth stimulation.
5. Conclusion and further research
Accumulating evidence indicates that E2F plays essential roles in cell-fate determination, to
grow, stop or die. Together with G1/S gatekeeper RB, E2F governs control of the restriction
point, deciding whether to grow or not. Upon normal growth stimulation, physiologically acti‐
vated E2F facilitates cell proliferation. Upon dysfunction of the RB pathway, deregulated E2F
suppresses cell growth by inducing p27Kip1 to restrain cells from aberrant cell growth. p21Cip1, in‐
duced by p53 through activation of the ARF gene, may also contribute to suppression of cell
growth. When the arrest mechanism failed to stop the aberrant cell cycle progression, E2F indu‐
ces apoptosis through activation of p53 and TAp73 to protect cells from tumorigenesis. E2F
seems to sense and discriminate between normal growth signals and abnormal growth signals
originating from various oncogenic changes, asking cells whether to grow, stop or die.
Deregulated E2F activity specifically exists in cancer cell lines but not in normal growing fi‐
broblasts, suggesting that deregulated E2F activity may be a useful means to discriminate
abnormally growing cancer cells from physiologically growing normal cells. Since the gen‐
eration of deregulated E2F activity is expected to be based on the mechanism of oncogene‐
sis, deregulated E2F activity could be a universal marker to discriminate cancer cells from
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normal growing cells. Analyses of atypical E2F targets suggest that deregulated E2F might
be qualitatively different from physiologically activated E2F. One of the most intriguing is‐
sues in the future studies would be the molecular nature of deregulated E2F. By elucidating
the molecular nature of deregulated E2F, we might be able to specifically approach cancer
cells without affecting normal growing cells. For this purpose, qualitative difference be‐
tween deregulated E2F and physiological E2F is eager to be elucidated.
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1. Introduction
Cancer is one of the most serious diseases around the world and it is the third leading cause
of death, exceeded only by heart and infectious diseases [1]. There are five major steps for
cancer development: initiation, promotion, malignant conversion, progression, and metastasis
[2]. Cancer is result of process, where somatic cells mutate and escape the controlled balance
of gene expression and cellular networks that maintain cellular homeostasis, which normally
prevent unwanted expansion. Perturbations in these pathways results in cellular transforma‐
tion, where cancer cells differ from their normal counterparts in many characteristics, as is loss
of differentiation, increased invasiveness, and decreased drug sensitivity [3-4]. There are six
primary hallmarks of cancer: unlimited cell proliferation, autonomous growth without the
need of external signals, resistance to growth inhibitory signals, escape from apoptosis the
ability to recruit new vasculature and increased tissue invasion and metastasis [5]. The
formation of cancer is therefore fundamentally genetic and epigenetic disease requiring
accumulation of genomic alterations to inactivate tumour suppressor and activate proto-
oncogenes [6]. These results in combined interaction of both tumour suppressors, that are not
able to inhibit tumour development and protect cells against mutation that initiate transfor‐
mation, and cancer inducers, which promotes cancer development as initiators of cellular
transformation. When cells exhibit abnormal growth and loss of apoptosis, it usually results
in cancer formation [2].
Genetic studies have revealed the mutational and epigenetic alterations of protein-coding
genes that control DNA damage response, growth arrest, cell survival and apoptotic pathways
[4]. Until recent years ago, the central dogma of molecular biology was that genetic information
is stored in protein-coding genes with RNA as an intermediate between DNA sequence and
its encoded protein [7]. Recent studies suggest that advanced stages of cancer are possessing
more severe molecular perturbations and that this could be due to function of non-coding
RNAs (ncRNAs), which were previously known only to have infrastructural functions (as
© 2013 Boštjančič and Glavač; licensee InTech. This is an open access article distributed under the terms of
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ribosomal RNA, transfer RNA, small nuclear and nucleolar RNA). Eukaryotic genomes are
extensively transcribed into thousands of long and short ncRNAs, which are group of
endogenous RNAs that also function as regulators of gene expression. They are involved in
developmental, physiological as well as pathological processes [7,8].
However, in this review, the following characteristics of ncRNA in human cancers will be
summarized: (i) the current understanding of the critical role that lncRNAs and miRNAs may
play in cancer as tumour suppressors; (ii) outline current knowledge about some specific
lncRNA and miRNAs and their target genes in cancer; (iii) highlight their potential as bio‐
markers for patho-histological subtype classification; and (iv) highlight their potential as
biomarkers and as circulating biomarkers and therapeutic targets in cancer.
Since the majority of research regarding regulatory ncRNAs as tumour suppressor was
performed on miRNAs and in lesser extend on lncRNAs/lincRNAs, will this review further
focused on these two groups of ncRNAs.
2. Brief overview of non-coding RNAs (ncRNAs)
Classification
Of transcribed eukaryotic genomes, only 1-2 % encode for proteins, whereas the vast majority
are ncRNAs that are in more or less functional transcripts. The regulatory ncRNAs are
important regulators of gene expression in many eukaryotes and are involved in a wide range
of functions in eukaryotic biology [8,9].
Based on their function, ncRNAs can be divided into two groups. First is infrastructural group,
with ribosomal RNAs (rRNAs), transfer RNAs (tRNAs), small nuclear RNAs (snRNAs) and
small nucleolar RNAs (snoRNAs). Second is regulatory group, with microRNAs (miRNAs),
piwi-interacting RNAs (piRNAs), small-interfering RNAs (siRNAs), long non-coding RNAs
(lncRNAs), large intergenic non-coding RNAs (lincRNAs), promoter-associated small RNAs
(PARs), repeat-associated short interfering RNAs (rasiRNAs) and enhancer RNAs (eRNAs)
[8,9]. Recent findings suggest that some structural ncRNAs (e.g. snoRNAs) not only have
infrastructural function but have regulatory as well [8].
Based on length, the regulatory ncRNAs can be divided in two groups: larger than 200
nucleotides (nt) are lncRNA, lincRNA, eRNA, whereas the others are smaller than 200 nt, with
exception of PARs that are 16-30 nt long or up to 200 nt. Distinct classes of small RNAs are
distinguished by their origins, and these are: snRNAs, snoRNAs, miRNAs, piRNAs, siRNAs,
and rasiRNAs [8,9].
miRNAs and snoRNAs share similarities in processing pathways and protein interaction
partners, genomic organization and location, as well as levels of conservation. However,
similarities in sub-cellular localization have been also observed, since large proportion of
human mature miRNAs have been detected in the nucleus as well as a subset of small RNAs
derived from snoRNAs have been detected in the cytoplasm [10].
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Functional role
The most widely studied and characterized of all the regulatory ncRNAs are miRNAs. The
roles of regulatory ncRNAs, other than miRNAs, in the mediating transcriptional regulation,
chromatin remodelling, post-transcriptional regulation, and other processes are less well
understood. The contexts of gene regulation by ncRNAs in non-human systems provided
insights into how these processes could function in human cells. Regulatory ncRNAs are
involved in diverse cellular pathways, such as development and stem cell maintenance,
response to stress and environmental stimuli, regulating chromatin structure and remodelling,
chromosome architecture and genome integrity, transcription (positive or negative impact),
and post-transcription processing (splicing, transport) and most commonly mRNA stability
(translation, degradation) [8,9]. Some ncRNAs trigger different types of gene silencing that are
collectively referred to as RNA silencing or RNA interference [11].
RNA interference (RNAi)
RNAi is RNA-guided regulation of gene expression, historically known by other names,
including post-transcriptional gene silencing. It is believed to be an evolutionary conserved
mechanism in response to presence of foreign dsRNA in the cell. A key step in this silencing
pathway is the processing of dsRNAs into short RNA duplexes of characteristic size and
structure. The enzyme Dicer, which initiates the RNAi pathway, cleaves dsRNA to short
double-stranded fragments of 20–25 base pairs (bp), named siRNAs. siRNAs usually possess
perfect complementarity to the mRNA of target gene, thus causing its degradation. When the
dsRNA is exogenous, coming from infection by a virus with RNA genome or laboratory
manipulations, the RNA is imported directly into the cytoplasm where it is cleave by the Dicer.
On other hand, the initiating dsRNA could be result of endogenously expressed RNA-coding
genes from the genome. Some of small regulatory RNAs are processed in a similar way or with
components of RNAi pathway [11].
2.1. Brief introduction to miRNAs
Genomic organization
miRNAs are endogenously expressed small (~22 nt), single-stranded ncRNAs. It is predicted
that they constitute ~1-5 % of human genes [1,12] and in an update from August 2012, miRBase
v19 was released with a list of 2019 unique mature human miRNAs. miRNAs are encoded as
a single gene or gene clusters, with some of miRNA clusters being co-regulated and co-
transcribed. Intergenic miRNAs are transcribed as an independent transcription unit, as a
monocistronic, bicistronic or polycistronic primary transcripts [13]. Up to 60 % of currently
known miRNAs are proposed to be from intronic sequences of either protein coding or non-
coding transcription units and suggestion has been made that some miRNAs are also encoded
in antisense DNA, which is not transcribed to the mRNA. Intronic miRNA are preferentially
transcribed in the same orientation as the host gene and are together with their host transcripts
co-regulated and co-transcribed from the same promoter. They are processed from introns, as
are many snoRNA. Within the genome, there might be more than one copy of particular
miRNA [13,14].
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Biogenesis
miRNAs expression is determined by intrinsic cellular factors and diverse environmental
variables  [1].  As  for  protein-coding  genes  it  is  known,  that  regulation  of  miRNA tran‐
scription  and  expression  depends  on  transcription  factors  and  epigenetic  mechanisms
(e.g. p53, Myc, and myogenin). In general, from genes encoding miRNAs is transcription
guided by RNA-polymerase II (Pol II). Resulting primary transcript (several hundred bas‐
es  to  several  kilobases),  named  pri-miRNA,  forms  distinctive  hairpin-shaped  stem-loop
secondary  structure  and  contains  poly-A  tail  and  a  cap,  similarly  to  protein-coding
mRNA. pri-miRNA  is processed in the nucleus by Drosha, an RNase III enzyme. The re‐
sulting 70-nt stem-loop structure called pre-miRNA  with a 5' phosphate and 3' 2-nt over‐
hang  is  imported  into  the  cytoplasm by  a  transporter  protein,  Exportin  5.  The  double-
stranded RNA portion of  pre-miRNA  is  bound and cleaved by Dicer,  another  RNase III
enzyme,  which produces a  miRNA:miRNA* duplex (a  transient  intermediate in miRNA
biogenesis,  20–25 nt).  One of the two strands of each fragment is together with proteins
argonaute  (Ago),  incorporated  into  a  complex  called  the  miRNA-containing  ribonucleo‐
protein complex (miRNP).  It  is  believed that the guide strand  is  determined on the basis
of the less energetically stable 5' end. The resulting complex base-pair with complementa‐
ry  3'-UTR  mRNA  sequences.  The  other  strand,  miRNA*  is  presumably  degraded,  al‐
though there are increasing evidence that either or both strands may be functional [2,9].
The schematic overview of canonical miRNA biosynthesis pathway has been represented
elsewhere [15].
Numerous  alternative  pathways  differing  from  canonical  miRNA  biogenesis  pathway
have been described recently and subset of several diverse longer non-coding RNAs can
serve as precursors for miRNAs [10,16]. As an example, intronic miRNAs presumably by‐
pass  Drosha  cleavage,  since  through  pre-mRNA  splicing/debranching  machinery  is  pro‐
duced  an  approx.  60-nt  hairpin  precursor  miRNA  (pre-miRNA)  that  enter  biogenesis
pathway at the step of Exportin 5 [14]. However, some of the post-transcriptional mecha‐
nism include miRNA editing, which is mechanism mediated by adenine deaminase of al‐
teration of  adenines to  inosines,  and not  yet  thoroughly studied regulations of  miRNA,
such as export step from nucleus or miRNAs turnover rate [17].
miRNAs mechanism
The functional role of miRNA varies, but the primary mechanism of miRNA action in
mammals is believed to be base-pairing to 3'-UTR of target mRNA followed by inhibition of
mRNA translation (when base pairing between these two molecules is incomplete) or deade‐
nylation and degradation (perfect complementarity of miRNA:mRNA binding) [9]. Especially
in animals, the primary mechanism of miRNA action is reducing mRNA translation and each
miRNA can inhibit the translation of as many as 200 target genes. In addition, mRNA can be
regulated by more than one miRNA. The cooperative action of multiple identical (multiplicity)
or different miRNPs (cooperativity) appears to provide the most efficient translational
inhibition. Additional mechanism to increase the specificity of miRNAs is combinatorial
control of gene expression, which may be also provided by a set of co-ordinately expressed
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miRNAs. Proteins or mRNA secondary structures could restrict miRNP accessibility to the
UTRs, or may facilitate recognition of the authentic mRNA targets [12,13,18,19].
There is the prospect that some miRNA might specify more than just post-transcriptional
repression [9,13]. miRNAs may also target promoter to regulate transcription through
epigenetic mechanism. miRNAs have been paradoxically also shown to up-regulate gene
expression by enhancing translation under specific conditions [9].
Biological function
Translational repression, as major mechanism of miRNAs, may in normal cell conditions occur
in different ways: as switch off the targets, that is for mRNAs that should not be expressed in
a particular cell type, the protein production is reduced to inconsequential levels; as fine-tuners
of target expression, that is when miRNAs can adjust protein output for customized expression
in different cell types; as neutralizers of target expression, that is when miRNAs act as
bystanders, where down-regulation by miRNAs is tolerated or reversed by feedback processes
[13]. Role of miRNA can be further divided in three paradigms: combinatorial control (defined
as cooperativity), cell-to-cell variation, specific (tissue-specific and/or cell-type specific) and
housekeeping functions [20].
Despite the large number of identified miRNAs, the scope of their roles in regulating cellular
gene expression is not fully understood [11]. It is believed that miRNAs through negative gene
regulation influence at least 50 % of genes within the human genome [9]. Expression profiling
of many miRNAs in various normal and diseased tissues have demonstrated unique spatial
and temporal expression patterns. Many miRNAs are important at distinct stages of develop‐
ment and have been found to regulate a variety of physiological and pathological processes
[11]. miRNAs are involved in a numerous biological processes, such as stem cell division and
developmental timing, proper organ formation, embryonic pattering and body growth,
proliferation and differentiation, apoptosis, epithelial-mesenchymal-transition (EMT),
cholesterol metabolism and regulation of insulin secretion, resistance to viral infection and
oxidative stress, immune response etc. [2,11]. All these effects may occur by regulating or being
regulated by the expression of signalling molecules, such as cytokines, growth factors,
transcription factors, pro-apoptotic and anti-apoptotic genes [21]. With all different genes and
expression patterns, it is reasonable to propose that every cell type at each developmental stage
might have a distinct miRNA expression profile.
Defining miRNA targets and databases
Up  to  date,  over  2000  human  miRNAs  have  been  identified  and  this  number  is  still
growing. All  annotated miRNAs are collected in miRBase [22].  The first  step in miRNA
target identification is usually defining reciprocally regulated miRNA-mRNA or miRNA-
protein. Since miRNAs target mRNA mainly by incomplete base-pairing, many computa‐
tional  methods  have  been  recently  developed  for  further  identifying  potential  miRNA
targets [23].  Most of  these methods search for three criteria in predicting miRNA target
genes:  first,  multiple  conserved  regions  of  miRNA  complementarities  within  3'-UTR  of
target mRNA (evolutionary conservation); second, interaction between seven consecutive
nucleotides in the target mRNAs 3'-UTR and the 1-8 nt (“seed sequence”) at the 5' miR‐
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NA end; third, stability of base pairing and predicted binding energy. Further complicat‐
ing  target  site  prediction  in  mammals  is  the  fact  that  not  all  3'-UTR sites  with  perfect
complementarities to the miRNA seed nucleotides are functional. Moreover, mRNAs sites
with  imperfect  seed  complementarities  can  themselves  be  very  good  miRNA  targets
[24,25].  Bioinformatics  is  therefore  much  noisier  and  more  prone  to  false  positive  and
false negative predictions. Among many available programs for predicting mRNA targets
for specific miRNA, none of these programs can be used as an independently approach
for  validating the targets,  and all  predicted targets  must  be  validated in  vitro  and/or  in
vivo.  Thus the gold standard for miRNA target identification is the experimental demon‐
stration that a luciferase reporter fused to the 3'-UTR of the predicted target is repressed
by over-expression of  the  miRNA and that  this  repression is  abrogated by point  muta‐
tion in the target sequences in 3'-UTR [26,27]. Finaly, expression profiling in human dis‐
ease  gives  the  starting point  for  target  verification/validation and association to  disease
prognosis and pathogenesis.  All  identified disease related miRNAs are listed in The hu‐
man microRNA disease database (HMDD), where you can search for specific miRNA, for
tissue expression of annotated miRNAs, and for disease related miRNAs [28].
2.2. Brief introduction to lncRNA
Genomic organization
LncRNAs are those longer than 200 nt,  and many of them can also act as primary tran‐
scripts for the production of short RNAs [9]. It is estimated that total number of lncRNA
transcripts,  including  new  unexplored,  is  approx.  15000.  Thousands  of  protein-coding
genes  in  humans  harbour  natural  antisense  transcripts  (approx.  61  % of  transcribed re‐
gions  show  antisense  transcription)  belonging  to  the  lncRNA,  and  majority  of  known
lncRNAs in some way overlap protein-coding loci.  All  these data are giving the impor‐
tance to lncRNA annotation [29].
Classification
LncRNAs can  be  classified  according  to  their  proximity  to  protein  coding genes.  There
are five categories of lncRNAs: sense, antisense, bidirectional, intronic, intergenic. Just to
mention  a  few  of  them,  lincRNAs,  a  class  of  ncRNAs,  exhibit  a  high  conservation  be‐
tween different species;  they both up- and down- regulate hundreds of gene expression
and  participate  in  the  establishment  of  cell  type-specific  epigenetic  states  [9].  Further,
ncRNAs were found expressed at enhancer regions, suggesting that some enhancer RNA
is  also  transcribed with  an average  size  of  800  nt;  these  transcripts  are  termed eRNAs.
Studies  propose  a  possible  role  for  eRNAs as  transcriptional  activators,  however,  ques‐
tion remains whether such eRNAs are in fact a subset of the activating lncRNAs. Similar
to  eRNA,  a  novel  diverse  class  of  ncRNAs  has  been  linked  to  the  promoters,  called
PARs,  ranging from 16-36 nt  to 200 nt.  It  is  suggested that  they participate in the tran‐
scriptional regulation [9].  Most lncRNAs are characterized by low expression levels,  low
level of sequence conservation, by composition of poly-A tail and without poly-A tail as
well  as by spliced and un-spliced forms. They are believed to have nuclear localization,
but can also accumulate in cytoplasm of cells [3].
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Function
lncRNAs may act through diverse molecular mechanisms, and play regulatory as well as struc‐
tural roles in different biological processes [3]. Many of the identified lncRNAs show spatial-
and temporal-specific patterns of expression. Almost every step in the life cycle of genes –
transcription, mRNAs splicing, RNA decay, and translation – can be influenced by lncRNAs.
Generally lncRNAs have been implicated in gene-regulatory roles, such as chromatin dosage-
compensation, imprinting, epigenetic regulation, cell cycle control, nuclear and cytoplasmic
trafficking, cell differentiation etc. [7]. A number of studies suggest that lncRNAs are key com‐
ponents of the epigenetic regulatory network [4]. Two general modes of lncRNAs regulation
seem to be important: interaction with chromatin remodelling complexes that promote silenc‐
ing of specific genes; and modulation of splicing factors. Chromatin remodelling guided by
ncRNAs contributes to the establishment of chromatin structure and to the maintenance of epi‐
genetic memory. Various ncRNAs have been identified as regulators of chromatin structure
and gene expression [30]. Additional mechanisms of action are yet to be revealed [3].
Database
The lncRNA database provides sequence, structural, and conservation evidence for multi-
species lncRNAs, together with a list of lncRNAs that are experimentally known to interact
with coding mRNAs, harbouring other short ncRNAs and other characteristics of specific
lncRNA [29].
3. Involvement of ncRNA in cancer
Three major mechanisms are known to give rise to deregulated ncRNAs function, genetic
alterations, epigenetic alterations, and in case of miRNAs, an aberrant miRNA biogenesis
machinery. Since brief overview of first two mechanisms is described below, will be here
mentioned only aberrant machinery of miRNA processing. Proteins involved in miRNA
biogenesis (Drosha, Dicer, Ago) are deregulated in several cancers. Co-factors involved in
miRNA biogenesis can be mutated causing consequently deregulation of Dicer; Exportin 5,
mediating pre-miRNA nuclear export, is often mutated and truncated, leaving pre-miRNAs
within nucleus [31,32].
3.1. Mutations, SNPs and epigenetics of ncRNAs
Cancer cells have different genetic and epigenetic changes from their normal counterparts and
the role of ncRNAs in mediating these differences is beginning to emerge. Specific genetic
polymorphisms are associated with the risk of developing several types of cancer [7-9].
Multiple studies have identified small-scale and large-scale mutations and genomic alterations
affecting also noncoding regions of the genome. Some of these mutations are structural
alterations, rearrangements and chromosomal translocation, amplification, loss of heterozi‐
gocity and copy-number variation, nucleotide expansion, and single-nucleotide polymor‐
phisms (SNPs), and they are linking distinct types of mutations in ncRNA genes with diverse
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diseases [7]. First, lncRNA have already been implicated in human diseases such as cancer and
neurodegeneration [33]. Second, approx. half of miRNA genes are encoded in genomic region
prone to cancer-associated rearrangements or in fragile chromosomal sites (amplified, deleted
or rearranged) that are often associated with cancer, such as ovarian and breast carcinomas,
and melanomas [8,11]. Third, presence of SNPs in miRNAs, where disruption of miRNA target
interaction either in the miRNA gene or its target site (3′-UTR mRNA) can lead to complete
gain or loss of the miRNA function or target gene thus causing disease [34,35]. In contrast to
the miRNA target sites in mRNA transcripts, where the potential of variation is huge, variants
identified in miRNA precursor sequences tend to be rarer [36]. The presence of SNPs in pri-
miRNA or pre-miRNA can in addition affect the processing of miRNAs, their expression
and/or binding to target mRNA [27,37]. Forth, recent advances in miRNA research have
provided evidence of a miRNA association with epigenetic mechanisms activated in diseased
human tissues [38]. Heritable changes in gene expression that do not involve coding sequence
modification are referred as epigenetics. Gene regulation by ncRNAs was considered as an
epigenetic mechanism, but ncRNAs can be regulated by the same mechanism in which they
participate [39]. DNA methylation, one of the two major epigenetic mechanisms, leads to gene
silencing, and serves as an alternative mechanism of gene inactivation. The aberrant DNA
methylation of gene promoters has been shown to result in the inactivation of tumour
suppressor genes [40]. For an example, miR-34 family is a family of tumour suppressors’ genes,
with miR-34a being deregulated by DNA methylation in both epithelial and haematological
cancers. miR-34 is an important component of the p53 tumour suppressor network, and p53 is
a predicted target for members of the miR-34 family. miR-34a reinforces the tumour suppressor
function of p53, transactivation of miR-34a by p53 was also shown to promote apoptosis
[11,41-44]. Another example is that miR-29s could target two enzymes of methylation process,
DNMT3A and DNMT3B [39]. Antisense ncRNAs have been recently showed to be implicated
in the silencing of tumour suppressor genes through epigenetic remodelling events [30]. All
these miRNAs abnormalities suggest that they play a broad role in cancer pathogenesis.
3.2. Promising role of ncRNAs in cancer: As cancer-subtype classifiers and detection in body
fluids
ncRNAs have been recognized as gene-specific regulators. They are similar in activity to a
large number of protein transcription factors that are known to be critical in the transformation
of cells to a malignant state. Majority of research has been involved in defining the role of
miRNAs in cancer; however, lincRNAs have been shown to play role in tumour development
by promoting the expression of genes involved in metastasis and angiogenesis [9]. Genome-
wide analyses have shown that ncRNAs have distinct signatures specific for a certain cancer
type. Importance of combining ncRNAs with other biomarkers for cancer detection and
prognosis would improve cancer risk assessment, detection, and prognosis. Thus, there is a
need to combine genomic mutations with ncRNA markers to develop marker panels for more
accurate risk assessment and early diagnosis [7-9].
Most cancers are diagnosed in advance stages, leading to poor outcome. Intense investiga‐
tion is going on seeking specific molecular changes that are able to identify patients with
early cancer or precursor lesions [1]. Genome-wide expression profiling has examined miR‐
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NAs in preneoplasia or their usefulness to predict progression from preneoplasia to cancer.
Several lines of evidence suggest the potential usefulness of ncRNAs, particularly miRNAs:
first, as signature of early events in carcinogenesis and as biomarkers in early cancer detec‐
tion, second, as differential indicators of benign tumours, preneoplasia, and neoplasia, and
third, that miRNAs and perhaps other ncRNAs might be useful in determining which pre‐
neoplastic lesions are likely to progress to cancer. Distinguishing benign diseases and cer‐
tain non-precancerous lesions from precancerous lesions and metastatic tumours would
improve patient outcomes, survival, and reduce patient discomfort [45]. Characterization of
ncRNAs involved in the development or maintenance of oncogenic states may therefore de‐
fine ncRNAs as early biomarkers for the emergence of cancer, and could have have an im‐
pact on the development of tools for disease diagnosis and treatment [30].
miRNAs are believed to be promising potential biomarkers for cancer diagnosis, prognosis
and targets for therapy. As potential markers for diagnosis are better classification factors
than mRNAs. miRNAs seems to be evolutionarily selected gene regulatory molecules, their
expression profiles might therefore be rich in gene regulatory information. Only small per‐
centage of the 16000 genes on the mRNA-expression arrays are regulatory molecules. This
difference may be responsible for more efficient microRNA expression arrays in classifying
cancer than mRNA-expression arrays [21,45,46]. Some of the key features of miRNAs that
make them useful as potential biomarkers can be briefly summarized. First, expression pat‐
terns of miRNAs in human cancers appear to be tissue specific. Second, miRNA profiles ap‐
pear to reflect developmental lineage and differentiation state of the tumours. Third,
miRNAs can successfully classify poorly differentiated tumours with high accuracy (~70 %).
In contrast, mRNA profiles in the same set of specimens had an accuracy of only 6 %. There‐
fore, a combination of both miRNA and mRNA profiling data has the potential of enhancing
accuracy of tumour classification. Forth, miRNAs can also be profiled and quantitatively
measured in formalin-fixed paraffin-embedded tissues. And last, miRNAs are stable in hu‐
man body fluids of plasma and serum and can be quantitatively measured in microliter
quantities of human sera or plasma using qPCR. [45-47].
Highly stable cell-free circulating nucleic acid (cfCNA), both RNA and DNA, has been dis‐
covered in the blood, plasma, and urine in humans. Since there is good correlation between
tumours and genetic, epigenetic and/or transcriptomic changes and alterations in cfCNA
levels, it gives a usefulness of cfCNA as biomarkers for clinical applications. Release of
cfCNA in body fluids is probably related to apoptosis and necrosis. Circulating RNAs are
stable in serum and plasma in spite of high amounts of RNAase in blood of cancer patients
[48]. They are packed in microparticles, of which the most analyzed are in recent years exo‐
somes [3,49,50]. Tumour derived exosomes are small membrane vesicles of endocytic origin
released by the tumour and found in peripheral circulation. Several recent reports showed
that exosomes could be an important resource of cf-lncRNA/cf-miRNA in serum or plasma
[51]. Small size, relative stability and resistance to RNAase degradation make the miRNAs
more superior molecular markers than mRNAs [1]. Using non-invasive diagnostic proce‐
dures, the extraction and reliable determination of cf-miRNAs, circulating in body fluids
like plasma, serum, and others, could serve as circulating tumour biomarkers [52,53].
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LncRNAs show greater tissue specificity compared to protein-coding mRNAs, making them
attractive in the search of novel diagnostics and/or prognostics cancer biomarkers in body fluid
samples. For an example, lncRNA PCA3 was initially identified as over-expressed in prostate
tumours relative to benign prostate hyperplasia and normal epithelium. It was latter showed
that is very specific prostate cancer gene, whose mechanism is not yet identified, but it can be
detected in urine samples and has been shown to improve diagnosis of prostate cancer [3].
3.3. ncRNAs can act as both tumour suppressor genes and oncogenes
There are different ways in which miRNAs appear to be involved in cancer:  as tumour
suppressors,  as oncogenes,  or as agents involved in affecting genome stability.  Below is
discussed role of miRNAs acting both, as tumours suppressor and as oncogenes, since are
much more investigated in this field than are lncRNAs. Care must be taken in assigning
oncogenic or tumour suppressor activity to a miRNA, since miRNA expression patterns
are highly specific for cell-type and cellular differentiation status.  The same miRNA can
function as  tumour suppressor  in  one cell  type and as  potential  oncogene in  other  cell
type. Some of the aberrant miRNA expression observed in tumours may also be a secon‐
dary  consequence  of  the  loss  of  normal  cellular  function  that  accompanies  malignant
transformation. Up- or down-regulation of a miRNA in a given tumour type is not obvi‐
ous a causative role in tumorigenesis [6].
The increased expression of oncogenic miRNAs appears to act in a manner analogous to an
oncogene. Over-expression of oncogenic miRNAs are presumed to function by down-
regulating the levels of protein product of target tumour suppressor gene or by reduction of
tumour suppressor processes, such as apoptosis [2,6,20]. A loss of expression of tumour
suppressor miRNA may lead to elevated levels of the protein products of target oncogenes [6],
activation of an oncogenic processes, such as proliferation [2,20]. MicroRNAs with anti-
proliferative and pro-apoptotic activity are likely to function as tumour suppressors and thus
may be under-expressed in cancer cells. Figure 1 represents schematic overview of miRNAs
acting as tumour suppressors or oncogenes in comparison to non-cancerous cells.
There should be at least four type of evidence before assigning tumour suppressor function to
ncRNAs: (i) data about widespread deregulation in diverse cancer, (ii) gain or loss of function
in tumours owing to deletion, amplification or mutation, (iii) direct documentation of tumour
suppressing activity using cell line or animal models, (iv) the identification and verification of
cancer relevant targets that define mechanisms through which miRNAs participate in onco‐
genesis [6].
4. ncRNAs as potential therapeutic targets in cancer
4.1. RNAi in therapeutic applications
Using RNAi approaches, ncRNAs may in future serve as therapeutic targets. For ncRNA that
is under-expressed and possess tumour suppressor function, re-introduction of the mature
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Figure 1. Schematic overview of miRNAs acting as tumour suppressors or oncogenes.
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ncRNA into the affected tissue would restore the regulation of the target gene. By contrast,
over-expressed ncRNA with oncogenic function could be down-regulated by reducing mature
ncRNA level by its direct targeting [54].
Due to the interferon response it is difficult to introduce long dsRNAs into mammalian cells,
however, the use of RNAi as a therapeutic approach has been successfully used. Among the
first applications to reach clinical trials were in the treatment of macular degeneration and
respiratory syncytical virus infection, reversal of induced liver failure in mouse models,
antiviral therapies, neurodegenerative diseases, and cancer. Cancer was treated by silencing
up-regulated genes in tumour cells or genes involved in cell division. A key area of research
in the use of RNAi for clinical applications is the development of a safe delivery method, which
to date has involved mainly viral (lentivirus, adenovirus, adeno-associated virus) and non-
viral (nanoparticles, aptamers, stable nucleic-acid-lipid particle, e.g.) vector systems similar to
those suggested for gene therapy [55].
4.2. ncRNAs with tumour suppressor function as therapeutic targets
Replenishing small RNAs/miRNAs
Pharmacological manipulation of miRNAs is still  in its infancy; however, the correlation
between the expression of miRNAs and their effects on target oncogenes, on tumorigene‐
sis, and on the proliferation of cancer cells has gained experimental support. miRNAs are
small  molecules,  making their  in vivo  delivery feasible.  It  has been shown that miRNAs
can  be  delivered  systematically,  and  can  reduce  invasion,  proliferation  and  growth  as
well as induce radio-sensitivity and resistance. miRNAs may therefore serve as therapeu‐
tic targets in the future.
For miRNA that is under-expressed, re-introduction of the mature miRNA into the affected
tissue would restore regulation of the target gene. For this purpose, artificial miRNA (miRNA-
mimic) have been developed to enhance the expression of beneficial miRNAs or the introduc‐
tion of short hairpin duplex, similar to pre-miRNA, into the cell. This suggests that individual
miRNAs are potential therapeutic agents, provided that their expression or delivery can be
targeted to appropriate tissue. Most of the developed protocols have used local administration
in easily accessible tissue; systemic delivery has also give some promising results; the major
challenge remains tissue and cell-type specific targeting [56].
miRNA mimic can only last a couple of days and the long term biological effects were not
observed very effectively. To overcome this, the cells were infected with a lentivirus that
expressed mature miRNAs. This generated stable cell expressing miRNAs. miRNA mimics
and lentiviral miRNAs showed great potential in restoring tumour suppressor miRNAs.
However, viral and non-viral delivery systems have been developed. Viral vector-directed
methods show high gene transfer efficiency, but have some limitations. However, non-viral
gene transfer vectors have been also developed: cationic liposome mediated gene transfer
system, lipoplexes, neutral lipid emulsion, etc. [57].
Expression  of  miRNA-mimic  would  simultaneously  suppress  many  gene  targets.  miR‐
NAs-mimic would be useful in conjunction with standard chemotherapy or radiotherapy,
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by influencing drug resistance or enhancing responsiveness to therapy. Current limitation
is need for improvement of efficiency of delivery to target tissue,  for systemic drug ad‐
ministration,  potential  inhibition  of  non-target  genes  (“off-target  effect”),  redundancy
among miRNAs efficacy, potential toxicity and immunogeneic responses. However, stud‐
ies  introducing  miRNAs  strategies  to  inhibit  cancer  propagation  in  animal  models  are
showing promising results [32].
Examples for miRNA
Therapeutic delivery to animal models was demonstrated using miRNA-mimics of the tumour
suppressor miRNAs, miR-34a and let-7a, both of which are often down-regulated or lost in lung
cancer. It has been shown that re-introduction of let-7 directly represses cancer growth in the
lung [58] and that development of chemically synthesized therapeutic miR-34a and lipid-based
delivery vehicle block tumour growth in mouse models of non-small-cell lung cancer (NSCLC)
[59]. Systemic treatment of these mice led to significant decrease in tumour burden. Mice
treated with miR-34a displayed a 60 % reduction in tumour area compared to mice treated with
a miRNA control. Similar results were obtained with the let-7 mimic [60].
Targeting lncRNAs
Successful inhibition of lncRNAs seems to be more difficult than inhibition of miRNAs. Our
growing knowledge of other ncRNAs might exploit in future to develop new therapeutic
strategies not only against cancer, but also for other diseased states. The findings regarding
lncRNA and Alzheimer disease are attracting the attention of pharmaceutical and biotechnol‐
ogy industries [8]. Therapy using small RNAs that targets ncRNA transcripts, such as eRNAs
or PARs, may represent a new way to treat disease conditions caused by epigenetic changes [9].
Targeting both, lncRNAs and miRNAs
Another possible approach for manipulation of ncRNAs level may also be by altering DNA
methylation. As mentioned above, DNA methylation is a crucial mechanism associated with
epigenetic regulation. It has been shown that in cancer cells treated with DNA demethylating
agent reactivation of certain miRNAs occurs [40]. ncRNAs mediated therapy may also be
useful in combination with DNA methyltransferase inhibitors that are other way toxic [39].
5. ncRNAs as tumour suppressor in different types of cancers
5.1. miRNAs as tumour suppressors
In the following section, down-regulated miRNAs will be describe and miRNAs with sug‐
gested tumours suppressive roles in different types of cancer. However, down-regulation does
not ncessary mean that miRNA is tumours uppressor.
Hematological cancers
Leukaemia. Chronic lymphocytic leukaemia (CLL) is characterized by overexpression of the
protein Bcl-2 in B cells and represents the most common human leukaemia. In less than 5 %
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of cases, over-expression of Bcl-2 is due to a translocation of the Bcl-2 gene, whereas for the
majority of CLL cases no explanation for the deregulation of Bcl-2 has been reported. It has
been demonstrated that mutations in genomic regions containing miRNAs were associated
with disease progression in a number of CLL patients. In this type of cancer, miR-15 and miR-16
expression is often reduced and indeed, one of the first associations between miRNAs and
cancer development was observed for miR-15 and miR-16 in CLL [46]. Both miRNAs are located
in a 30 kb region on chromosome 13 that had been found deleted in more than half of B cell
CLL (chromosome 13q14 deletion) [8,46], and miR-15a and miR-16-1 have been shown to be
deleted or translocated in approx. 65 % of CLL patients [2,11]. Several papers indicate that
miRNA regulates cell growth and apoptosis. Indeed, over-expression of miR-15 and miR-16
directly inhibit anti-apoptotic Bcl-2, a key player in many types of human cancers, and thus
activate apoptotic processes [2,11]. However, it was further demonstrated that other mutations
in miRNA genes are frequent in CLL; many mutations were located in the flanking sequence
of pre-miRNA, thus cell culture assay indicated that a point mutation of the miR-16-1 precursor
abolishes expression of mature miR-16 [21]. Few other miRNAs were also recognized as
tumour suppressors in CLL. miR-29a and miR-29b are associated with fragile site FRA7H that
is not associated with any known tumour suppressor gene. Over-expression of miR-29b may
target TCL1 and reduces anti-apoptotic Mcl-1 protein in CLL patients [11]. Another well-
known tumour suppressor was analysed. Low expression of miR-34a in CLL was found to be
associated with p53 inactivation, impaired DNA damage response, apoptosis resistance and
chemotherapy-refractory disease irrespective to p53 mutation (cases with CLL with p53
mutation are resistant to chemotherapy). It was latter showed that miR-34a is induced by p53.
In another type of leukaemia, particularly acute myeloid leukaemia, an inverse correlation
between miR-34b and CREB expression has been observed. After restoring expression of
miR-34b, cell cycle abnormalities, reduces growth and altered CREB expression has been
observed, suggesting tumour suppressor potential of this miRNA [47].
Lymphoma.miR-142 gene was found at the junction of the t(8;17) translocation, which may
contribute to the progression of an indolent lymphoma into aggressive B-cell leukaemia [21].
Breast cancer
Breast cancer is one of the most important cancers in adult females. miR-125b, miR-145, miR-21
and miR-155 were significantly reduced in breast cancer tissue and this expression was
correlated with specific breast cancer pathologic features, such as tumour stage, proliferation,
oestrogen and progesterone receptor expression, and vascular invasion. Some of these
miRNAs act as oncogenes (e.g. miR-21) in many cancer types, so it is suggested that some
miRNAs act as tumour suppressors in one cancer type and as oncogenes in another [2].
miR-125b-1 is located on a fragile site on chromosome 11q24, which is deleted in a subset of
patients with breast cancer [61]. Down-regulation of mir-221 in breast cancers was detected,
whereas germ line mutation in mature miR-125a is highly associated with breast cancer
tumorigenesis, suggesting its tumour suppressor role. miR-125a is also down-regulated in
human breast cancer and when over-expressed post-trancriptionally regulates CYP24 result‐
ing in an anti-proliferative effect. Ectopic expression of miR-30e suppresses cell growth in
breast cancer, probably through targeting Ubc9 [47]. miR-17-5p was down-regulated in breast
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cancer cells, and enhanced expression decreased tumour cell proliferation [11]. Cyclin D1 has
been identified as a direct target for miR-17/20 that functions to suppress proliferation of breast
cancer cells. Additional miRNAs have also been shown to be down-regulated and have tumour
suppressor function in other types of cancer: let-7, miR-145, miR-34a, miR-214, and miR-205.
MicroRNAs, miR-31, miR-126, miR-146a/b, miR-206 and miR-335 have been shown as anti-
metastatic miRNAs [62,63].
Colorectal Cancer (CRC)
Colorectal cancer is the third most commonly diagnosed cancer in the world, but it is more
common in developed countries. Also in colorectal neoplasia miRNAs expression is associated
to the tumour formation. Reduced expression of miR-143 and miR-145 have been shown to be
a frequent feature of colorectal tumours (adenomatous and cancer stage) when compared to
normal mucosa [2,6,64]. A tumour suppressive role of miR-143 has been elucidated in the
epigenetic aberration of CRC with DNMT3A as a target. Restoration of miR-143 expression in
CRC decreases tumour cell growth and down-regulates DNMT3A expression [47]. let-7 has
been implicated in development of colon cancers and progression of colorectal cancers;
together with miR-143 and miR-18a was observed to be down-regulated and target KRAS [11,
64]. miR-145 has been proposed as a tumour suppressor and it has been shown that target
IRS-1, and when over-expressed it dramatically inhibits the growth of colon cancer cells. A
ubiquitous loss of miR-126 expression in colon cancer lines was observed and its reconstitution
resulted in a significant growth reduction. Also, in a panel of matched normal colon and
primary colon tumours, each of the tumours demonstrated miR-126 down-regulation [64].
Down-regulation of miR-200 family is a hallmark of EMT as well as up-regulation of ZEB1
transcription factor, and it was shown that in colorectal cells ZEB1 directly suppress tran‐
scription of miR-141 and miR-200c [57]. It was found that miR-192 and miR-215 was down-
regulated in CRC, and their anti-proliferative effect was identified in CRC cell lines. It was
further defined that both are regulated by p53 and that their targets are a number of transcripts
that regulate cell cycle checkpoints [57]. An inverse correlation between COX-2 and miR-101
was reported in CRC cell lines, and this was further confirmed in colon cancer tissue and liver
metastases derived from CRC patients. miR-16, miR-125b, miR-31, miR-133b, and miR-96 were
along with already mentioned miRNAs showed to be down-regulated in colorectal cancer [1].
Aberrant DNA methylation may further induce silencing of specific miRNAs in CRC. While
methylation of miR-129 and miR-137 CpG islands is frequently observed in CRC, is methylation
of miR-9-1 associated with the presence of lymph node metastasis and expression of miR-9 in
CRC inversely correlated with the methylation of its promoter regions [47]. In human colon
cancer cell lines, miR-34a was showed to participate in the apoptotic program triggered by p53
activation and loss of miR-34a expression occurs frequently in cancer cells. p53 directly binds
to the genomic region defined as the miR-34a promoter with consequent miR-34a targeting
genes of cell cycle, DNA repair, mitotic checkpoint, DNA integrity checkpoint, cell prolifera‐
tion, and angiogenesis. Among the down-regulated targets of miR-34 family were well-
characterized p53 targets, such as CDK4/6, cyclin E2, E2F5, BIRC3 and Bcl-2. These effects were
nearly identical irrespective of whether miR-34a, miR-34b or miR-34c was introduced into cell
lines. Another target was identified for miR-34a, SIRT1, negative regulator of apoptosis.
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miR-34a promoter hyper-methylation was observed in 3 of 23 cases of colon cancer, miR-34b/c
were found to be epigenetically silenced in 9 of 9 cell lines and in 101 of 111 primary CRC
tumours [42,64].
Gastric cancer
Gastric cancer is the fourth most common cancer and the second leading cause of cancer death
in the world. It was reported that loss of Ago2, which leads to premature stopping of miRNAs
biogenesis and general deregulation of miRNAs expression, was observed in 40 % of human
gastric cancer patients with high microsatellite instability. A number of miRNAs were reported
to be down-regulated. Among these, miR-141 was significantly low expressed in 80 % of
primary gastric carcinoma compared to non-cancer adjacent tissue. It targets FGFR2 and its
down-regulation means proliferative potential and poor differentiation of gastric cancer cells
[65]. It appears that down-regulation of miR-451 is related to the worse prognosis of the gastric
cancer patients. Over-expression of miR-451 in gastric cancer cells regulates the oncogene MIF
production, reduces cell proliferation and increases sensitivity to radiotherapy [47]. miR-101
was down-regulated in gastric cancer cells, its targets are: EZH2, Cox-2, Mcl-1, and Fos [65].
Other potential tumour suppressor miRNAs in gastric cancer are: miR-181b/c and miR-432AS,
and for miR-181 it was proposed that modulate expression of Bcl-2. Low level or loss of
expression in gastric cancer also showed let-7a, miR-486, and miR-449. However, a proposed
role for miR-107 and miR-126 is controversial in gastric cancer, either tumour-suppressive or
oncogenic [66].
An epigenetic silencing of miR-512-5p was observed in gastric cancer cells. As its target is was
shown anti-apoptotic protein Mcl-1 and after epigenetic treatment (demethylation), it results
in apoptosis of gastric cancer cells [65].
The association between genetic  polymorphism of  miR-196a-2  and risk  of  gastric  cancer
has  been  identified;  it  was  found that  the  variant  homozygous  genotype  of  miR-196a-2
was associated with significantly increased risk of gastric cancer [65].
Pancreatic cancer
Pancreatic cancer is the eighth most common cause of cancer-related deaths worldwide and it
has a poor prognosis for all stages. It is usually diagnosed at advent stages, therefore it is an
urgent need to find some specific biomarkers and key components of carcinogenesis. Several
miRNAs were reported to suppress metastasis. In pancreatic cancer cell lines, miR-146a was
decreased compared to normal ductal epithelial cell line, and its ectopic expression inhibited
invasive capacity of pancreatic cancer cell lines. miR-96 is believed to be a potential tumour
suppressor through targeting KRAS. It is significantly down-regulated in pancreatic cancer,
its ectopic expression induces apoptosis, inhibits cell proliferation, migration and invasion. In
human clinical samples there is observed inverse correlation between miR-96 and KRAS.
Further, ectopic expression of miR-520h has inhibitory effect on pancreatic cancer cell migration
and invasion, miR-20a, with metastasis-suppressing effect, is reduced in pancreatic cancer and
its cell lines. [67]. In pancreatic ductal carcinoma, miR-345, miR-139, and miR-142-p were the
most down-regulated miRNAs in tumour tissue compared to normal tissue [1]. Other potential
Future Aspects of Tumor Suppressor Gene60
tumour suppressor miRNAs involved in pancreatic cancer are: miR-100, miR-181a, and
miR-15b, but are as well as miR-200 family up-regulated [67].
miR-200 family, potential tumour suppressors, is up-regulated in pancreatic cancer. Low
expression of miR-200 family genes and higher expression of their target is common in different
cancers. However, most pancreatic cancer cell investigations showed hypo-methylation of
miR-200a/b and its over-expression, in contrary its targets are hyper-methylated, suggesting
that this pathway is not involved in metastases in most pancreatic cancer [67]
Hepatocellular Carcinoma (HCC)
Primary liver cancer mainly refers to HCC, which is one of the most common malignant
tumours in liver and accounts for 85-90 % of primary liver cancers. Cyclins D2 and E2 were
validated as direct targets for miR-26a, which exhibit reduced expression in HCC [68]. In
another early study on animal models, down-regulation of number of miRNAs has been
detected, including known tumour suppressor miRNAs, such as: miR-15/16, miR-34a,
miR-150 and miR-195 [69]. miR-122, which represents 70 % of all liver miRNAs, was found to
be frequently down-regulated in HCCs. Loss of miR-122 expression in tumour cells segregates
with specific gene expression profiles linking to HCC progression. miR-122 is specifically
repressed in a subset of primary HCCs that are characterized by poor prognosis and is therefore
suggested as tumour suppressor miRNA [47,68]. As one of miR-122 targets, cyclin G1 was
identified, through its regulation miR-122 influences p53 protein stability and transcriptional
activity. Two other miR-122 targets, which promote tumorigenesis, are SRF and IGF1R. The
cellular mRNAs and protein levels of Bcl-w were also repressed by miR-122. Other pro-
apoptotic functions were assigned for let-7 through targeting Bcl-xL, for miR-101 through
targeting Mcl-1, and for miR-29 through targeting Mcl-1 and Bcl2. miR-195 was significantly
reduced in HCC tissues and cell lines, it suppress tumorigenicity through targeting cyclin D1,
CDK6, and E2F3. CDK6 was showed to be also target for miR-124, which is silenced through
CpG methylation in HCC; miR-124 in addition targets vimentin, SET, and MYND. Let-7g
inhibits the proliferation of HCC by down-regulating c-Myc. Methylation of miR-1 in HCC
results in enhanced tumour cell growth, probably through release of its oncogenic targets c-
Met, FoxP1, HDAC4. miR-223 targets Stahmin 1 and is down-regulated in HCC whereas
miR-375 inhibits the proliferation and invasion of HCC cells by targeting Hippo-signalling
effectors YAP [68,70]. Research on expression profiling in HCC and adjunct non-tumour tissue
defined that miR-199a*, miR-195, miR-199a, miR-200a, and miR-125a were also under-expressed
in HCC tissue [2]. Anti-metastatic functions were showed for miR-122 by targeting desintegrin
and metalloprotease, and let-7g by targeting type I collagen A2. c-Met is target for miR-1,
miR-34a, miR-23b and miR-199a-3p, and all of these miRNAs are down-regulated in HCC
[68,70].
Lung cancer
Lung cancer is one of the most common cancers of adults and is also leading cause of cancer-
related deaths in many economically developed countries [2]. Let-7 family is a family of
miRNAs, whose genes map to different chromosome regions that are frequently deleted in
lung cancer [71]. Significantly worse survival was observed among patients with low expres‐
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sion of let-7a-2 compared to those with opposite expression pattern, independent of disease
stage [2]. Over-expression of let-7 in lung adenocarcinoma cell lines inhibited cancer cell
growth and reduced cell cycle progression. These findings reflect that let-7 mediates tumour
suppressive function [2,45]. It has been shown that let-7 regulates the expression of several
oncogenes, RAS, MYC, HMGA2, and cell-cycle progression regulators, CDC25, CDK6, cyclin
D2. let-7 is down regulated in lung tumours and its expression anti-correlated with that of RAS
relative to the normal lung tissue [46,71]. In animal models, ectopic let-7g expression reduces
tumour burden and intranasal administration repress lung adenocarcinoma. A SNP in let-7
complementary site 6 in 3'-UTR of its target KRAS is significantly associated with increased
risk for NSCLC among moderate smokers [71]. The let-7 family was subsequently found to be
deregulated in a large number of tumour types [46].
Mutations in EGFR gene are more frequent in NSCLC patients who never smoked tobacco; a
significant down-regulation of miR-145 has been demonstrated in the cancer tissues of these
patients. Restoration of this miRNA can inhibit cancer cell growth in EGFR mutant lung AD
[47,71]. miR-128b has been also showed as direct regulator of EGFR, whereas miR-128b loss-of-
heterozigocity is frequently found in NSCLC. miR-7 is frequently down-regulated in lung
cancer, it suppress EGFR and Raf1, it attenuates activation of Akt and ERK, suggesting that is
negative regulator of EGFR pathway [71].
It was proposed that miR-140 regulates PDGF in lung cancer development, but this has not yet
been thoroughly investigated. miR-29 is down-regulated in lung cancers, its targets are Mcl-1,
DNMT3A and DNMT3B, suggesting that it is pro-apoptotic and that it has role in regulating
epigenetic DNA methylation. Further, in lung cancer cells induction of miR-34 results in
apoptosis; miRNA profiling revealed that miR-34a/b/c are directly correlated with expression
of p53. Decreased expression of miR-126 and increased expression of VEGFA was found in
various lung cancer cell lines. Introduction of miR-126 down-regulates VEGFA, inhibits
growth, and reduces average tumour weight. Mouse model of lung adenocarcinoma showed
that miR-200 family possess anti-metastatic abilities [5]. miR-125b-1 is located on a fragile site
on chromosome 11q24 which is deleted in a subset of patients with lung cancer [61].
Human brain cancer
The phrase “brain tumours” describes an inhomogeneous collection of various tumours of the
brain, which represents primary tumours of nervous central system or metastases. Glioblas‐
tomas (belongs to family of gliomas) are the most frequent occurrence and malignant form of
primary brain tumors in contrary to medulloblastomas, which have a better prognosis [2,11].
Several articles have described the effects of ectopic miRNA modulation on medulloblastoma
cell proliferation and growth.
Rescued expression of miR-9 and miR-125a were shown to promote medulloblastoma cell
growth arrest and apoptosis by targeting TrkC, whereas miR-29 has been shown to be down-
regulated in neuroblastoma and brain tumour [47,72]. Further, miR-34a induces apoptosis in
neuroblastoma cells, possibly by targeting the transcription factor E2F3 [11]. Transient
transfection in medullablastoma cells with miR-34a strongly inhibited cell proliferation, cell
cycle progression, cell survival and cell invasion. miR-34a was shown to inhibit c-Met, Notch-1,
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Notch-2 and CDK6. Ectopic up-regulation of miR-124 was shown to inhibit cell proliferation,
and it was demonstrated that miR-124 target and regulates CDK6. miR-125b, miR-324-5p, and
miR-326 over-expression inhibit medulloblastoma cell growth by targeting Hedgehog signal‐
ling pathway. miR-128 also inhibits growth by targeting Bmi-1 oncogene. Another miRNA,
miR-199b-5p negatively regulates proliferation and cell growth [72].
In contrary to medulloblastomas, are gliomas the most common and deadly primary human
brain tumours, and its subtype glioblastomas are highly invasive, very aggressive, and one of
the most incurable [2]. miR-181a, miR-181b and miR-181c were originally identified as down-
regulated in glioblastoma cells and tumours when compared to normal brain controls.
miR-181a and to a greater extent miR-181b were subsequently described as tumour suppressors
that inhibit growth and induce apoptosis of glioma cells. miR-181a over-expression down-
regulates Bcl-2. Several other miRNAs have been implicated in glioma malignancy as tumour
suppressors. miR-15b was suggested to target CCNE1, the gene encoding cyclin E1, however,
a direct link between CCNE1 down-regulation by miR-15 and cell cycle regulation was not
demonstrated. miR-146b was shown to inhibit glioma cell migration and invasion, and was
identified as one of miRNAs that is significantly deregulated in human glioblastoma tissue.
miR-146b over-expression or knock-down did not affect the growth of human glioblastoma
cell line, while it significantly reduced the migration and invasion of one glioblastoma cell line.
MMP16 was identified as one of the downstream targets of miR-146b. miR-125b was shown to
induce cell cycle arrest and inhibits CDK6 and CDC25A expression in glioma cell lines.
However, another study suggested oncogene function for miR-125b. miR-153 decrease cell
proliferation and increased apoptosis (pro-apoptotic miRNA), it inhibited Bcl-2 and Mcl-1.
miR-17 and miR-184 were identified as two miRNAs with reduced expression in higher grades
of glioblastomas. Their over-expression inhibited viability, proliferation, invasion and
decreased expression of AKT 2 and several other genes. let-7 over-expression effect was
investigated in glioma cells, its transfection reduced expression of RAS oncogenes, prolifera‐
tion in vitro, migration of the cells, and reduced the size of tumours generated [73].
Head and Neck Squamous Cell Carcinoma (HNSCC)
Head and neck tumours are a heterogenous group with different behaviour at the various sites
arising from anatomical factors, cell-type variation, and differences in exposure to risk factors
including tobacco, alchocol, and viruses [74]. Head and neck squamous cell carcinoma is
represented by epithelial cancers of the oral cavity, pharynx, nasal cavity, paranasal sinuses,
salivary glands and larynx [75]. Studies were made in expression profiling regarding different
sites of head and neck tumours, tongue, tonsil, larynx, hypopharynx, nasopharynx, saliva, oral
cavity, salivary gland and animal models. Several miRNAs were identified as down-regulated,
and for some of their target genes were validated [74].
Low expression of miR-205 is significantly associated with local-regional recurrence inde‐
pendent of disease severity at diagnosis and treatment. Combined low expression of let-7d and
miR-205 is significantly associated with poor survival. In nasopharengyal carcinoma down-
regulation of miR-34 family, miR-145 and miR-143 was also observed [47]. Tumour suppressive
role in HNSCC has been suggested for let-7 family, miR-125a/b, miR-200, miR-133a/b, and
miR-100 [75]. General down-regulation of miR-1, miR-133a and let-7b was also observed [74].
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Reduced expression for majority of members of the let-7 family (except let-7i) was observed in
HNSCC. KRAS and HMGA2 have been characterized as targets for let-7 [75]. Notable among
down-regulated was also miR-98. However, another group identified miR-98 as another
regulator of an oncogene HMGA2 [74]. A possible molecular mechanism of miR-125a/b down-
regulation might be through targeting ERBB2, since its higher level of expression was observed
in oral SCC. Other target were also suggested for miR-125, namely KLF13, CXCL11 and FOXA1
[74,75]. Down-regulation of miR-133a/b in primary HNSCC may further contribute to increased
cell proliferation and decreased apoptosis. PKM2 has been validated as cellular target for both,
miR-133a and miR-133b, and increased expression of PKM2 has been associated with cancer
progression. Finally, miR-100 has been observed at suppressed levels in primary HNSCC and
derived cell lines. A few of its targets are known, namely FGFR1, MMP13, ID1, FGFR3, EGR2.
The exact role has to be investigated yet, but suggestion has been made that down-regulation
of miR-100 means higher rate of cell proliferations.
Deregulation of miRNAs in cancer can occur through epigenetic changes (promoter CpG
island hyper-methylation in the case of miR-200 family) [8]. Suppressed miR-200a was detected
in primary oral SCC. Members of miR-200 family inhibit EMT by directly targeting ZEB1/ZEB2,
suppressed levels of miR-200a may promote EMT. At last, it was observed that miR-137 and
miR-193a could be also silenced via hyper-methylation, CDK6 and E2F6 has been suggested
as their major targets. It was also shown that miR-137 hyper-methylation is associated with
poorer average survival [74,75].
Urological tumours
Renal  cell  carcinoma (RCC).  The VHL tumour suppressor  signalling pathway is  the most
important deregulated pathway in clear cell  RCC, the dominant subtype of  kidney can‐
cers. The VHL gene can be spontaneously deleted or hyper-methylated. The regulation of
the VHL pathway by miRNAs has not been well studied in RCC. The interactions have
been proposed but a direct relation between miRNAs and VHL or HIF1A were not pro‐
ven. A subset of miRNAs has been identified as regulated by VHL pathway, 3 miRNAs
were up-regulated and 6 were down-regulated. The second commonly deregulated path‐
way is VEGF signalling pathway, which is transcriptionally regulated by HIF (after hypo‐
xia)  or  due to  loss  of  VHL.  Interaction between miRNAs and VEGF has  not  been well
studied in RC, and only miR-29b  has been shown to indirectly regulate VEGF. However,
strong inverse  correlation between miR-200  family  and VEGFA has  been observed with
suggestion that VEGFA is direct target of these miRNAs [76]. Down-regulation of miR-141
was found in malignant compared to matched non-malignant tissue samples [47].
Bladder cancer. Mutation or over-expression of the FGFR3 gene occurs in approx. 80 % of
all patients with low-grade non-invasive urothelial carcinomas. Some well-established de‐
regulated  miRNAs  in  bladder  cancer  are  predicted  to  target  FGFR3,  and  regulation  of
FGFR3 by miR-99  and miR-100  of  four predicted miRNAs has been experimentally vali‐
dated. Family miR-200 is associated with an epithelial phenotype; its ectopic expression in
bladder cancer cell lines induces up-regulation of epithelial and down-regulation of mes‐
enchymal markers. Up-regulation of miR-143 is accompanied by down-regulation of RAS
[76].  Transfection of  bladder cancer  cell  lines  with pre-miR-129  exerts  significant  growth
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inhibition and induces cell death. mir-129  is shown to target GALNT1 and SOX4. Trans‐
fection of miR-30-3p, miR-133a and miR-199a* results in decrease of tumour cell growth in
bladder cancer. miR-101 inhibits cell proliferation in bladder transitional cell carcinoma by
targeting EZH2 and altering global  chromatin  structure.  Down-regulation of  miR-145  in
bladder cancer has been also observed [47].
Prostate cancer. A major signal transduction pathway in prostate cancer is PI3K/Akt signalling
pathway that is hyper-activated in approx. 30-50 % of prostate cancer. Many of the predicted
miRNAs that are predicted to target proteins of this pathway are differentially regulated in
prostate cancer. Second pathway is androgen receptor (AR) pathway. miR-125b is an androgen-
sensitive miRNA, which has been shown to regulate apoptosis through inhibition of BAK1.
miR-101 has been shown to be up-regulated in human prostate cancer and it seems that through
inhibition of EZH2 reduce invasion and induce morphological changes in prostate cancer cells
[76]. miR-221 is found to be progressively down-regulated in aggressive forms of prostate
cancer. Down-regulation of miR-221 is linked to cancer progression and recurrence in a high
risk prostate cohort. Progressive miR-221 down-regulation also hallmarks metastasis [47,76].
miR-499a has been shown to be down-regulated in prostate cancer tissue. Its introduction into
prostate cancer cells results in cell cycle arrest and apoptosis, where it regulates cell growth
and viability in part by repressing the expression of HDAC1 [47]. miR-15a-miR-16-1 cluster,
located at chromosome 13q14, is deleted in most cases of prostate cancer [21].
Melanomas
Melanoma is the most aggressive type of skin cancer, and it is resistant to therapy in its
advanced stages  [77].  Abnormalities  in  several  signal  transduction pathways,  which are
important for normal melanocyte development, only partly explain molecular mechanism
directly linking UV radiation to the development of melanoma. miRNAs are emerging as
important causal factors to melanoma initiation and progression [78].  In 45 primary cul‐
tured melanoma cell  lines,  there was observed that  many genomic loci  containing miR‐
NAs  are  frequently  affected  (85.9  %)  by  copy  number  abnormalities.  For  an  example,
copy number losses of the region containing miR-218-1 and SLIT2 were shown in 33 % of
all  investigated  melanoma  lines  [79].  Proteins  involved  in  miRNA  biogenesis,  Drosha,
Dicer and Ago, are over-expressed in melanoma [32].
However, deregulation of miRNAs expression is not always explained. let-7  plays a role
in melanoma development and progression, its targets are many cancer-promoting mole‐
cules, such as NRAS, Raf, c-myc, cyclin D1/D3, and CDK4 [77]. Analyzing 10 melanocytic
nevi  and 10  primary  melanomas,  it  was  revealed that  five  members  of  the  let-7  family
were significantly down-regulated in melanoma [80]. Over-expression of let-7b leads to in‐
hibition of cell cycle progression and inhibition of its targets (cyclin D1/D3/A and CDK4)
[77]. A direct interaction of let-7b with the cyclin D1 3'-UTR was showed. Let-7a was thus
demonstrated to regulate expression of integrin beta3 and RAS oncogene, which is highly
related to melanoma progression.
Another family, miR-34, has tumour suppressive role. Expression of miR-34a is silenced due
to an aberrant CpG methylation in 43.2 % of melanoma cell lines and in 62.5 % of primary
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melanoma samples. The tumour suppressive function of miR-34a has not yet been investigated,
however, there was shown a reduced expression of miR-34b/c and miR-199a* and it was
proposed that their target is MET oncogene [80]. Another miRNA with potentially tumour
suppressor role is embedded in CpG island and epigenetically regulated in melanoma, this is
miR-370 [79].
miR-203 has also an important tumours suppressor role in a lot of cancers, and it is often lost
due to deletion or due to promoter CpG hyper-methylation. miR-203 target p63, and their
relationship might be relevant also in melanoma, since it is known that miR-203 functions as
switch between epidermal proliferation and differentiation [81].
Gynaecological tumours
miR-125b-1 is located on a fragile site on chromosome 11q24 which is deleted in a subset of
patients with ovarian and cervical cancer [61].
Cervical cancer. Cervical cancer aetiology is strongly linked to HPV infection, and involvement
of virus protein E6 and E7 in pathogenesis is well established. The exact pathway from infection
to tumorigenesis has not been elucidated yet. However, down-regulation was observed for:
let-7b/c, miR-23b, miR-196b, miR-143, and miR-145. miR-143 and miR-145 were equally down-
regulated in all cell lines of cervical cancer (HPV infected and HPV not infected), whereas
miR-218 was the unique miRNA down regulated only in HPV-16 and HPV-18 positive cell
lines. Down-regulation of miR-214 is related to the ability of this miRNA to inhibit HeLa cells
proliferation through targeting MEK3 and JNK1 transcripts. HPV protein E6 induces destabi‐
lization of p53, down-regulation of miR-34a and increased proliferation of pre-malignant HPV
infected cervical cancer cell lines [82].
Endometrial cancer. Reciprocal association between down-regulation of miR-192-2 and SOX4
expression was determined; it was further established that restoration of miR-192-2 induced a
decrease in SOX4 expression and this resulted in diminished cell proliferation. Decreased
expression for miR-152 and miR-101 was found to consist of an independent risk factor for
disease free survival. Restoration of those miRNAs by transfection in cell lines lead to dimin‐
ished cell proliferation. Down-regulation of miR-101 was correlated with strong positive
immunoreactivity of COX2, which was previously shown to be associated with worse
prognosis. To date, no data are available for relationship between miRNAs and oestrogen
response in endometrial cancer [82].
Ovarian cancer. Inconsistencies are observed between results in ovarian cancer studies for well-
known tumour suppressors. These could be due to the differences in study populations and
methodologies used, due to the choice of control group and type of control. For instance, the
number of studies used as control cell lines and another number of studies used whole normal
ovaries. The existence of significant discrepancies in expression profiles of certain miRNAs
indicate the need of further and more in-depth research that would establish those results [82].
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5.2. lncRNAs as tumour suppressors
lncRNAs are known to mediate epigenetic modifications of DNA by recruiting chromatin
complexes to specific loci [8]. Only a handful of lncRNAs have been characterized, and their
involvement in control of gene expression [3]. We therefore presented four lncRNAs with
proposed tumour suppressor function in cancer.
MEG3
MEG3, located in chromosome 14q32, is maternally expressed imprinted gene, which repre‐
sents lncRNA, but also hosted miRNAs and snoRNAs. It plays role in cell proliferation, and
its expression is under epigenetic control. MEG3 and its hosted miRNAs and snoRNA could
represent a tumour suppressor gene, since aberrant CpG methylation (promoter hyper-
methylation, and hyper-methylation of the intergenic region) has been observed in several
types of cancer, as well as their gene copy number loss [9].
MEG3 ncRNA might modulate binding of p53 on the promoter of its target genes [9]. It was
later verified that MEG3 was associated with p53 and that this association was required for
p53 activation, further suggesting tumour suppressor role for MEG3. It was demonstrated that
MEG3 expression is markedly decreased in glioma tissues compared to adjunct normal tissues.
Ectopic expression of MEG3 inhibited cell proliferation and promoted cell apoptosis in glioma
cell lines [83]. Growth inhibition is partially due to apoptosis induced by MEG3, which induces
accumulation of p53, stimulates transcription from p53-dependent promoter and regulates p53
target gene expression. Loss or significantly reduction of MEG3 expression has been further
found in other cancer cell lines examined, bladder, bone marrow, breast, cervix, colon, liver,
lung, meninges, and prostate, as well as in other primary tumours, neuroblastoma, hepato‐
cellular carcinoma, and meningioma. It has been suggested that DNA methylation plays a
major role in silencing the MEG3 gene in tumours [84].
GAS5
LncRNA GAS5 is highly expressed in cells that have arrested growth and can sensitize a cell
to apoptosis by regulating activity of glucocorticoids in response to nutrient starvation. It has
been linked with breast cancer. GAS5 transcript levels are significantly reduced compared to
un-affected normal breast epithelia, suggesting that could act as tumour suppressor. GAS5
maintain sufficient caspase activity to activate appropriate apoptotic response in diseased cells.
Chromosomal translocation affecting 1q25 locus that contains the GAS5 gene has been detected
in melanoma, B-cell lymphoma, prostate and breast cancer [7,85]. GAS5 regulates expression
of a critical subset of genes with tumour suppressive consequences [4].
LincRNA-21
LincRNA-p21 is required for the global repression of genes that interfere with p53 function
regulating cellular apoptosis; it physically interacts with a protein hnRNP-K, allows it
localization to promoters of genes that need to be repressed in a p53-dependent manner [4].
In response to DNA damage, lncRNAs are induced by the p53 tumour suppressor pathway.
lincRNA-p21 plays an important role in cellular response to apoptotic signal, it is induced by
p53 and act as an inhibitor of the p53-dependent transcriptional response by repressing the
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transcription of genes that interfere with apoptosis (guidance of hnRNP-K to the promoters of
genes repressed by p53). LincRNA-p21 has not been directly associated with disease yet, but
loss of function of lincRNA-p21 might be involved in cancer initiation since functions to trigger
cell death through the induction of apoptosis program [7,9,85].
CCND1
It is involved in the regulation of Cyclin D1 gene expression. Cyclin D1 is a cell cycle regulator
often mutated, amplified and over-expressed in various types of cancer. After binding of this
lncRNA on RNA-binding protein, consequently inhibition of enzymatic activities of the
histone acetyltransferases occurs, leading to silencing of cyclin D1 gene. These studies suggest
that this lncRNA is a tumour suppressor RNA, which can be rapidly induced by cellular stress
to regulate it sense gene expression [85].
6. Conclusion
The rest of ncRNAs, other than miRNAs, in regulation biological functions are more or less
unexplored, and this should be further investigated in future research. Regarding therapeutic
approaches, we still need more knowledge concerning which miRNAs to target, how to
produce and stabilize them, how to direct them to the target tissue. The specificity of drug-like
oligonucleotides is important, because of the off-target effect. The off-target effect is also a
significant challenge, especially considering that miRNA-mediated repression often requires
a homology of only six to seven nucleotides in the seed region of the miRNA and mRNA target
site. Toxicity due to chemical modifications, which is used to facilitate cellular uptake and
prevent degradation, should be take into account. However, only recently was described the
possibility of using exososmes and exosomal tumour-suppressive miRNAs as novel cancer
therapy [86].
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1. Introduction
The pioneering landmark, established by Takahashi and Yamanaka (Takahashi et al., 2007;
Takahashi and Yamanaka, 2006) in reprogramming somatic cells into induced pluripotent
stem (iPS) cells using the four transcriptional factors of Oct4, Sox2, Klf4, and c-Myc, represents
one of the most important paradigm shifts in current stem cell biology. This unprecedented
discovery could potentially revolutionize regenerative medicine, cell-based therapy and
personalized medicine. Despite recent great advancement in cell reprogramming, there are
still considerable technical challenges to circumvent restrictions of applications of reprogram‐
ming technology (Kawamura et al., 2009; Saha and Jaenisch, 2009). The utilization of over-
expressed transcriptional factors, which of many play oncogenic roles, during somatic
reprogramming posts the risk of malignant transformation, thus, limiting its clinical applica‐
tions. Moreover, the reprogramming process using these factors is still inefficient in some of
cell types, and is not always successful in other kinds of cells (Kawamura et al., 2009; Marion
et al., 2009; Menendez et al., 2012). Therefore, the underlying mechanisms for signaling control
of these factors still need to be further explored.
Somatic cell reprogramming is a complicated cellular process that is controlled by many
signaling networks. Accumulated evidence indicated that stemness transition can be detected
in some tumor cells following the introduction of relevant signal stimulation, and cancer cells
or differentiated cells can be changed into stem cell-like cells that go through less-differentiated
stages (Chen et al., 2008; Fodde and Brabletz, 2007; Huang et al., 2009; Liu et al., 2009a).
© 2013 Cheung et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
However, stemness transition may not lead to a full reprogramming of treated cells, which is
determined by the delicate controls of signaling network activities in living cells. Interestingly,
stemness transition may accompany epithelial-mesenchymal transition (EMT) events in cancer
cells, and both programs are closely linked to the core stem cell gene network activities. Not
surprisingly, multiple signaling pathways have been reported to be involved in EMT events
and generation of stem cell-like cells. Wnt/β-catenin and TGF-β signaling are two potent
inducers of EMT during embryonic development and cancer progression (Li et al., 2010; Mani
et al., 2008; Morel et al., 2008; Scheel et al., 2011). Other involved pathways in these cellular
activities may include BMP/Activin/Nodal, Notch, Hedgehog, Fibroblast growth factor
signaling, and others (Chen et al., 2008; Huang et al., 2009; Kang and Massague, 2004;
Natalwala et al., 2008; Thiery, 2002, 2003; Wu and Zhou, 2008).
The Wnt/β-catenin signaling pathway, highly conserved among various species and composed
of a large family of proteins that control many biological properties (Fodde and Brabletz,
2007; Kikuchi et al., 2009; ten Berge et al., 2008b), may play a central role in the control of
reprogramming and stemness process. This pathway includes more than two hundred genes
and plays a critical role in modulating the delicate balance among stemness, proliferation, and
differentiation in certain stem cell niches and tumor cells (Gu et al., 2010; Katoh, 2007; Lowry
et al., 2005; Reya and Clevers, 2005). The established evidence reveals that various levels of
Wnt/β-catenin signaling are likely to contribute to distinct cellular activities such as stemness
transition, differentiation, carcinogenesis, and the EMT program. Therefore, the cellular
activities and fate decisions are determined by this signaling activity in both dosage-dependent
and tissue-dependent fashions (Anton et al., 2007; Kikuchi et al., 2009; Lluis et al., 2008; Reya
and Clevers, 2005; Slack et al., 1995; Tapia and Scholer, 2010a; ten Berge et al., 2008a; Vermeulen
et al., 2010). However, whether and how this signaling pathway has its direct influence on
pluripotency gene networks and EMT events is largely unexplored.
As mentioned previously, cell fate decisions are controlled by both positive and negative forces
in human cells. It has been well-established that tumor suppressor genes (TSGs) are important
regulators to control cell proliferation, differentiation and cell death. Not surprisingly, these
genes also play important roles in programming, reprogramming, and stemness transition in
human cells. The well-studied TSGs, such as p53, p16, and RB1, serve as key regulators for the
cell programming (Bonizzi et al., 2012; Hong et al., 2009; Liu et al., 2009b; Marion et al., 2009;
Molchadsky et al., 2010; Wenzel et al., 2007). There are a number of reports on p53 / p21 pathway
that are involved in the reprogramming process and stemness transition in somatic cells. It
should be noted that Wnt signaling was linked to the p53 pathway a long time ago, suggesting
that both signaling pathways may play interactive and critical roles in cell fate determination
(Damalas et al., 1999; Kinzler and Vogelstein, 1996; Lee et al., 2010). Recent findings demon‐
strated that several mechanisms play a limiting role in somatic reprogramming and cell
stemness transition (Figure 1) (Kawamura et al., 2009; Menendez et al., 2012; Menendez et al.,
2010; Takahashi, 2010; Tapia and Scholer, 2010b). In most situations, these genes serve as active
players or barriers for cell reprogramming. However, many essential questions on the roles of
TSGs in cell fate decision remain unclear. For example, whether p53-induced inhibition in
reprogramming is transient or just in the early stage is still in question (Cox and Rizzino,
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2010; Krizhanovsky and Lowe, 2009; Wahl, 2011). Also, it was reported that the loss of RB1 is
critical for the expansion of the stem cell populations (Liu et al., 2009a; Wenzel et al., 2007).
Undoubtedly, there is an urgent need to further elucidate the molecular mechanism and
signaling pathways in regulating and controlling the process of somatic reprogramming and
stemness transition.
Epigenetic regulation is one of the important mechanisms in the regulation of TSG activities.
Recently, epigenetic modification has been shown to influence the reprogramming process,
suggesting that many known TSGs may be involved in these cellular activities. Some reports
illustrated that a dedifferentiation process of somatic cells to iPS cells involves dynamic
epigenetic remodeling. In addition, there seem to be interactions between reprogramming
transcription factors and epigenetic modifiers during these cellular activities (Takahashi, 2010).
In this chapter, the role of TSGs in cell reprogramming and stemness process, and regulation of
these genes during stem cell renewal will be discussed, as described in Figure 1. We will review
the role of TSG-mediated pathways and epigenetics as a barrier in cell fate determinations.
Figure 1. Schematic representative of somatic reprogramming. The reprogramming efficiency is markedly influence
by TSG-mediate pathways and epigenetic modifications.
1.1. CDKN2A (p16INK4A and p14ARF) gene
The CDKN2A (INK4/ARF) locus encodes two important TSGs, the p16INK4A (or p16) and p14ARF.
They are important regulators for two other critical tumor suppressive signaling pathways for
controlling cell proliferation, namely RB1 and p53. Utikal et al. reported that secondary murine
embryonic fibroblasts (MEFs) were capable of generating iPS cells at early passage, but the
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efficiency decreased after serial cell culture passaging and the concomitant onset of cellular
senescence (Utikal et al., 2009). This phenomenon was mainly correlated with accumulation
of molecular changes in the late passage senescent MEFs (Utikal et al., 2009). Indeed, up-
regulation of p16INK4A (INK4A), p14ARF (ARF), and p21CIP was concurrently observed in the late
passage of the MEFs (Utikal et al., 2009). Deficiency and knockdown of INK, ARF, and p53
expression resulted in higher efficiency of iPS cell formation. Interestingly, when MEFs were
cultured in low oxygen condition (4%), both the expression of INK4A and p53 were reduced.
Most importantly, the efficiency of the iPS reprogramming was increased in the low oxygen
condition. This further supports the role of CDKN2A and p53 in inhibiting the reprogramming
process (Utikal et al., 2009).
Concurrently, Li et al. also worked on the role of INK4/ARF locus which encodes three TSGs,
p16IN4A, p14ARF, and p15INK4B on the reprogramming of differentiated cell into iPS cells. They
showed that the locus is completely silenced in iPS and embryonic stem cells. The three
transcription factors, Oct4, Klf4, and Sox2 repressed the gene expression of p16INK4A, p14ARF,
and p15INK4B with concomitant appearance of iPS cells. In addition, genetic knockdown of the
INK4/ARF locus improved the efficiency of iPS cell generation. In mouse cells, ARF played
more significant role as compared to INK4A. In contrast, the INK4A function was more
prominent than the ARF in human cells (Li et al., 2009). Interestingly, ageing up-regulated the
gene expression of the three genes at the INK4/ARF locus and, in turn, led to less efficient
reprogramming in cells from old organisms; this defect can be rescued by genetically inhibiting
the INK4/ARF locus. Taken together, these findings provide strong evidence that supports the
role of CDKN2A in regulating cell reprogramming in iPS cells.
The epidermis is a tissue that undergoes continual and rapid self-renewal,  and which is
dependent on the presence of stem cells and transient amplifying keratinocytes. In primary
human keratinocytes, INK4A  also plays an important role in regulation of their stemness
properties  (Maurelli  et  al.,  2006).  The  INK4A  inactivation  enabled  the  primary  human
keratinocytes  to  escape  replicative  senescence  and  blocked  clonal  evolution  and  main‐
tained keratinocytes having the stemness phenotypes.  A persistent  INK4a  inactivation is
necessary for  maintenance of  immortalization of  the keratinocytes,  which was accompa‐
nied  by  reactivation  of  B  cell-specific  Moloney  murine  leukemia  virus  site  1  (Bmi-1)
expression and telomerase activity. Bmi-1 expression is necessary to maintain the immortal‐
ization induced by INK4a inactivation. In contrast, the INK4a inactivation in the transient
amplifying  keratinocytes  did  not  undergo  immortalization  but  senescence.  Thus,  INK4a
inactivation appears to selectively inhibit clonal conversion in highly proliferative somatic
cells. Interestingly, inactivation of INK4a up-regulated the ARF/p53/p21Waf1 pathway but this
up-regulation of the p53 pathway was unlikely to suppress the cell proliferation. The p53
pathway was necessarily inactivated during immortalization of human keratinocytes. This
study clearly  indicates  the  regulation  of  keratinocyte  clonal  evolution  by  INK4a  regula‐
tion and its inactivation in epidermal stem cells is necessary for maintaining the stemness
phenotypes (Maurelli et al., 2006).
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1.2. RB1 gene
RB1 (pRB1 family members: RB1, RBL1, and RBL2) was identified as a TSG in patients with
inherited retinoblastoma. It is one of the well-studied TSGs. It involves in cell cycle G1/S
transition regulation and binds to an important transcription factor family, E2F. Based on the
Knudson two-hit hypothesis, loss of single copy of pRB1 gene is not sufficient to induce tumor
formation, loss of another copy is necessary for inducing tumor formation (Knudson, 1971).
Mouse pRB1was found to be crucial during embryonic development; loss of two copies of RB1
gene in mouse embryo is lethal (Clarke et al., 1992; Jacks et al., 1992; Lee et al., 1992; Wu et al.,
2003). Trophoblasts are cells forming the outer layer of a blastocyst, which provide nutrients
to the embryo and develop into a large part of the placenta. Specific loss of mouse pRB1 gene
in trophoblast stem cells resulted in an overexpansion of trophoblasts, profound placental
abnormalities, and eventually fetal death (Wenzel et al., 2007). Loss of pRB1 resulted in an
increase of E2F3 expression and the combined depletion of pRB1 and E2F3 in trophoblast stem
cells rescued the pRB1 mutant phenotypes by restoration of placental development and by
extending the lifespan of embryos. As can be seen, the pRB1 pathway plays a critical role in
the maintenance of a mammalian stem cell population for proper development of both extra-
embryonic and fetal tissues.
Humans and other mammalians are unable to regenerate large portions of lost limbs or other
internal organs after traumatic injury or surgical excisions. In contrast, lower vertebrates are
able to regenerate entire limbs, the lens of the eye, and portions of the heart (Brockes and
Kumar, 2008; Poss et al., 2002; Tanaka and Weidinger, 2008). The difference can be explained
in part by the observation that inactivation of pRB1 alone in lower vertebrates was sufficient
to induce skeletal muscle regeneration by reversing differentiation and post-mitotic arrest in
the muscle cells (Tanaka et al., 1997). In mammalian muscle cells, suppression of pRB1 alone
was not sufficient to reverse the post-mitotic arrest and terminal differentiation (Camarda et
al., 2004; Huh et al., 2004; Pajcini et al., 2010). The tumor suppressor ARF which is present in
mammals, but absent in regenerative vertebrates, is a regeneration suppressor in addition to
pRB1 (Pajcini et al., 2010). Concurrent inactivation of both ARF and pRB1 resulted in mamma‐
lian muscle cell cycle re-entry cell proliferation and dedifferentiation (Pajcini et al., 2010). These
results indicate that suppression of both pRB1 and ARF will result in the ability of skeletal
muscle cells to lose their differentiated characters, and the skeletal muscle cells will then
proliferate and dedifferentiate in a manner that mimics the regenerative lower vertebrate cells.
Furthermore, pRB1 is not only restricted to serve as a cell cycle regulator, but also to impact
differentiation and tissue-specific gene expression directly by binding histone deacetylase 1
(HDAC1) and promoting activation of muscle genes such as the myogenic activator MyoD
(Puri et al., 2001).
The pRB1 gene family plays an important regulatory role in neuronal differentiation (Slack et
al., 1995). When treated with retinoic acid, the embryonal carcinoma p19 cells were induced
to differentiate into cultures primarily consisting of neurons and astrocytes. During this
neuroectodermal differentiation, a dramatically increase of pRB1 protein levels was observed.
When the pRB1 family proteins in the p19 cells were inactivated by the E1A mutant, the
differentiating p19 cells underwent apoptosis. The dying cells were those committed to the
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neural lineages because neurons and astrocytes were lost from the differentiating cell culture.
The results suggest that the pRB1 family proteins are essential for the neural lineage develop‐
ment and the absence of functional pRB1 activities will trigger cell death of the differentiating
neuroectodermal cells.
The pRB1 pathway is also critical for inducing the cellcycle arrest that mediates cell-cell contact
inhibition in fibroblasts; when all three pRB1 family members, RB1, RBL1, and RBL2, were
inactivated by triple knockouts (TKOs), the fibroblasts escaped from contact inhibition and
grew into 3D colonies or stacks in cell culture (Dannenberg et al., 2000; Sage et al., 2000). The
outgrowth of TKO MEFs into spheres triggered reprogramming to produce cells with cancer
stem cell properties. Whereas the fibroblasts with a single pRB1 mutation retained contact
inhibition, when this inhibition was bypassed by forcing the cells to form outgrowth spheres,
the fibroblasts were reprogrammed to generate cells with a cancer stem cell phenotype (Liu et
al., 2009a). These findings suggest a potential mechanism for generation of cancer stem cells
from differentiated somatic cells as a result of tumor outgrowth.
1.3. p53 gene
p53, as the “guardian of the genome” (Lane, 1992), plays a pivotal role in regulating the delicate
balance of cell proliferation and cell death (Molchadsky et al., 2010). Since its discovery more
than three decades ago, the role of p53 in suppressing tumor initiation and progression is well
established. It is, therefore, not surprising that p53 is lost, inactivated, or mutated in the
majority of cancers. In respond to external stress stimuli, p53 prevents cancer development by
inducing cellcycle arrest, DNA repair, senescence, and apoptosis.
Researchers have newly identified roles played by p53 including regulation of pluripotency
and dedifferentiation, as a potent barrier in reprogramming. (Hong et al., 2009). Undoubtedly,
the function of p53 is now far more complex than just simply playing the role as the classical
tumor suppressor (Bonizzi et al., 2012; Kawamura et al., 2009; Marion et al., 2009; Menendez
et al., 2010; Molchadsky et al., 2010; Tapia and Scholer, 2010a; Wahl, 2011; Zhao and Xu,
2010). This provides us with a new insight on the complexity of p53 signaling in controlling
cell fate decisions. Despite accumulating effort in deciphering the diversified roles played by
p53, the cellular and molecular mechanism underlying the acquisition of “stemness” involved
in the p53 signaling is still largely unexplored.
During somatic cell reprogramming, the p53 pathway is activated, thus disrupting iPS
reprogramming (Kawamura et al., 2009). p53 may act as a limiting factor in the iPS reprog‐
ramming efficiency. Inhibition of the p53 pathway either by mutating, deleting or knocking
down p53 or its target gene , p21, further enhances the reprogramming efficiency (Kawamura
et al., 2009; Liu et al., 2009b; Marion et al., 2009; Tapia and Scholer, 2010b).
The p53/p21 pathway was reported to suppress the iPS cell generation. Suppression of p53
increased the efficiency of the generation of iPS cells (Hong et al., 2009). A dominant negative
p53 mutant, P275S, was used to study the effect of p53 on regulating the iPS cell generation.
Results suggested that inhibition of p53 function by introducing the dominant negative p53
mutant into the MEFs increased GFP-positive colonies in the p53-heterozygous MEFs (Hong
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et al., 2009). Similar experiments were also performed in terminally differentiated somatic cells
(T-lymphocytes from Nanog-GFP reporter transgenic mice with either p53 wild-type or null
genotype). In this study, the four important stem cell reprogramming factors, Oct4, Sox2, Klf4,
and c-Myc were introduced into the T-lymphocytes. No GFP-positive colony can be observed
in the p53 wild-type T lymphocytes (Hong et al., 2009). On the other hand, GFP-positive
colonies can be observed in p53-null lymphocytes and the cells were expandable and have a
similar morphology with the mouse ES cells (Hong et al., 2009). The increased GFP-positive
cells can also be observed in the adult human dermal fibroblasts (HDFs) by introducing the
dominant negative p53 together with the reprogramming factors into the HDFs (Hong et al.,
2009), suggesting the importance of p53 in regulating the iPS cell reprogramming.
The function of p53 in regulating stem cell multipotency was confirmed in germ-line stem cells
(GSCs). Depletion of p53 function in the GSCs increased the efficiency of reverting GSC
multipotency status (Kanatsu-Shinohara et al., 2004). This finding can also be observed in a
p53 knockout mouse study (Lam and Nadeau, 2003). Hanna et al. suggested that depletion of
p53 function in clonal B cells can only enhance the kinetics of reprogramming somatic cells
into iPS cells with a higher cell division rate (Hanna et al., 2009). However, it does not regulate
the overall efficiency (Hanna et al., 2009). A p53 mutant, R172H, which induces conformation
change of the p53 protein, was reported to associate with higher reprogramming efficiency
than WT p53 in the MEFs (Lang et al., 2004). Lang et al. showed that reprogramming efficiency
in that particular p53-mutated MEFs, which was induced by utilizing a two factor system (Oct4
and Sox2), is higher than the p53 knockout MEFs that was induced by using the three factors
system (Oct4, Sox2, and Klf4) (Lang et al., 2004), suggesting the importance of p53 in regulating
the reprogramming process.
Cicalese et al. suggested that the function of p53 in stem cells is critical to maintain a constant
number of stem cells by imposing an asymmetric mode of self-renewing division. In the
p53-/- and ErbB2 tumor mammospheres, up-regulation of Nanog is observed. These studies
also revealed the importance of p53 in regulating the stem cell polarity, and the loss of p53
induces  increased  frequency  of  symmetric  division  and  tumor  initiation  and  growth
(Cicalese et al., 2009).
The suppression of the reprogramming efficiency of iPS cells by p53 can be associated with the
maintenance of genomic integrity of iPS cells. Deficient p53 resulted in shorter telomeres in
the reprogramming MEFs (Marion et al., 2009), suggesting the low efficiency of reprogram‐
ming in the WT p53 cells to prevent the spreading of cells upon DNA damage and to ensure
iPS cell genomic integrity (Marion et al., 2009).
Another barrier affecting the reprogramming is the INK4A/ARF tumor suppressor locus, as
described previously. A recent report by Li and colleagues illustrated that the INK4A/ARF
locus was suppressed during the early stage of reprogramming, leading to inactivation of the
p53 and pRB1 pathways (Li et al., 2009). Interestingly, cells with p16INK4A knockdown alone are
sufficient to enhance the reprogramming efficiency (Li et al., 2009). Together, these observa‐
tions indicate that both p53 and pRB1 may work synergistically as barriers in somatic cell
reprogramming (Li et al., 2009; Menendez et al., 2010; Utikal et al., 2009).
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In a recent report by Lee K.H. et al., p53 preferentially targets the Wnt signaling pathway in
the murine ESC differentiation program (Lee et al., 2010). Evidently, the crosstalk between p53
and Wnt signaling pathway plays an integrated role in stemness acquisition. A p53 down‐
stream phosphatase, Wip1, which shows high expression in the intestinal cells, was reported
to associate with p53-dependent apoptosis of stem cells in the mouse intestine (Demidov et al.,
2007). Removal of Wip1 reduced the polyp formation in the APCMin mice. The APCMin/+ mice
contain a nonsense mutation in the APC gene. Constitutively activated Wnt signaling pathway
increased the apoptosis events of intestinal stem cells in the Wip1-deficient mice (Demidov et
al., 2007). Low level of Wip1 reduced the threshold of p53-dependent apoptosis of stem cells.
However, Wip1 deficiency does not affect the activities of β-catenin in terms of its nuclear
localization level. A high level of β-catenin can be observed in the nuclei of polyp cells and
this contributes to up-regulation of c-Myc and Cyclin D1 in the Wip1 null/ApcMin/+mice. The β-
catenin signaling pathway activation and attenuation of p53 resulted in increasing efficiency
of intestinal stem cell apoptosis (Demidov et al., 2007).
Recently, researchers demonstrated that the p53-miR34-Wnt network is a determinant factor
of dichotomy between stem cell properties and tumor progression. miR34, one of the direct
downstream targets of p53, is found to interact with Wnt and EMT genes, including β-
catenin, AXIN2, LEF1 and Snail. With the loss of p53 due to miR34, the Wnt pathway is activated,
which further induced the transformation of EMT (Liu et al., 2011). Therefore, the p53 gene
plays an important role in the controlling EMT.
Chang et al suggested that p53 induced transcriptional activation of microRNA, miR-200c,
through direct binding to its promoter region. The miR-200c was reported to regulate the EMT
process through inhibition of transcriptional suppressors of an epithelial marker, E-cadherin
(Chang et al., 2011). The miR-200c can target to and suppress ZEB1/2 (Wellner et al., 2009),
which is a well-studied E-cadherin transcriptional suppressor and thus, regulates the EMT
process. The knockdown of p53 in MCF12A cells resulted in loss of epithelial phenotype and
shows a significant elevation of the CD24-CD44+ population. Re-expression of p53 in TGF-β-
treated MCF12A showed inhibition of TGF-β-induced increase of the stem cell population.
p53 is not a sole player in deciding the cell fate determination. In fact, p53 works as an integrated
network, interplaying with other important pathways, depending on the external stimuli and
microenviroment. However, there is a great need to further elucidate the roles of the p53
network in reprogramming, dedifferentiation, self-renewal, and pluripotency.
2. Signaling pathways involved in the reprogramming and stemness
transition
2.1. TGF–β signaling pathway
TGF-β signaling pathways play multiple roles in regulating tumorigenesis and other cellular
processes, including reprogramming, stemness transition, and EMT events. Many components
in this signaling pathway were defined to participate in both oncogenic and tumor suppressive
pathways in various tumors. This provides a complicated story for researchers to study the
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function of TGF-β signaling pathways in stem cells or reprogrammed cells. The ligands of the
TGF-β family have multiple functions and can cause opposite effects in different cell types.
The TGF-β can regulate cell proliferation, growth arrest, differentiation, survival, cell migra‐
tion, and also the pluripotency of cells. In cancer, over-expression of TGFβ1 and deregulation
of the TGF-β receptor type II (TGFBRII) were reported to associate with skin cancer tumori‐
genesis and invasiveness (Cui et al., 1996). However, the role of TGF-β signaling in regulating
reprogramming is still not well-defined. In a previous report, TGF-β family ligands play an
important role in reprogramming of somatic cells into iPS cells, regulating ESCs self-renewal,
pluripotency maintenance, and controlling differentiation.
TGF-β signalling may have the ability to induce reprogramming of somatic cells into iPS cells.
Treatment of TGF-β/activin inhibitor in partially reprogrammed iPS cells can induce Nanog
expression (Ichida et al., 2009; Maherali and Hochedlinger, 2009). Furthermore, the functional
role of TGF-β in regulating the reprogramming was defined by utilizing chemical TGF-β
inhibitors. Interestingly, inhibition of TGF-β signaling can enhance the mouse fibroblast
reprogramming efficiency. A substitute of Sox2 (E-616452) and TGFBR1 kinase (SB-431542)
inhibitor, were reported to replace the function of Sox2 in MEFs with Oct4, Klf4, and c-Myc
expression (Ichida et al., 2009; Maherali and Hochedlinger, 2009). These results suggest the
important roles TGF-β plays in the controlling reprogramming process.
Maintenance of the pluripotencies and self renewal properties are important for both ESCs
and iPS cells.The canonical TGF-β signaling pathway may play important regulatory roles in
ESCs maintenance and generation of pluripotency. BMP4 together with the LIF protein can
induce Oct4 expression (Ying et al., 2003). The BMP activated Smad signaling to support self-
renewal properties of stem cells. The inhibition of Smad activities by the Smad6 and Smad7 in
the ES cells induced smaller and fewer ES cell colon formation (Ying et al., 2003). Secretion of
BMP4 by the feeder cells is necessary for ES cell self-renewal (Ying et al., 2003). Inhibition of
the Erk and p38 MAPK pathways can further enhance the BMP4-associated effect on self-
renewal of mouse ESCs (Qi et al., 2004). Besides this, bFGF (basic fibroblast growth factor) and
activin are also important to maintain the pluripotency in human ESCs (Greber et al., 2010;
James et al., 2005). The TGF-β signalling may play multifunctional roles in regulating pluri‐
potency of cells. Smad1 was reported to suppress the expression of Nanog by inhibiting its
promoter activities (Jiang and Ng, 2008; Xu et al., 2008). The Smad proteins were reported to
bind directly to Nanog promoter (Xu et al., 2008) and this is the major mechanism for Smad
proteins to regulate Nanog expression. These results suggest the multiple roles of TGF-β
signaling in the regulation of stem cell renewal.
Furthermore, TGF-β also plays a role to control the differentiation of ESCs. One of the TGF-
β family members, BMP4, was reported to associate with induction of inhibitor of differentia‐
tion (Id) gene via interaction with the LIF/Jak-Stat3 and Smad pathways. The Id gene is an
important factor to block ESC differentiation. The undifferentiated ES cells expressed BMP
signaling ligands (Ying et al., 2003) and regulated downstream molecules, the Smads, to control
the cell differentiation process (Ying et al., 2003).
Collaborating with Wnt signaling, TGF-β signaling is also involved in the EMT program and
both pathways are regarded as the axis of EMT in breast cells (Scheel et al., 2011). The hy‐
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pothesis of these two pathways linked to the stem cell networks and TSG pathways is
presented in Figure 2.
2.2.Wnt pathway
Cellular reprogramming can be achieved by overexpression of defined transcription factors
in somatic cells (Ichida et al., 2009; Takahashi et al., 2007). However, the underlying mechanism
of signaling activities that regulated these factors are not fully understood now. Overexpres‐
sion for certain genes may not be suitable for all pathways, such as β-catenin, a mediator of
Wnt signaling, because discrete levels of expressed genes are usually needed for maintaining
the pluripotent status or direct programming through this pathway (Gu et al., 2010; Lluis et
al., 2008; Marson et al., 2008; Merrill, 2008). It still remains unclear the gene-dosage effects of
critical factors on somatic cell reprogramming and stem cell renewal. Recent studies revealed
that activation of Wnt/β-catenin signaling may directly control reprogramming of fused
somatic cells. For example, Wnt stimulators, Wnt3a and BIO, strikingly enhanced reprogram‐
ming ability after cell fusion (Lluis et al., 2008; Merrill, 2008). The fusion clones derived from
both ESCs and somatic cells had an obvious β-catenin accumulation with increased expression
of Axin2, a β-catenin-dependent gene, suggesting that basic or lower levels of stabilized β-
catenin might drive somatic cell reprogramming.
The lower levels of Wnt signaling play a critical role in the control of development of several
types of tissues through a dosage-dependent manner, as reported in crypt progenitor cells
(Batlle et al., 2002; Korinek et al., 1998), hair follicles (Lowry et al., 2005), and hematopoietic
stem cells (Luis et al., 2011). Taken together, observations from both in vitro and in vivo studies
indicated that Wnt/β-catenin signaling was a single dominant force in the control of cell fate
determinations in some of tissues, which suggests that basic or physiological levels of Wnt
signaling may be required for many cellular activities.
More and more evidence revealed that Wnt signaling plays important roles in maintenance of
pluripotency in ESCs and cell self-renewal (Cole et al., 2008; Lluis et al., 2008; Macarthur et al.,
2009; Marson et al., 2008; Takao et al., 2007). For example, expression of β-catenin was confirmed
Figure 2. The cell fate determination is delicately controlled by positive and negative forces. Cellular activity balance
regulated by both core stem gene-mediated pathways and TSGs is the key determinant in reprogramming process.
Future Aspects of Tumor Suppressor Gene84
to associate with hemtopoietic stem cells and neural stem cell growth (Kalani et al., 2008; Reya
et al., 2003). Wnt3A activation associated with expression of the stem cell reprogramming
markers, Oct4 and Nanog (Ogawa et al., 2007) and maintenance of the pluripotency of mouse
ES cells (Hao et al., 2006; Singla et al., 2006). Wnt3A induced generation of iPS cells in the
absence of Myc (Marson et al., 2008). Those cells contained iPS cell properties and were able
to form teratomas during subcutaneous injection into SCID mice (Marson et al., 2008). The Wnt
signaling pathway is also involved in regulating pluripotency factors, Oct4, Nanog, and Sox2
expression (Anton et al., 2007; Sato et al., 2004). This observation was confirmed by down-
regulation of the stem cell pluripotency genes in the β-catenin deficient mouse ES cells (Anton
et al., 2007). Wnt signaling pathway was also associated with cell reprogramming through the
telomerase reverse transcriptase (TERT) and Brahma-related gene 1 (BRG1) interaction (Barker
et al., 2001) to modulate chromatin structure during reprogramming (Miki et al., 2011).
Interestingly, previous study demonstrated that Wnt3a can also stimulate human ES cell
differentiation, rather than only regulate human ES cell proliferation. The canonical Wnt
signaling levels are minimal in the undifferentiated human ES cells but greatly increase after
Wnt3a treatment and induce differentiation (Dravid et al., 2005). Dramatic increase of reprog‐
rammed cell numbers can be observed when ES cells, which have a low level of nuclear β-
catenin, are fused with neural stem cells. This is mainly due to the low nuclear β-catenin level
being able to protect fused cells from apoptosis (Lluis et al., 2010), suggests the importance of
β-catenin levels in the regulation of stem cell reprogramming. This finding may help to explain
the balance between the maintenance of pluripotency of stem cells and apoptosis, as excess
β-catenin can induce p53 expression (Damalas et al., 1999), which was found to induce
apoptosis in stem cells to maintain genome integrity. The p53 protein was reported to be a
transcription regulator of the Wnt signaling and it bound on the promoter regions of some
Wnt signaling members for a general stress response in the mouse ES cells (Lee et al., 2010),
which may provide a feedback mechanism to control the deregulation of the β-catenin during
the reprogramming process.
It should be noted that inappropriate activation of components of this signaling pathway have
been observed in many human cancers and differentiated stem cells, in which the high levels
of β-catenin signaling were usually detected (Dravid et al., 2005; Fodde and Brabletz, 2007; ten
Berge et al., 2008a; Vermeulen et al., 2010). Except for p53 described previously, some compo‐
nents of the Wnt pathway can be regarded as both oncogenes and TSGs. For example, AXIN2,
APC, DKK1, and WIF1 are negative regulators of this pathway, and are called TSGs. In
summary, the detailed mechanism of Wnt signaling in the control of stemness transition and
reprogramming of somatic cells needs to be further explored.
3. Possible mechanisms to regulate TSGs expression in reprogramming
It is well-accepted now that epigenetic regulations are important events to control gene
expression in human cells. Promoter hypermethylation and histone modification are two major
events to regulate gene expression in various human tumors. The DNA methyltransferase
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(DNMTs), histone deacetylases (HDACs), histone acetyl transferase (HATs), and histone methyl‐
transferase are the key regulators to controlgene expression in the genome. Epigenetic changes
of gene expression were reported to be important during the iPS cell reprogramming (Han
and Sidhu, 2008). The epigenetic changes can also help to maintain the pluripotency by
regulating the expression of the key transcription factors, Oct4, Nanog, and Sox2 (van Vlerken
et al., 2012). In previous studies, mouse ES cell genomes were found to contain less methylation
than the somatic cells, while human ES cells show a distinct epigenetic profile, when compared
to somatic cells (Jackson et al., 2004; Lagarkova et al., 2006; Zvetkova et al., 2005). A silenced
TSG, p16, was found to be re-expressed during the reprogramming process (Ron-Bigger et al.,
2010). On the other hand, a previous study suggested that the promoter region of INK4A/ARF
was found to be hypermethylated in the iPS and ES cells. Inhibition of DNMTs by inhibitor
and siRNA increased the INK4A and p21 (CIP1/WAF1) expression in human umbilical cord
blood-derived multipotent stem cells (So et al., 2011). However, the epigenetic regulation of
TSGs during the reprogramming process is still not fully understood now. It is necessary to
further explore epigenetic changes of TSGs in the reprogramming process and relevant other
cellular activities.
Figure 3. Hypothesis of integrated networks of TGSs, Wnt/β-catenin and TGF-β pathways in controlling reprogram‐
ming, stemness transition and EMT events. These pathways may play central roles in regulating other TSGs, transcrip‐
tional factors and other signaling pathways.
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4. Conclusions
The known and unknown TSGs are the important participators in the regulation of cell
reprogramming and stemness transition. These genes are components of various signaling
pathways, and play different roles in maintaining cell pluripotency, regulating cell differen‐
tiation and proliferation, cell cycle control, apoptosis, and other cell fate decisions. These genes
controlling cellular activities act in a time-dependent or a dosage-dependent manner in various
tissues. Although detailed underlying mechanisms are not fully clear now, more and more
evidence indicates that some TSG signaling activities are determinant forces in important
cellular processes, including cell reprogramming. A proposed hypothesis illustrates this in
Figure 3. Understanding of the delicate control of these signaling networks in living cells will
provide more insight in reprogramming studies and regenerative medicine.
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1. Introduction
1.1. Tumor suppressor genes, a historical perspective
Cancer is essentially considered to be a genetic disease caused by the accumulation of multiple
genetic or epigenetic lesions in tumor-suppressor genes and oncogenes [1]. Although the
notion that retinoblastoma could be an inherited disease was already formulated at the end of
the 19th Century, a solid genetic basis was established with the discovery of both proto-
oncogenes, whose gain-of function mutations or altered expression is associated with the
cancerous state, and tumor suppressor genes (TSGs), whose inactivation releases the “brakes”
inhibiting cell proliferation. Analysis of both proto-oncogenes and TSGs revealed also that
cancer results from an alteration of the normal pathway of cell fate and differentiation. The
hallmarks of cancer, as laid down by Hanahan and Weinberg to explain the complex biology
of cancer, comprise of six major developmental changes taking successively place in human
tumors. These cancer “characteristics” include sustained proliferative signaling, evasion of
growth suppressors, resistance to cell death, replicative immortality, angiogenesis as well as
cell invasion and metastasis. Underlying these hallmarks are genome instability, inflamma‐
tion, reprogramming of energy metabolism and evading immune destruction [2].
Cancer cells are the foundation of the cancer disease, as they initiate formation of tumors and
drive tumor progression forward. Based on the sequence of events in which cells accumulate
genetic lesions, tumor progression and metastasis are highly variable, even among tumors of
the same type [3]. Previously, cancer cells within tumors were thought to be largely made of
homogenous cells until relatively late in the course of tumor progression, when hyperprolif‐
eration combined with increased genetic instability spawn distinct clonal populations. Now
we know that tumors rather than homogenous masses of proliferating cancer cells are complex
© 2013 Papagiannouli and Mechler; licensee InTech. This is an open access article distributed under the terms
of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
tissues composed of distinct cell types, participating in heterotypic interactions with each
another. Reflecting such clonal heterogeneity is the finding that many human tumors display
a complex histological pattern, characterized by regions exhibiting various degrees of differ‐
entiation, proliferation, vascularity, inflammation and invasiveness [2]. In addition, tumors
exhibit another dimension of complexity arising from the surrounding normal cells of the
“tumor microenvironment” [2] (analyzed in part 3).
Over the last decades the origin of oncogenesis has been the subject of different theoretical
“fashions”. In the current view taking into account the role of oncogenes and tumor suppressor
genes, cancer results from a failure occurring more in the control of cell differentiation than in
cell proliferation [4, 5]. Nowadays, cancer is generally considered to result from a block or an
error in the normal progression of differentiation. As a result, the cancer cells escape the
mechanisms controlling normal growth and proliferation. Several decades ago, pioneer
studies in the field of Drosophila, mouse somatic cells and human genetics revealed that
neoplasia may result from a loss of function in regulatory genes controlling cell growth and
differentiation [6-9]. In the following years, research in developmental biology has greatly
contributed to cancer research. Indeed very often the initiating event in the formation of a
malignant tumor is a block of a critical step in normal differentiation, usually through
inactivation of a single gene, and can be accompanied by events occurring in parallel. In the
case of tumor-suppressor genes, proliferation of tumor cells is suppressed by the same set of
genes that suppress the proliferation of normal cells, in the same cell type during the process
of differentiation. Studies of the Drosophila lethal [2] giant larvae (lgl) gene, the first cloned tumor
suppressor gene, have shown beyond doubt that tumors can be produced at a defined period
of development by the impairment of a gene that normally regulates a critical step of differ‐
entiation [5, 10, 11]. At that time, such precise time delimitation in the process of development
would not have been possible to achieve with mammalian cells, but the observations made
thereafter in mammals were consistent with the conclusion derived from the Drosophila study.
1.2. Identification of the first tumor suppressor genes in Drosophila melanogaster
Over the past 40 years it has become increasingly evident that cancer is causally related to
mutations in specific genes. These genes are instrumental to developmental processes such as
cell-cell communication, signal transduction, regulation of gene expression, translation,
cytoskeletal organization, protein folding and transport, and differential regulation of cell
cycle [12]. The Drosophila field has made marked contributions in many of the mechanisms
that are fundamental to cancer processes, several of which have been later validated in
vertebrates. Less well known is the precursor role of Drosophila in the cancer field, as some of
the earliest tumor suppressors were identified in flies. The first tumor-containing mutant was
recognized in 1967 in a wild type laboratory stock of Drosophila melanogaster [6]. The mutant
gene was soon identified by Ed Lewis as an allele of the already known lgl gene, which was
discovered by Bridges in 1933 [13]. During the 1940-50s, this gene has been the subject of a
number of developmental studies performed by Hadorn and his collaborators. The phenotypic
studies performed by Hadorn’s group on lgl and other Drosophila genes have greatly contrib‐
uted to the conceptual basis of developmental genetics. In 1955 Hadorn published in German
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his seminal monography on “Lethalfaktoren und ihrer Bedeutung für Erbpathologie und Genphy‐
siologie der Entwicklung” which in 1961 was translated into English as “Developmental Genetics
and Lethal Factors”. Comparative developmental studies conducted thereafter showed that one
of the pleiotropic effects of the mutation was the formation of a malignant neuroblastoma in
the larval brain and the appearance of imaginal disc tumors [7, 14]. Molecular studies on the
lgl gene were initiated in 1985 by Mechler and his co-workers by cloning the first tumor
suppressor gene [10]. Subsequent analysis of lgl has demonstrated unequivocally that the
tumorous phenotype results from the lack of lgl function and showed that tumorigenesis can
be rescued by reintegrating a wild type copy of lgl into the genome of lgl-deficient animals [15].
Biochemical and genetic analysis of the lgl gene and its human homologue hugl-1, showed that
the encoded proteins are components of the cytoskeleton and interact physically with a domain
located near the carboxyl terminal of the non-muscle myosin II heavy chain [11, 16-20]. Further
studies also revealed that the Lgl protein can interact with the Nucleosome Assembly Protein-1
(NAP-1), a component of the cyclinB-p34cdc2 kinase complex [21, 22] and NAP-1 is intimately
associated with the cytoskeletal matrix during interphase and accumulates in the nucleus
during prophase where it becomes associated with the spindle apparatus [21].
Recent contributions show that the Lgl protein may directly contribute to genetic regulation
in association with the heavy chain of nonmuscle myosin II, or nmMHC II [23, 24]. In particular
mutations in lgl or heteroallelic combinations between lgl and zipper, encoding nmMHC, were
found to block the disintegration of the salivary glands by blocking the program induced by
the molting hormone ecdysone [23]. An interaction between both proteins was found to be
required for the binding of specific nuclear remodeling proteins to chromatin [24]. Defect in
this interaction may result in a block of genetic cascade initiated by the ecdysone hormone and
lead to a transcriptionally frozen genome. The outcome of these analyses shed light on the key
roles that tumor suppressor genes may play not only in the mechanism of cell shape and tissue
organization but also in the regulation of developmental programs.
Subsequently to these initial studies, Gateff isolated a series of other recessive mutations in
distinct genetic loci, which gave rise to four specific types of tumors. These tumors affected
either the developing larval brain, the imaginal discs, the hematopoietic organs, or the germ
cells [25, 26]. Shortly after lgl was reported [6], a genetic screen assaying imaginal disc
morphology identified a mutation in the discs large (dlg) gene, coding for a septate junction
tumor suppressor gene [27] with a second mutation identified few years later [28]. Twenty
years later, a third mutation with the strikingly similar phenotypes, called scribble (scrib), was
independently isolated in two different labs. Initially scrib was found in a screen for regulators
of epithelial architecture [29]. Parallel to this investigation, a P-element mutagenesis screen led
to the identification of the recessive scribvartul mutation causing late larval lethality, imaginal
disc overgrowth and brain tumors with a complex syndrome reminiscent of that observed in
mutations of the other tumor suppressors [30]. Therefore, already at the very early days of
tumor genetics, Drosophila has been an extremely favorable object of study. Since then a great
number of tumor suppressor genes have been identified and Drosophila has largely contributed
to our understanding of the basic biology and cellular mechanisms of tumorigenesis including
cell growth and proliferation, apoptosis, maintenance of cell polarity and architecture.
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Figure 1. Size comparison between wild type 3rd instar larvae and scrib, l(2)gl and dlg giant larvae.
2. Drosophila as a unique model system to study tumor suppression
In order for an animal species to serve as a model of human biology it must fulfill two key
criteria. The model system should be amenable to a broad set of experimental approaches and
to be similar enough to humans so that findings from the model system can be exported to
higher organisms and facilitate research in humans. Drosophila, being at the forefront of genetic
research for the past one hundred years, together with the high degree of conservation with
humans at the gene and cellular level, has proved itself as an essential partner in discoveries
related to genetics, cell biology, human disease and cancer metastasis.
There are also many technical advantages in using Drosophila over vertebrate models. Flies are
easy and inexpensive to culture in laboratory conditions, have a much shorter life cycle,
produce large number of offsprings with feature-rich morphology and large numbers of
externally laid embryos that can be genetically modified in numerous ways. Each female fly
lay up to approximately 50 to 100 eggs per day for up to 20 days. It takes approximately 10
days at 25oC for an embryo to develop into a fertile adult fly. Thus, it is easy to generate large
numbers of embryos or flies for experimental studies and genome-wide screens. Moreover,
there are generally few limited restrictions on their use in the laboratory as there are minimal
ethical and safety issues [31, 32].
Future Aspects of Tumor Suppressor Gene100
2.1. Drosophila in a century of “tool-building” research
The first documented use of Drosophila in the laboratory was in William Castle’s group at
Harvard in 1901, but the “father” of Drosophila research is without doubt Thomas Hunt Morgan
[33]. It was almost 100 years ago that Thomas Hunt Morgan reported the identification of the
white gene in Drosophila [34]. Morgan greatly refined the theory of inheritance first proposed
by Gregor Mendel, by using Drosophila to define genes and establish that they are found within
chromosomes, long before it was even established that the DNA is the genetic material [31,
35]. Morgan won the Nobel Prize in Physiology or Medicine in 1933 “for his discoveries
concerning the role played by the chromosome in heredity”. One of Morgan’s students,
Hermann Muller, won the Nobel Prize in Physiology or Medicine in 1945 “for the discovery
of the production of mutations by means of x-ray irradiation”. Using Drosophila in 1920s, Muller
discovered that x-rays cause massive increase in the rate of mutations and that the mutations
can be passed from one generation to the other [36]. The genetic approaches used in the first
50 years of research in Drosophila (1910-1960), led to the development of important concepts
and tools e.g. balancer chromosomes, that allowed the study of many other biological processes
in the years to come [35, 37].
Interestingly, researches realized in the early fifties that genetic approaches could be used to
study problems other than heredity. The continuous development of research tools between
the years 1960-2010 has driven numerous new discoveries in fruit flies. In the mid-seventies,
the available genetic tools in Drosophila offered the opportunity to address how embryonic
pattern formation is controlled and to identify the genes involved in these processes [37, 38].
By carrying out a systematic chemical mutagenesis screen on the different fly chromosomes
and analyzing the larval cuticle patterns, Nüsslein-Volhard and Wieschaus identified 139
genes that affect the development of the fly larva [39-41]. This analysis led to the identification
of numerous genes participating in the Hedgehog, Wingless, Decapentaplegic (the Drosophi‐
la Tumour growth factor-β; TGF-β), and Notch pathways. In 1995, Christiane Nüsslein-
Volhard, Eric Wieschaus and Ed Lewis won the Nobel Prize in Physiology or Medicine “for
their discoveries concerning the control of early embryonic development”. These findings have
clearly demonstrated the power of forward genetics in solving complex developmental
questions. Further genetic screens shed light on factors involved in various developmental
aspects such as neuronal migration and growth cone guidance, circadian rhythms, learning
and memory [37]. All these studies proved that despite the great morphological differences
between flies and humans, many of the underlying building blocks and cellular processes are
strikingly similar and conserved through evolution [31].
The range of genetic tools that have become available for Drosophila over the past century
surpass by far those of any other multicellular organism [31]. Two experimental key features,
namely the successful and efficient removal or addition of single genes or gene products, are
important for any model organism to be successfully used in the laboratory. In Drosophila,
genes can be inactivated in a random fashion using chemical mutagenesis followed by
screening for specific phenotypes. Current tools allow very rapid mapping of chemically
induced mutations that have robust phenotypes, permitting the isolation of null alleles,
hypomorphs, neomorphs as well as conditional alleles, making possible the functional analysis
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of single genes. These screens, combined with duplications and deletions covering almost all
chromosomes, have greatly facilitated gene mapping. The recent improvements in whole
genome sequencing techniques and single-cell profiling will enhance even more the speed of
accessibility to genomic information [37, 42]. Apart from the imprecise excision of transposable
elements [43], one can create mutations by selective removal or replacement of sequences using
the “targeted-knockout” technology [44], as well as by using RNA interference (RNAi) to
reduce expression on any gene in a tightly regulated temporal and spatial pattern [45, 46].
The use of P-element-mediated transformation, available since 1982 [47] has allowed the
insertion of single genes and any DNA fragment of interest in the fly genome, and has opened
the field to even more sophisticated genetic manipulations [37]. This technique was signifi‐
cantly improved with the P[acman] technology that allows the insertion DNA fragments in
specific docking sites spread throughout the Drosophila genome [48, 49]. Efficient transforma‐
tion has been achieved by using the Flipase-Flipase Recognition Target (FLP-FRT) recombi‐
nation system, which enables the creation of mutant patches of tissues or cells in an otherwise
heterozygous background [50, 51]. This system led to the development of a highly efficient
“mitotic recombination system” that knockouts defined genetic functions in specific cells,
tissues and organs. The yeast site-specific recombinase FLP, coupled with centromere-linked
insertions of the FRT target site on all major chromosome arms of Drosophila [52], allows the
generation of genetic mosaics, within an otherwise wild type organism, by removing almost
every fly gene function. Generation of genetic mosaics is particularly useful for elucidating the
function of genes which, when mutated, would otherwise kill the organism and subsequently
laid the carpet in understanding how cells within tumors can interact with their surrounding
microenvironment. A considerable improvement of the FLP-FRT system for analyzing mosaic
tissue was the development of the MARCM (Mosaic Analysis with Repressible Cell Marker)
technique [53]. Prior to the introduction of MARCM, homozygous mutant cells were identified
by the absence of a visible marker such as GFP or lacZ in comparison to the surrounding
heterozygous environment and the wild type “twin clone”. By using the MARCM technique
the homozygous clones can be positively marked using e.g. GFP or RFP, which can be of
particular importance for the analysis of single cells in a disease model.
Another use of the P-element-mediated transformation facilitated the development of the
UAS-GAL4 system in order to ectopically express or overexpress a gene of interest in almost
any tissue or cell [54]. The binary UAS-GAL4 system allows a gene DNA sequence fused to the
UAS (upstream activating sequence) to be ectopically expressed via the enhancer/ promoter
of a second gene that drives synthesis of the UAS-binding GAL4 transcription factor. Thou‐
sands of UAS and GAL4 fly lines are now available and their use can either modify or even
abrogate gene expression in selected cell populations, in a specific temporal and spatial pattern
[37, 55, 56]. Moreover, the “Vienna Drosophila RNAi Center” and “Bloomington Stock Center”
house a collection of transgenic fly lines carrying inducible UAS-RNAi constructs against single
protein coding genes. Currently they accommodate over 22.000 different transgenic lines,
which provide knockdowns for over 90% of Drosophila genes. Further development of the
UAS-GAL4 system led to the TARGET (temporal and regional gene expression targeting)
system, which utilizes a temperature-sensitive form of GAL80 repressor that binds GAL4 and
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blocks its transcription activity at the restrictive temperature, while a shift to a permissive
temperature results in GAL80 losing the ability to bind GAL4 [57, 58].
Finally, P-element technology also allowed the tagging of most genes in vivo e.g. with GFP,
RFP or YFP, permitting sophisticated manipulations in a genomic context [59]. Transgen‐
ic flies containing enhancer-trap or protein-trap versions of individual genes allowing the
analysis of the gene expression pattern and protein localization are available at “FlyTrap”
(http://flytrap.med.yale.edu/index.html) [60-63] and “FlyPROT” (http://www.flyprot.org/
index.php) [64].
2.2. Drosophila is a model system relevant to human biology
While Drosophila has long served as a model for basic biological research, more recently its
potential as a model for unraveling molecular mechanisms of human diseases has become
widely appreciated, and numerous publications and conferences illustrate the use of Droso‐
phila to unravel the mechanisms of human diseases [65-69]. Release of the first sequence of the
Drosophila genome in March 2000 (11 months ahead of the human genome release) allowed
the actual comparison to the human genome. This comparison has greatly consolidated
Drosophila’s legitimacy as a model organism for medical research [31, 70]. The sequence and
annotation are freely available in “Flybase”, an outstanding online database combining all
current knowledge on single Drosophila genes including sequence and expression data,
mutations, interactions and up to date scientific references. Comparative studies have shown
that the molecular mechanisms underlying the development of Drosophila and humans are
highly conserved. Since the Drosophila genome contains functional homologues of nearly 75%
of the human disease genes, we can understand why this aspect of Drosophila research
continuously expands. Moreover, over 85% of human genes that have been associated with a
disease, have a Drosophila counterpart. These findings constitute a strong basis for the contin‐
uous expansion of Drosophila research in relation to human diseases.
What makes Drosophila also practical in the analysis of gene function is the nearly complete
absence of genetic redundancy. The duplication of the vertebrate genome during evolution
has resulted in the occurrence of multiple paralogs, e.g. Hox genes that control the body plan
along the anterior-posterior axis [71], with their subsequent evolution that has generated gene
expansion and diversity in protein function [72, 73]. Genetic expansion means that when
knocking down a gene, other genes or homologues can compensate for its function. Yet, the
extra genes rarely represent novel functions as they simply allow more complex and subtle
regulation of core molecular mechanisms. In this respect, the absence of gene duplication in
Drosophila provides the advantage of elucidating more readily the fundamental function of
single genes, e.g. in tumor development, and then apply it back to vertebrates and humans as
the mechanism is very likely conserved [74]. Indeed, lack of redundancy can expose the
physiologically relevant phenotype of gene homologues.
The similarities between flies and humans are further supported by the fact that components
of signal transduction pathways and the molecular mechanisms involved in specification,
development, cell cycle regulation and human diseases were first identified in flies. The genes,
which have been characterized in flies, were subsequently studied in mice and humans, and
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their names were adopted or adapted from their Drosophila homologues. For example, the
mammalian Notch 1-4 named after the Drosophila Notch (fly wings having a large notch on
the wing), “sonic hedgehog” named after the Drosophila “hedgehog” (round larvae with extra
bristles) and Wnt from the Drosophila “wingless and INT-related” gene [31].
3. Recent advances in modeling tumor progression and metastasis in
Drosophila melanogaster
Since the discovery of oncogenes and tumor suppressor genes, intense research in many
laboratories all over the world has brought us to the point where we are starting to understand
the main principles underlying molecular changes in the course of tumor progression [3, 75].
The development of new technologies revealed the complex molecular nature of tumorigenesis
in which tumor progression can be envisaged as a network of simultaneous events within both
tumor cells and the stroma. Because cancer is an age-associated disease in humans, using
Drosophila to model cancer development, progression and metastasis was debatable [76, 77].
However, over the last decades the study of Drosophila has significantly contributed to the
understanding of key cancer events, including the loss of cell polarity, the competition between
tumor and normal cells, as well as metastasis [78].
In addition to the importance of tumor cells themselves, their neighboring cells and the
surrounding stroma are now recognized as important regulators of cancer progression [79].
Cell competition is a type of short-range cell-cell interaction in which cells expressing different
levels of a particular protein are able to discriminate between their relative levels so that the
one cell, the “loser”, disappears from the tissue whereas the other, the “winner”, survives and
proliferates to cover the space left by the disappearing cell. Some tumor-promoting mutations
in Drosophila are able to induce cell competition between the cancer cells and their micro- and
macroenvironment [80-86]. Metastasis is the latest phase of cancer progression during which
cells detach from their original niche to invade distant tissues [87]. For several decades, our
understanding of the molecular processes leading to metastasis was largely derived from
studies of cancer cell lines in vitro, xenografts of human tumors and a limited number of
transgenic or knockout mouse models [1, 88, 89]. However, understanding the individual steps
leading to tumorigenesis or analyzing multiple genetic interactions in mice is difficult. Existing
models are currently being re-evaluated given the increasing awareness of tumor complexity.
Therefore, using a model system that allows the efficient analysis of the combinations of genetic
events that trigger tumor initiation and metastasis during cancer development is the major
challenge in cancer research at the moment. Drosophila melanogaster provides a model of choice
for cancer analysis as the collection of sophisticated genetic manipulation techniques have been
invaluable for dissecting signaling pathways that affect cell specification, differentiation and
growth [90-93]. Indeed, Drosophila cancer models are very helpful in unraveling the chrono‐
logical sequence of events leading to human cancer. For example, in metastasized human
tumors elucidating the identity of the initial mutations is often tedious as oncologists are in
most cases looking at the end point of the disease progression. Finally, Drosophila genetics is
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very powerful as we can dissect the triggering events initiating cancer and the subsequent
steps leading to the progression of the disease [94].
3.1. Modeling cell competition and metastasis
With these added complexities in mind, the analysis of cancer-disposing mutations in only a
subset of cells or in clones within the context of a wild type surrounding tissue is gaining more
interest because it offers a reasonable approximation of the clonal nature of human cancers,
compared to the analysis of the multi-step model of tumor progression in the context of a whole
organism. A great number of very interesting publications provided us with information about
new and unexpected findings on the role of the polarity genes scrib, lgl and dlg in cancer
initiation, progression and metastasis. Nowadays, it becomes obvious that they play a broader
role than initially thought, through the cooperation with individual partners and signaling
pathways and have helped us to understand the role of cell competition and of the tumor
microenvironment during tumor survival and progression.
Analysis of scrib- mutant clones in the Drosophila eye imaginal discs has shown that tumor
development is suppressed by the JNK-mediated apoptotic pathway activated by the sur‐
rounding wild type cells, whereas the neoplastic and metastatic potential is regained through
the synergistic effect of a simultaneous up-regulation of Ras signalling within the same clones
[84, 95, 96]. These results underline the effect of the surrounding normal cells on the trans‐
formed scrib- clonal cells, which leads to a cell competition similar to the one observed in the
mammalian cancers [1, 96-100]. In a model for scrib tumorigenesis, the analysis of the down‐
stream pathways in scrib- epithelial clones revealed that excessive cell proliferation is restrained
by JNK-mediated apoptosis. Upon simultaneous activation of either Ras or Notch, JNK-
mediated apoptosis is blocked, and Ras/Notch together with JNK cooperatively promote
tumor growth and invasion [96]. In other words, whereas JNK activity normally promotes the
apoptosis of scrib-deficient cells, it becomes a driver of cellular overgrowth, tumorigenesis and
invasion in the presence of oncogenically activated Ras or Notch signalling [76, 101]. These
tumors present similar characteristics to human cancers that lack Scrib, including basement
membrane and extracellular matrix degradation, loss of E-cad expression, combined with
migration, invasion and secondary tumor formation [101] Another report provided a molec‐
ular link between loss of polarity and tumorigenesis, since scrib-, dlg- and lgl- clonal cells in a
wild type surrounding become metastatic only in combination with Rasv12 activation, resulting
in JNK activation and E-cad inactivation [102]. The analysis of the JNK-mediated tumorigen‐
esis, which in Drosophila cells reveals a cooperation with Ras similar to that taking place in
mammalian breast epithelial cells, indicates that the knowledge gained from the analysis in
Drosophila can help us elucidate tumor formation in the mammalian system.
Mutations inactivating the Salvator-Warts-Hippo (Sav-Wts-Hpo) pathway can also cause
super-competition, contributing to the overgrowth of cells expressing these mutations in the
presence of wild type cells [80, 103]. Since the first discovery of the Sav-Wts-Hpo pathway in
Drosophila, the role of these genes in restricting cell growth and proliferation, and inducing
apoptosis has triggered a great interest in its study. The components of this pathway act as
important tumor suppressors that regulate tissue growth by promoting cell cycle exit and
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apoptosis [80, 104-112]. Recent data from mammals and Drosophila show the occurrence of a
very conserved pathway that links the pathway of cell polarity to the regulation of tissue
growth.
In the model of Scrib tumorigenesis, induction of apoptosis in scrib clones could not explain
how scrib- cells are prevented from overproliferating. This was answered by the finding that
cell competition between scrib and wild type cells prevents overproliferation by suppressing
Yorkie (Yki; a transcription factor, which is suppressed by the Sav/Wts/Hpo pathway) activity
in scrib- cells [113, 114]. Suppressing Yki activation is critical for scrib- clone elimination by cell
competition. Cell competition leads to activation of JNK in scrib- cells and JNK antagonises Yki
activity, which leads to elimination of the clone. Experimental Yki elevation is sufficient to
promote neoplastic growth in scrib- cells [114]. Along the same line, when lgl is mutated in a
mosaic tissue, the lgl- clonal cells become the “losers” in cell competition. However, simulta‐
neous overexpression of the Ras signalling pathway or of yki in lgl- clones, causes overgrowths
and JNK-mediated apoptosis at the periphery of the transformed clones [115-120]. Moreover,
JNK-mediated elimination of lgl- clonal cells is relieved and the overgrowth potential is re-
established by upregulation of c-Myc, demonstrating the the death of lgl- clones is essentially
driven by c-Myc-induced cell competition [121]. Simultaneous downregulation of the lgl and
the JNK pathway in the whole-animal system results in a phenotypic reversion of tumor
growth, absence of the giant larvae and recurrence of pupariation, thereby showing that JNK
activity is essential for overgrowth and invasion of lgl tumorous discs [122]. Moreover, in the
developing Drosophila eye and imaginal disc epithelia Lgl, αPKC and Crumbs proteins regulate
cell proliferation and survival by controlling the activity of the Sav-Wts-Hpo pathway [115,
123-125].
Among the wide palette of cellular events leading to JNK activation is the dTNF (tumor
necrosis factor)/Eiger. Eiger is the only Drosophila member of the TNF superfamily and its
deregulated expression in imaginal disc cells results in JNK-mediated apoptosis [76, 126]. JNK-
dependent cell death in scrib and dlg clones requires dTNF, acting as a “tumor death factor”
[127]. On the other hand, in tumors deficient for scrib and dlg that also express Ras, the TNF
signal is converted into a signal, which promotes tumor growth and invasion [126]. More
precisely, upon dTNF downregulation, cell death in dlg and scrib clones was blocked and in
situ outgrowths appeared, probably by TNF-mediated extra-cellular matrix (ECM) remodel‐
ling [76, 126]. When generated in an eiger- mutant background, Rasv12scrib- clones displayed
non-invasive in situ overgrowth. Similarly, in whole Rasv12scrib-dTNF- animals, development
proceeded up to pupal stages, overcoming the “giant larvae” phenotype [76, 126]. These recent
results suggest that several of the critical overgrowth phenotypes of scrib, dlg and lgl in the
clonal and whole-tissue context are mediated by dTNF and that dTNF pro-tumor function
depends partially on JNK activation in tumor cells, which provides a switch from in situ to
invasive growth. Immunostaining experiments detected dTNF in a punctuated, intracellular
vesicle pattern at the periphery of hemocytes in association with the dlg- clones, indicating that
dTNF expression in hemocytes is sufficient for dTNF/JNK pathway activation within the dlg-
clones, and mark the importance of hemolymph and non-cell autonomous immune response
in tumor progression [76, 126].
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Until very recently, the mechanism by which surrounding normal tissue exerts antitumor
effects against dlg, scrib or lgl clones remained elucive. New results from clonal analysis in
Drosophila imaginal discs have shown that JNK activation from the wild type surrounding
leads to upregulation of PVR, the Drosophila PDGF/VEGF receptor, that activates the
ELMO/Mbc phagocytic pathway, which in turn eliminates the oncogenic clonal cells by
engulfment [128]. From an evolutionary point of view, the development of such mechanism,
which senses and eliminates “neoplastic” tumor-suppressor mutant cells such as those of scrib-
and dlg- but not “hyperplastic” ones (in which despite of overproliferation, cells are normally
shaped and retain a differentiated epithelial monolayer, such as those of the Hippo pathway
and PTEN) [128], shows the necessity to specifically eliminate the high-risk malignant
neoplastic cells before they confer any harm to the organism. Taken together, these studies
demonstrate that hemocytes together with the tumor microenvironment act as regulators of
epithelial delamination required for tumor invasion. Due to the ease of genetic manipulations,
Drosophila research can bring meaningful insights to our understanding of the mechanisms of
communication between cancerous and normal cells as well as between tumor tissue and the
immune system [87].
3.2. Drosophila provides critical insights on how conserved mechanisms contribute in
cancer and tumorous development
Drosophila research has also contributed to cancer analysis by identifying genes and signaling
pathways later found to be critical for tumorigenesis in mammalian systems. In several cases
Drosophila has been used to establish specific model systems in order to understand processes
that seem to be more complex in vertebrates and mammals [81, 101, 129, 130]. One of the most
extensively studied Drosophila models of tumor biology is the asymmetric cell division of
neuroblasts, the Drosophila neuronal stem cells. In Drosophila neuroblasts (NB), the PAR3-
PAR6-atypical protein kinase C (aPKC) complex segregates apically and recruits the adaptor
protein Inscutable (Insc), which connects this complex to the partner of Insc (Pins), guanine
nucleotide associated protein-α1 (Gα1), mushroom body defect (MUD), and p150glued to the
crescent directing the orientation of the mitotic spindle during asymmetric cell divisions. aPKC
promotes the exclusion of partner of numb (PON), Lgl and Numb, which along with Miranda
(Mira), Brain Tumor (Brat) and Prospero (Pros), localize to the basal crescents [101, 130, 131].
Interestingly, most of these genes have functional mammalian homologues and a very recent
study points out the role of the Par3 in mammalian skin tumorigenesis [132]. In mouse skin
tumorigenesis, Par3 deficiency results in reduced papilloma formation and growth. Further‐
more, Par3 expression is reduced in both mouse and human keratoacanthomas, indicating the
tumor-suppressive properties of Par3. More insights into tumor physiology came from a very
interesting study in Drosophila NBs that indicates the critical role of starvation in promoting
the overgrowth of pins larval brains. Energy stress, mediated by loss of TOR and Phosphati‐
dylinositol 3-kinase (PI3K) components, in combination with loss of pins results in loss of
asymmetric NB division and brain overgrowth (Rossi, 2012). Since the PI3K and TOR signaling
pathways are vital to the growth and survival of mammalian cancers [133, 134], using
Drosophila in order to dissect the cross talk of these pathways to preexisting tumor suscepti‐
bility defects e.g. polarity defects, in a simple animal model is of great importance.
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The usefulness of Drosophila is further illustrated in the development of a Drosophila model for
human brain cancer. Glioblastoma (GMB) is the most frequent and malignant form of high-
grade glioma that infiltrate the brain, grow rapidly and are refractory to current therapies
[135]. One key to development of new and effective therapies against these tumors is to
understand the fundamental genetic, cellular and molecular logic underlying gliomagenesis.
Signature genetic lesions in glioblastomas include mutation of the epidermal growth factor
receptor tyrosine kinase (EGFR) and mutations activating components of the PI3K pathway.
Drosophila studies using lineage analysis combined with cell-type specific markers demon‐
strated that EGFR-Ras and PI3K can induce fly glial neoplasia through activation of a combi‐
natorial genetic network composed in part of other genetic pathways also commonly mutated
in human glioblastomas [135]. In the future, large-scale forward genetic screens with this
model may reveal new insights into the origins of glioblastoma and may also provide new
therapeutic strategy for the treatment of this form of human tumor.
Drosophila has been also used to elucidate the molecular mechanisms of human heredita‐
ry  diffuse  gastric  cancer  (HDGC) [136].  Gastric  cancer,  as  several  human cancers,  origi‐
nates from epithelial cells. Mutations in the CDH1 gene, which encodes the cell adhesion
molecule  E-cadherin  (E-cad),  are  associated with  HDGC in  humans.  In  order  to  under‐
stand the role of E-cad in this disease, a Drosophila  model has been developed in which
mutated forms of E-cad can be studied in vivo [136, 137]. Moreover, genetic and molecu‐
lar  studies  of  Drosophila  hematopoiesis  can  also  contribute  to  our  knowledge  of  the
hematopoietic niche and hematopoietic malignancies in humans. Vertebrate hematopoiet‐
ic stem cells give rise to an hierarchically organized set of progenitors and deregulation of
the  hematopoietic  differentiation  program  can  lead  to  numerous  pathologies  including
leukemias.  With  the  discovery  that  many transcriptional  regulators  and  signaling  path‐
ways controlling blood development are conserved between humans and flies, Drosophila
is particularly suitable model for investigating the mechanisms underlying the generation
of blood cell lineages and blood cell homeostasis [138].
Interesting results using a Drosophila cancer model demonstrated that apoptosis activation in
differentiation-compromised cells constitutes a mechanism for early prevention of cancer
[139]. Apoptosis is a highly conserved cellular function to remove excessive or unstable cells
in diverse developmental processes and disease-responses. An important example is the
elimination of cells unable to differentiate, which have the potential to generate tumors. Using
cell-type specification in Drosophila, Ingrid Lohmann and her colleagues identified a conserved
regulatory mechanism that underlies cell-type specific removal of uncommitted cells by
apoptosis as a cancer prevention mechanism [139]. Under normal conditions the transcription
factor Cut activates differentiation, while it simultaneously represses cell death via the direct
regulation of a pro-apoptotic gene. However, loss of Cut and subsequent release of apoptosis
leads to overproliferation of the mispecified cells that can acquire metastatic potential in a
sensitized background. Importantly, this regulatory wiring is also found in vertebrates in
which other cell-type specification factors may similarly be employed to suppress tumor
formation. Thus, coupling of differentiation and apoptosis by individual transcription factors
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is a widely used and evolutionarily conserved cancer prevention module, which is hard-wired
into the developmental program [139].
Furthermore, genetic analysis of border cell migration in the Drosophila melanogaster ovary
provides clues that improve our understanding of ovarian cancer metastasis at the molecular
level that might also lead to therapeutic targets [140]. The border cells of the Drosophila ovary
provide a particularly simple example of cell migration in which cells derived from an
epithelium invade a neighboring tissue. The large numbers of genes that control border cell
migration identified in genetic screens emphasized also the requirement of multiple extracel‐
lular signals for border cell motility [141]. Interestingly, the motile and invasive properties of
the border cells seem to share common characteristics with mammalian ovarian carcinoma
cells. Based on work done in Drosophila, the function of some mammalian proteins such as
myosin VI, have been tested for their ability to regulate motility of ovarian carcinoma cells.
1 Drosophila flies are easy and inexpensive to culture in laboratory conditions, have relatively low set-up and
maintenance costs
2 Short life cycle
3 High fecundity (produce large number of off-springs with feature-rich morphology)
4 The Drosophila community is open and generous in sharing reagents within the community.
5 No ethical issues and regulatory considerations.
6 Genetic advantages
• flies have only 4 pairs of chromosomes
• males lack genetic recombination, making genetic crosses easier
• flies tend to lack genetic redundancy
7 Signaling pathways controlling growth, differentation and development, which are involved in tumor
formation in the fly are largely conserved between Drosophila and humans
8 Availability of numerous genetic tools & reagents for generating mutants and analysis of gene expression
by using methods producing over- & ectopic- expression.
• The use of “balancer chromosomes” with multiple DNA inversions prevent female recombination and
allows the perdurability of mutations on the original carrier chromosome
• Wide variety of gene targeting strategies, e.g. UAS-GAL4 system combined with RNAi knock-down allow
the tissue-specific analysis of tumor suppressor gene and oncogene function
• Mosaic analysis of animals containing mutant clones next to wild type tissue, using FLP-FRT and MARCM
recombination systems, allows the analysis of tumor microenvironment in invasion, metastasis &
inflammation.
9 Possibility to perform genome-wide screens using chemical mutagenesis, tissue-specific RNAi knockdown,
effectors and modifier screens to identify genes involved in specific developmental pathways and assign
and validate new gene functions.
10 Use of Drosophila tumor models for pharmacological screening and development of new therapeutic
strategies for cancer.
Table 1. Advantages of Drosophila melanogaster for the analysis of cancer.
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Another example can be found in the EGFR pathway, which functions redundantly to PVR to
stimulate border cell migration [142]. Overexpression of EGFR has been reported in up to 70%
of ovarian carcinomas [143]. The role of E-cad is also here critical. Normal cells of ovarian
surface epithelium express little or no E-cad. However, many primary ovarian carcinomas,
similar to border cells, express E-cad at the cell surface and in the cytoplasm [144, 145].
Although cell-surface expression of E-cad is reduced in many metastatic carcinomas, these
tumors frequently still have detectable intracellular E-cad [146], indicating that these cells,
similar to border cells, have acquired the ability to downregulate E-cad activity at a post-
transcriptional level [140].
Numerous molecules identified in Drosophila genetic screens have proven to be important to
human cancers [140, 147]. For example, the Hedgehog gene and the Wnt homologue Wingless
were originally identified in genetic screens for mutations that disrupt embryonic patterning.
Subsequent studies of signaling proteins such as Hh, Wnt [140, 148-150], Notch [151, 152] and
RhoGTPases [153] as well as of integrin-related adaptor proteins [154, 155] and Hox genes
[156, 157], revealed crucial functions not only in normal mammalian development but also in
various cancers. It is therefore well accepted that genetic approaches to the study of normal
cellular behavior in simple model organisms can yield fundamental insights into the molecular
underpinnings of cancer.
4. New perspectives in modeling tumorigenesis in Drosophila
melanogaster
Drosophila is emerging as a valuable system for use in clinical drug discovery and therapeutic
process [52, 129, 158-160]. So far, Drosophila was not a favorable model in drug discovery. The
main reason was that “Drosophilists” were mainly concerned with answering fundamental
development and cell biology questions, and elucidating principles of basic mechanisms and
not practical issues of therapeutics [129]. This view is slowly changing as interest in therapeu‐
tics and pressure for practical outcomes increases, and combined with the development of
powerful tools allows Drosophila to catch-up in the field.
The remarkable degree in conservation of biochemical pathways that control processes such
as cell proliferation, differentiation and migration as well as nervous system function in
behavior and cognition, sustains perfectly the use of invertebrate model genetic organisms as
tools for drug discovery and validation [52]. Drosophila’s genetic and genomic tools can be
adapted to build sophisticated disease models for studying cancer and metastasis, and for
therapeutic development. While testing with mammalian models is essential prior to approval
for human trials, the use of invertebrate animal models that are amenable to molecular genetic
manipulations, provides experimental and biological advantages that can streamline drug
discovery and testing process. Among the benefits of a genetics-based approach is the ability
to screen for proteins that may be novel drug targets, and in genetic backgrounds that could
more accurately reflect a specific disease state [52]. New drugs can be tested in Drosophila much
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faster than in mammalian models and can even be used for high throughput screening
processes as an alternative to cell culture [31].
Drosophila may constitute an appropriate model system that can be used for screening a “whole
animal setting” as an alternative to cell-cultured based methods. In most pharmaceutical
industries the discovery of new compounds with potential positive pharmacological effect
relies on the screening of small molecule libraries for interactions with purified proteins, or
for the ability to induce a desired physiological response in cultured cells [52]. One of the main
problems is that complex processes such as tumor metastasis cannot be recapitulated in a cell
or an organ culture. Moreover, cells and organs are physiologically connected and their
interplay could be critical in the development of some diseases. Furthermore, the time
component of the disease progression cannot be easily recapitulated in vitro [161]. The second
problem is that after the initial screen, the next phase of drug testing, which requires the use
of intact mammalian animal models to assay the effectiveness of candidate compounds,
usually fails. If in this step of drug discovery process, the compounds isolated in vitro or in cell
culture, are invalid in mouse, the result is an enormous waste of funds and efforts [158]. At
the same time, whole animal vertebrate models are not particularly suitable for high-through‐
put methodologies and if then only at an extremely high cost. To by pass these limitations,
efforts are now being made to screen chemical libraries on whole-animals like Drosophila with
genetic amenability, low cost and culture conditions compatible with large-scale high-
throughput screening.
Furthermore, performing drug screening in the Drosophila “whole animal system” does not
dependent on the prior identification of a target and permits the selection of compounds with
an improved safety profile. A screen based on a phenotypic observation has the advantage of
being independent of the specific molecular target involved. Then, depending on the readout
used to assay the effectiveness of the candidate drug compound, a large variety of bio-active
molecules may be detected in the same screen [158]. Finally, similar to the established “en‐
hancer” or “suppressor” screens, Drosophila gives the possibility to test chemical libraries in
the genetic background of a disease for their ability to reverse the abnormal phenotype to wild
type or partially rescue the disease phenotype [158, 161].
Several groups today develop the associated technology to use Drosophila in the first phase of
screening for drug compounds, and subsequently test them in more expensive mammalian
models. Moreover, the fact that it is usually easier and more straightforward to manipulate
the genetic background of Drosophila and mimic a disease state, opens also new possibilities
for efficient drug testing in a disease-related content. For example, the development of
genetically modified animals with fluorescently tagged proteins would allow the use of
standard plate-reader spectrofluorometer for whole-animal screens [161].
When the development of mosaic tissues is essential for the analyses of a disease model, the
use of MARCM provides notable advantages for effective drug discovery. One is the ability
to follow the morphology of mutant cells and tissues which could be useful for assessing the
efficacy of a therapeutic compound [52]. When a mutation in a given gene causally produces
a disease, it is possible that this mutation elicits a change in expression of other genes and in
the function of proteins. These alterations may contribute to the pathologies associated with
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the disease. The characterization of these changes constitutes then the first step needed to
develop rational therapeutic strategies. Finally, the MARCM methodology should provide
ways to identify mutant cells or tissues for a given gene, isolate and subject them to proteomic
and genomic analyses which would determine modifications in gene expression and protein
interaction profiles [52].
The phenotypes of complex trait diseases such as obesity, heart disease and cancer are the
result of modifications occurring in multiple biochemical pathways. The disease phenotype
can be caused by improper activation or inhibition of a protein that acts in any of the contri‐
buting pathways. Restoration of the normal phenotype would be expected if the output from
the primary biochemical pathway affected is rescued via drug-based therapy [52]. However,
if multiple pathways contribute to a phenotype, it stands to reason that modifying the activity
of a parallel pathway could also elicit a positive therapeutic effect. The use of genetic model
organisms has long been a successful means for elucidation of biochemical and physiological
pathways, and one of the most powerful strategies available for uncovering genes that act
together in producing a phenotype is a search for genetic interaction or a modifier screen.
Modifier screens work by generating animals with a mutation in a gene of interest that elicits
a sensitized phenotype, and then screening for mutations in progeny that enhance or suppress
(i.e., modify) the primary phenotype [52]. Drosophila disease models are currently used in drug
screening for treatment of diseases such as Alzheimer’s and Huntingtons’s disease, Fragile X
Syndrome and muscular dystrophy [160, 161]. The use of drug discovery especially for muscle
diseases is of particular importance as the muscles are difficult to reconstitute in vitro and
elucidation of the physiology of muscle related diseases and relevant treatment is still poorly
understood. However, the similarity in architecture, composition and function between
Drosophila and vertebrates may trigger studies in the fruit fly and provide these diseases with
some valuable therapeutic answers [161].
Drug discovery has also proved very effective for the identification of cancer treatments such
as the multiple endocrine neoplasia type-2 (MEN2) [129, 162]. MEN2 is a “one-hit” solid tumor
syndrome, characterized by mutations in the Ret protein, a transmembrane receptor tyrosine
kinase. Patients with mutated oncogenic isoforms of Ret, develop medullary thyroid carcino‐
mas (MTC) that lead to metastasis, which seem to be resistant to traditional chemotherapies.
To develop a whole-animal transgenic model, various oncogenic Ret isoforms were targeted
to the developing fly eye epithelium. The fly ”rough-eye” phenotype is characterized by eye
overgrowth, switch in cell fate and other aspects, proving the effectiveness of fly as model and
useful readout for screening. The screening for clinical relevant compounds, in the tumorous
developing flies by Cagan and his group resulted in the identification of Vandetanib, a broad
kinase inhibitor, which Cagan called “the worst kinase inhibitor”. Although not very specific
and effective, this kinase inhibitor was indeed effective in rescuing the fly phenotype because
it regulated the activity of other kinases such as Ras, Src and PI3K (all of which are involved
in cancer). Other compounds were more capable of rescuing the rough eye phenotype but
reduced animal viability. Yet, Vandetanib displayed little toxicity to the animal as a whole,
indicating that tumors might display a lower tolerance threshold for drugs than the entire
animal. Obviously the “off-target” effects of Vandetanib, by suppressing kinases other than
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Ret, are important for its effectiveness. Classical drug screenings would reject Vandetanib as
too inefficient to the target and too low in its specificity [129, 162]. Cell-culture and subsequent
fly work proved to be extremely valuable, as Vandetanib was shown to be efficient in Phase
II clinical trials. Currently Vandetanib is in Phase III of clinical assays. This further proves the
power of Drosophila not only for clinical relevant drug discovery but also for shaping how we
should approach drug discovery for treating diseases.
A new in vivo drug screening in Drosophila has been performed to target cancer stem cells
(CSCs) in the group of Norbert Perrimon [163]. Cancer cells represent a small number of cells
within tumors with a self-renewing capacity that can regenerate tumor cells types through
their stem cell-like renewal capacity. Their resistance to chemotherapy is the main reason why
chemotherapeutic treatments are ineffective and the disease often relapses. In order to cope
with the challenge of finding drugs that specifically target the CSCs, the Perrimon laboratory
uses the Drosophila gut as the stem cell system to develop novel methods and approaches to
screen for anti-cancer drugs that target CSCs in vivo in the gut microenvironment. By directing
the expression of oncogenes in Drosophila transgenic fly models combined with a screening
method that involves monitoring of tumor size by luciferase reporter activity, they identified
25 compounds that reduced tumor size. Further confirmation was validated with dissection
of the gut, histochemical-imaging of the gut specific cells and determination of the specificity
of the drugs. For example, some drugs were targeting only the CSCs whereas others were
targeting CSCs but at the same time promoted growth of the wild type stem cells and in some
cases also affected stress pathways in the daughter cells.
5. Limitations in using Drosophila as a model system: how far can we go?
Drosophila melanogaster, as a model system for studying tumorigenesis and human disease has
certain limitations, especially in regard to the biological processes that evolved only within the
vertebrate lineage [164]. The main limitation of Drosophila arises from the fact that some
diseases cannot be modeled because the corresponding genes and organs present in humans
are missing in flies [161]. For example, Drosophila has a single cardiac chamber that functions
as a heart in the context of an open circulatory system. Moreover, the Drosophila myocardium
receives oxygenation through diffusion and does not have coronary arteries [165]. A second
limitation arises from differences in cellular and molecular processes of Drosophila in compar‐
ison to humans. For example, there are cases in which one or several key molecules mediating
a human disease-specific pathway are missing in flies [160]. Ultimately, some areas such as
learning, endocrine function and mammary gland development, may prove difficult to study
in a simple invertebrate like Drosophila and so the study of these particular disorders may not
benefit substantially from Drosophila genetics [166]. Another example is modeling tumor
metastasis. In mammals malignant cells undergoing metastasis enter the local blood or lymph
vessel before colonizing a distant tissue and forming metastatic tumors. This is very difficult
to model in Drosophila as flies have a rudimentary hematopoietic system and a dramatic
different lymphatic system compared to mammals [78]. However, one should point out that
despite these differences the “master regulators” of heart, eye, kidney etc. have proved to be
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remarkably conserved [162]. This means that in the case of e.g. spinal malformation, flies could
be used to model bone formation per se, but as Notch signaling has a pivotal role in regulating
this process, any knowledge obtained about interactions between components of this pathway
in Drosophila could be relevant to processes that these genes control during spinal formation
in humans [164].
Are there limitations in using Drosophila for treatment-relevant drug discovery? The limita‐
tions in this case result from the anatomical and molecular differences of small model organ‐
isms in comparison to humans, as this may cause the elimination of a significant fraction of
the hits generated. The use of Drosophila models should be viewed as complementary alter‐
natives to cellular assays and in vitro screenings made in mammalian cells, rather than the
absolute shortcut to screen drugs for human treatments [158]. Their added value for drug
discovery varies from disease to disease, and mainly depends on the availability of other
options. Indeed, assays in Drosophila are complementary to in vitro and cellular systems, and
in comparison to rodent model systems Drosophila’s small size and culture conditions fulfill
the requirements for large-scale screens [158]. Furthermore, another limitation also results
from the dose-dependence of the drug treatment. In rodent model systems the drug dosage
may differ according to the mode of penetration and the nature of the drug. In Drosophila dose-
response experiments are easily feasible but the compounds are essentially delivered to the
fruit flies through the media [167]. Thus, it is important that the results obtained with Drosophila
are compared with data obtained on laboratory rodents and, when possible, in humans.
Furthermore, in numerous cases the results will be more qualitative than quantitative.
Although the conclusions derived from Drosophila studies may remain too uncertain for
pharmacologists, the data obtained from invertebrate-based screening could lead to important
breakthrough, particularly for those diseases in which the pathophysiology is poorly under‐
stood [158, 161].
Often model systems are used to understand life and basic biological and cellular mechanisms.
A better understanding of a specific human disease often comes as a consequence of the better
overall understanding of biological processes [159]. Within this context, Drosophila is a valuable
tool to categorize putative candidate genes for further downstream functional analysis in
vertebrates. It can be used to dissect the likelihood that individual genes in a gene-cluster
contribute to disease susceptibility, identify the relevance of a gene to a disease-pathway and
get insights on gene specific functions manifested at the level of a tissue or involving cell-cell
communication. Using Drosophila models, preliminary experiments with other model systems
(such as mice) may be reduced and experiments in higher organisms can be better focused.
Using Drosophila in a systematic approach together with other models and tools, seems
promising in order to significantly reduce the turnout time from genetic results into biologi‐
cally meaningful data [168]. Conclusively, although Drosophila will probably not always serve
as a perfect model for human disease modeling, the common underlying molecular interac‐
tions and signaling pathways between flies and humans will continue to allow researchers to
use Drosophila in order to answer existing questions, pose new hypotheses, get entry points in
elucidating cancer and personalized cancer therapy, and complement studies from other
model systems and vertebrate organisms [164].
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6. The expanding role of Drosophila in cancer research: Bridging past,
present and future
Undeniably the study of Drosophila has brought major contributions in understanding to the
fundamentals of cancer and has further given strong impulses not only in basic but also in
applied research. The unrivalled advantages and tools offered by Drosophila ensure that it will
remain a premier research organism for many years to come. The advantages of Drosophila as
a model system includes the availability of genetic tools developed in a century of “tool-
building” research, its short life cycle and ability to unravel the basic function of genes in a
straightforward way. The use of visible mutations and chromosome mapping coupled to
currently available complex genetic databases including genomic and proteomic sequences,
together with help of systematic gene disruption (RNAi libraries), microarray analysis, protein
interaction maps and Flybase, lay the carpet for a renewed new age of research in Drosophila,
and will allow scientists to address new questions on biological processes which were
previously inaccessible. In turn, the new discoveries will foster new research and answer to
more precise questions about signaling pathways and behavior of individual cells in cancer.
The Drosophila research will continuously contribute to a better understanding of tumor
formation and progression, and may thus improve therapies in treating cancer.
Could Drosophila still be a valid model for understanding tumor formation and could it still
provide a lead for curing cancer? Although the fruit fly does not appear to be suited for
studying vertebrate-specific tissues, such as brain and heart development or neural crest
migration [37], Drosophila may still help to identify critical key-genes, discover new biological
pathways, define new research approaches, and therefore pioneer numerous fields in the
understanding of cancer, including vertebrate biology. Drosophila can also be used to unravel
the sequence of events leading to tumor formation and to trace the initial stages of tumor
formation. One of the main outcomes of the genome analysis has been the finding of a high
degree of conservation among genes and importantly 75% of the genes involved in human
diseases have homologues in Drosophila. There is also a high degree of functional conservation
between the signal transduction pathways and a high degree of structural and functional
conservation between cell adhesion proteins of Drosophila and humans showing that the
fundamental biological processes have a common origin and has been relatively conserved
during the 600 million years of evolutionary divergence between invertebrates and vertebrates.
New emerging challenges in the study of tumorigenic inflammation, in in vivo screening for
drug acting on cancer stem cells, in the therapeutic drug design and discovery will provide us
with new insights into a “multi-target” approach for treating cancer. Finally, innovative
technologies such as microarrays and nanotechnology, combined with novel methods in
computation and bioinformatics, could be used in combination with genome-wide analysis in
Drosophila, functional maps of the chromatin landscape [169-171], cis-regulatory map of the
Drosophila genome and pattern of co-binding partners in transcription [172], as well as high-
resolution of transcriptome dynamics throughout development [173, 174] to define more
accurately the network of genes and pathways that would permit initial cancer cells to build
expanding tumors. These new directions highlight not only the value of basic research but also
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the intrinsic advantages of Drosophila as a model organism for studying the complexity of
cancer.
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1. Introduction
The chemotherapeutic properties of polyphenols have recently received an increasing interest
since it has been established that these compounds can modulate each step of the cancer
progression process (initiation, proliferation, survival, migration, angiogenesis, and metasta‐
sis). Polyphenols are believed to be multi-targets drugs and in the present chapter we will give
an overview of recent investigations concerning apoptosis induction by three major com‐
pounds, resveratrol, curcumin and epigallocatechin-3-gallate (EGCG) mainly through the
regulation of the p53 tumor suppressor pathway. The potential regulation by polyphenols of
p53 expression at the transcriptional and post-translational levels has been extensively
described. Interestingly, polyphenolic compounds are also able to trigger apoptosis of
numerous cancer cells, independently of the p53 status (wild-type, mutated or deficient).
Moreover alternative mechanisms supported by recent studies highlight the role of p73, a p53
related tumor suppressor, as another key target for polyphenols. Then the molecular mecha‐
nisms involved in tumor suppressors (mainly p53 and p73) expression by polyphenols will be
discussed with a specific focus on the role of oxidative stress which is believed to be a key
element in polyphenols-induced cancer cells death.
2. Anticancer properties of polyphenols: Chemoprevention and
chemotherapy
Polyphenols are natural compounds characterized by a structure containing at least one
benzene ring substituted by at least one hydroxyl group. Beside this chemical hallmark,
© 2013 Etienne-Selloum et al.; licensee InTech. This is an open access article distributed under the terms of
the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
phenolic products currently constitute a large and still expanding complex and heterogeneous
family of molecules (more than 8000 phenolic structures currently known) with a great
diversity of structure and size ranging from the low molecular weight simple phenols up to
the high molecular weight tannins [1-3]. Polyphenols are also one of the largest and most
widespread classes of constituents present in plant kingdom and more particularly in plant-
derived foods and beverages giving them their color and taste properties. Polyphenols can be
structurally divided into two main families: flavonoids and non-flavonoids. Flavonoids are
especially abundant in fruits, vegetables, seeds, spices, herbs, tea, cocoa, and wine. The six
major subclasses of flavonoids are anthocyanidins (e.g., cyanidin, delphinidin; primary
sources: red berries, red cabbages, cherries, grapes, and onions), flavan-3-ols (e.g., catechin,
epicatechin, EGCG; primary sources: tea, grapes, cocoa, apples, and red wine), flavanones (e.g.,
hesperitin, naringenin; primary sources: oranges, lemons, and grapefruits), flavones (e.g.,
apigenin, luteolin; primary sources: celery, parsley, and thyme), flavonols (e.g., kaempferol,
myricetin, quercetin; primary sources: apples, beans, broccoli, and onions), and isoflavonoids
(e.g., daidzein, genistein; primary sources: legumes and soy products). Phenolic acids repre‐
sent a large subclass of non-flavonoid polyphenolic compounds which can be further divided
into two main types: benzoic acids (e.g., gallic acid, ellagic acid, vanillic acid; primary sources:
tea, red wine, berries, nuts, and herbs) and cinnamic acids (e.g., caffeic acid, chlorogenic acid;
primary sources: coffee, berries, plum, and apple). Other important classes of non flavonoids
with healthy properties are stilbenes, such as resveratrol (primary sources: red wine, berries
and nuts) and curcuminoids such as curcumin the main component of dried turmeric and
curry powder [4]. Polyphenols are considered as secondary plant metabolites and have been
associated with several functions in plants such as resistance against microbial pathogens and
insects, protection against DNA-damaging UV light, reproduction, nutrition and growth [3].
In parallel to their protective properties in plants, polyphenols have long been regarded as a
pool of bioactive natural products with potential benefits for human health. Plant extracts,
herbs and spice containing these compounds have been used for thousands of years in
traditional medicines. Nowadays, plant polyphenols enjoy an ever-increasing recognition not
only by scientific community but also, and most remarkably, by the general public because of
their presence and abundance in fruits, seeds, vegetables and derived foodstuffs and bever‐
ages, whose regular consumption has been claimed to be beneficial for human health [3, 5].
Indeed, epidemiological and experimental studies have shown the potential of polyphenols
or polyphenolic nutritional sources in reducing the risk of chronic diseases such as cardiovas‐
cular diseases [6-10] and cancers [10-14], as well as the risk of degenerative diseases [10, 15,
16]. Altogether these observations led to the current nutritional recommendations to eat five
servings of fruits and vegetables per days in order to keep healthy.
A wealth of data, including epidemiological and animal studies, has described the chemopre‐
ventive and anticancer properties of polyphenolic compounds, such as resveratrol, curcumin
or tea catechins, or polyphenol-rich nutritional sources [13, 14, 17-19]. Nonetheless, recent
investigations have highlighted additional mechanisms responsible for direct anti-prolifera‐
tive and chemotherapeutic properties of polyphenols. Indeed, these compounds can interfere
with the initiation, as well as the progression of cancer through the modulation of different
cellular events, such as cell cycle arrest by decreasing cyclins or apoptosis induction through
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cytochrome c release, activation of caspases and down- or up-regulation of Bcl-2 family
members, and inhibition of survival/proliferation signals (AKT, MAPK, NF-κB, etc.). Further‐
more, they play an important role in inflammation (COX-2, TNF secretion, etc.), as well as in
suppression of key proteins involved in angiogenesis and metastasis [13]. Importantly, it has
been established that tumor suppressors like p53 and its analogs are key molecular targets of
polyphenols responsible for their pro-apoptotic effect in human and animal cancer models.
Here we provide an overview of the molecular mechanisms involved in p53 family proteins
modulation by three major and well characterized polyphenolic compounds, resveratrol,
curcumin and EGCG.
3. p53 family proteins are chemotherapeutic targets of polyphenols
Since the discovery of p53 in 1979 [20-22] numerous studies have been conducted related to
its functions in response to stress and its regulatory mechanisms. p53 is a sequence-specific
nuclear transcription factor that binds to defined consensus sites within DNA as a tetramer
and represses transcription of a set of genes involved in cell growth stimulation, while
activating a different set of genes involved in cell cycle control, like p21. It causes growth arrest
providing a window for DNA repair or elimination of cells with severely damaged DNA
strands. In some conditions, p53 activation triggers the transcription of pro-apoptotic genes
such as Bax or PUMA, as well as the repression of anti-apoptotic genes like survivin [23].
Moreover, p53 can induce transcription-independent apoptosis. This mechanism involves
early p53 translocation to mitochondria where it binds to Bcl-2 family proteins, such as Bax,
Bak and Bcl-XL, activating cytochrome c release and caspases cascade [24]. Undoubtedly p53
exerts major anti-neoplastic effects and is considered actually as the “guardian of the genome”
[25]. Tumor suppressive capabilities of p53 are related to a coordinated regulatory circuit that
monitors and responds to a variety of stress signals, including DNA damage, abnormal
oncogenic events, telomere erosion and hypoxia [26]. Importantly, in unstressed cells, p53 is
latent and is maintained at low level by targeted ubiquitin-mediated degradation related to
its interaction with ubiquitine ligases, mainly MDM2 [27]. Regarding the “guardian” functions
of p53, mutations of p53 gene or disruptions of p53 coordination such as post-translational
inactivation, can disturb the normal physiological balance, and lead to cancer if genome
disarrangement reachs a critical value [28]. Indeed, low level of functionnal p53 is a common
characteristic of cancer from several localizations including lung, colon, rectum, breast, brain,
bladder, stomac, prostate, ovary, liver or lymphoid organs [29]. Somatic p53 missense
inactivating mutations are found in approximately 50% of human cancers [30] and this
inactivating mutations render the mutant p53 protein unable to carry out its normal function,
that is, transcriptional transactivation of downstream target genes that regulate cell cycle and
apoptosis [31-33]. On the other hand, p53 pathway can be also inactivated in wild-type (WT)
p53-carrying tumors via indirect mechanisms such as MDM2 amplification leading to p53
destabilization [34, 35].
Recently, cDNAs with strong homologies to p53 have been identified and their products were
termed p63 and p73 [36-38]. Both proteins are structurally similar and functionally related to
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p53, and consequently the entire p53 family may be regarded as a unique signalling network
controlling cell proliferation, differentiation and death. Interestingly, in contrary to p53, the
role of the other two p53-related proteins in tumor suppression is less obvious, since they are
rarely deleted or mutated in cancer, and the respective knockout mice die tumor-free from
developmental defects [39-41]. However, increasing number of evidences suggest that both
p63 and p73 have a role in tumor suppression. Indeed, different studies indicated that TAp73
and TAp63, the transcriptionally active isoforms, can induce cell cycle arrest, senescence, DNA
repair, and apoptosis in response to chemotherapeutic drugs, independently of p53 [42-45]. In
addition, even if not mutated, p63 and p73 can be aberrantly expressed in cancer. More
particularly, the dominant negative and transcriptionally inactive isoforms ∆Np63 and ∆Np73
are frequently overexpressed in a wide range of tumors, in which they are associated with
poor prognosis [46]. Actually, the imbalance in the TAp73/∆Np73 may be more critical for
tumorigenesis and response to chemotherapy than mutations [47]. In summary, despite their
differences, the three members of the p53 family may be considered as therapeutic targets for
cancer management.
Many in vitro studies as well as few in vivo studies have shown that resveratrol, curcumin and
EGCG, as well as nutritional sources of polyphenols induce overexpression of wild-type p53
(Table 1-4). The p53-related anticancer properties of these three isolated molecules have been
extensively evaluated but other polyphenolic compounds such as genistein, luteolin, querce‐
tin, and wogonin have been shown also to upregulate wild-type p53 protein in several cancer
cell lines [48-51]. The polyphenol-induced stabilization and expression of wild-type p53 is
often associated with a G1 or G2/M phase cell cycle arrest together with transcriptional
regulation of target genes such as p21, Bax, PUMA and apoptosis induction [52-56]. The key
role of p53 in polyphenol-induced anticancer properties is supported by studies indicating
that p53 downregulation counteracts apoptosis triggered by natural products. Indeed, p53
silencing by siRNA abrogate the cytotoxic effect of curcumin in chondrosarcoma cells [57] and
genetic invalidation of p53 by shRNA leads to inhibition of EGCG plus luteonin-induced
apoptosis of lung cancer cells [58]. In addition, EGCG fails to induce significant cytotoxic effect
in p53-null PC-3 prostate cancer cells, but forced expression of p53 in such cell line leads to
sensitization to the polyphenolic compound [53]. Indeed, in the later study EGCG induces p53
phosphorylation on Serine 15 and upregulation of p53 and p21 expression together with cell
cycle arrest and apoptosis. However the key role of p53 in the anticancer properties of
polyphenols is still controversial, especially for curcumin, since many studies have shown its
anti-proliferative properties in several p53-mutated or p53-null cancer cell lines (Table 2). For
instance, curcumin has significant anti-proliferative effects in two p53-mutated human
glioblastoma cell lines, indicating alternative and p53-independent pathway involved in such
anticancer properties [59]. Similarly, curcumin reduces glioblastoma cells viability irrespective
of p53 mutational status [60]. In this study, curcumin-induced cancer cell death was associated
with caspase-3 activity in p53-wild-type cells, but not in p53-mutated cells, indicating that
polyphenols can trigger p53- and caspases-independent cell death. p53-independent anticanc‐
er properties of polyphenols have been also described in many other cancer cells [61-67].
Interestingly, curcumin reduces the expression of the mutated form of p53 in MDA-MB-231
breast cancer cells together with cell cycle arrest [68], suggesting that a polyphenol-dependent
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regulatory process can also modulate the expression of a non-functional tumor suppressor.
However, despite potential apoptosis induction by polyphenols in absence of functional p53
protein, its wild-type expression makes cancer cells more sensitive to pro-apoptotic effects of
polyphenols. Recently, Ferraz da Costa et al. have demonstrated that transient transfection of
wild-type p53 in human non-small lung carcinoma cell line H1299 (p53 negative) dramatically
increased susceptibility to resveratrol-induced apoptosis [69]. Altogether these data indicate
that p53 participates to the cytotoxic effect of polyphenols but also that alternative pathways
might be involve in their anticancer properties.
One of this alternative pathway might involve Egr-1, an immediate early-response gene
induced by stress, injury, mitogens, and differentiation [70]. Egr-1 regulates the expression of
genes involved in the control of growth and apoptosis by transactivating many proteins
including p21. One study has shown that transcription of the p21 gene is activated by Egr-1
independently of p53 but under the control of MAPKs in response to curcumin treatment in
U-87MG human glioblastoma cells [71]. In addition, the apoptotic effect of resveratrol in
colorectal cancer cells as well as EGCG-mediated cytotoxicity in pulmonary cancer cells are
also associated with Egr-1 upregulation [72, 73].
Alternatively to p53, its functionally related proteins p63 and p73 might represent targets for
polyphenols. Nevertheless only few data are available concerning a potential regulatory effect
of polyphenolic compounds on p63 and p73 (Table1-4). Different flavones (luteolin, apigenin,
chrysin) and flavonols (quercetin, kaempferol, myricetin) are able to induce cytotoxicity in
p53-mutated oesophageal squamous carcinoma cells together with upregulation of p63 and
p73 [74]. Similarly, EGCG induces selective apoptosis in multiple myeloma cells with overex‐
pression of p63 and p73 without any change in the p53 expression level [75], as well as
overexpression of p73 in p53-mutated T-lymphocyte leukemic cells [76]. As previously
mentioned, different isoforms of p73 have been described and quercetin has been shown to
control the subcellular localization of the dominant negative isoform ∆Np73 in melanoma cells
expressing wild-type p53. In this model, quercetin caused redistribution of ΔNp73 into the
cytoplasm and nucleus, which has been associated with increased p53 transcriptional activity
and apoptosis [47, 77]. Beside isolated compounds, more complex sources of polyphenol such
as red wine polyphenolic extract or berries-derived product can also modulate p53 and/or p73
expression level, in vitro and in vivo (Table 4) [78-81]. Interestingly, a synthetic analogue of
curcumin increases p73 expression level in two distinct p53-wild-type pancreatic cancer cell
lines, BxPC-3 and Colo-357 together with upregulation of pro-apoptotic effector Bax and
simultaneous downregulation of the anti-apoptotic protein Bcl-2 [82]. Curcumin itself has been
shown to stimulate p53 and also p73 expression in p53-mutated C33A cervical cancer cells [83].
Moreover, EGCG upregulates transcriptional target of p53, in a p53-independent but p73-
dependent manner in mouse embryonic fibroblasts [84]. These data suggest that independ‐
ently of the p53 status (wild-type, mutated or deleted), p73 seems to be involde in the anticancer
effect of polyphenolic compounds. Many others studies have shown the potential of polyphe‐
nols to induce apoptosis of cancer cells in a p53-dependent but also a p53-independent manner
(Table 1-4). In summary data concerning the role of tumor suppressors in the polyphenol-
induced anticancer effects are inconsistent, probably dependent on the cell type, and conse‐
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quently remain controversial. Moreover, the molecular mecanisms responsible for p53-family
tumor suppressors regulation by polyphenols are only partially elucidated. However some
evidences indicate that polyphenols might modulate p53 or p73 expression as well as their
stabilization which are under the control of phosphorylation and acetylation levels.
Resveratrol
Cancer model Described effects on TSG (p53/p73) References
Prostate cancer cells (LNCaP,
DU145, p53-mutated
CWR22Rv1, p53-null PC-3)
- No change in p53 mRNA, increased expression of p53-p(ser15)
and/or p53-ac(lys382) and total p53 protein
- p53 translocation to mitochondria
- cell cycle alteration and apoptosis induction maintained in p53-
mutated cancer cells
- potentiation of radiation–induced p53 expression in p53-
mutated cancer cells
[135, 158, 164,
165, 175, 176]
Ovarian carcinoma cells
(OVCAR-3)
- nuclear accumulation of p53-p(Ser15) [110]
Breast cancer cells (MCF-7,
p53-mutated MDA-MB-231,
p53-mutated MDA-MB-435)
- increased expression of p53-p(ser15), p53-p(ser20), p53-
p(ser392) and p53-ac(lys382/lys373)
[177-180]
- no change in total p53 protein expression, p53-independent
apoptosis
[178, 181]
- increased expression of p53 mRNA and total protein [182-184]
- no change in p53 mRNA [185]
- p53-independent cytochrome c release [181]
- increased p53-dependent transcriptional activity [50]
Colon cancer cells (HCT116,
p53-null HCT116)
- increased p53-p(ser15) expression
- resveratrol-induced senescence is p53 dependent
[103]
Pancreatic cancer cells
(capan-2, colo357)
- upregulation and nuclear accumulation of p53 in both cell line
(restoration of wild-type expression)
[186]
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Resveratrol
Cancer model Described effects on TSG (p53/p73) References
Glioblastoma cells (A172,
p53-mutated T98G)
- no change in p53 mRNA [187]
Hepatocellular carcinoma
cells (HepG2)
- no change in p53 mRNA [185]
Osteosarcoma cells (U-2 OS) - increased p53-p(ser15) and p53-p(Ser37) expression [188]
Lung adenocarcinoma cells
(A549)
- increased p53-p(ser15) and p53-p(Ser37) expression [188]
Head and neck squamous
cancer cells (UMSCC-22B)
- increased p53-p(ser15) and total p53 expression [109]
Cervical cancer cells (HeLa) - increased p53-ac(lys373) and total p53 expression [185]
Hodgkin lymphoma cells
(L-428)
- increased p53-p(ser15) expression [129]
Follicular lymphoma cells
(LY8)
- increased p53-p(ser15) and total p53 expression [190]
Acute lymphoblastic
leukemia cells (MOLT-4)
- increased p53-p(ser15) expression [189]
Neuroblastoma cells (B65,
NUB-7)
- increased p53-p(ser15) and total p53 expression
- nuclear translocation of p53
[94, 132]
DMBA-TPA-induced mouse
skin tumor ; DEN-induced rat
hepatocellular carcinoma
- increased p53-p(ser15) and total p53 expression [18, 191, 192]
- increased wild-type p53 and decreased mutated-p53 expression [193]
Cancer cell lines express wild-type p53 except where otherwise stated; ac(lys.)=acetylated lysine, p(ser.)=phosphorylated
serine
Table 1. p53 family-related anticancer properties of resveratrol
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Curcumin
Cancer model Described effects on TSG (p53/p73) References
Breast cancer cells (MCF-7, p53-
mutated MDA-MB-231, p53-
mutated SkBr3)
- increased expression of p53-p(ser15), no change or
increased expression of total p53
-decreased expression of mutated p53
[68, 178,
194-197]
Cervical cancer cells (p53-
mutated C33A, Caski)
-increased expression of p53 and p73 [83, 198]
Ovarian cancer cells (HEY,
OVCA429, p53-mutated OCC1,
p53-null SKOV3, CaOV3,
Ho-8910)
-p53-independent cell death [106]
-increased expression of p53-p(ser15)
-increased expression of p53
[107, 199, 200]
Prostate cancer cells (LNCaP,
p53-null PC3)
-increased expression of p53-p(ser15),p53-ac(lys) and total
p53 protein
-p53-independent cell death
-p53 translocation to mitochondria
[95, 100, 201]
Bladder cancer cells (p53
mutated-T-24 and AY-27)
-no change or increased expression of p53 [202, 203]
Erhlich Ascite carcinoma cells -increased expression of p53-ac(lys373) and total p53 [120]
Colorectal cancer cells (LoVo,
HCT116, p53-null HCT116, p53-
mutated HT29, p53-mutated
Colo205)
-increased expression of total p53 [52, 204]
-increased expression of p53-p(ser15), p53-p(ser33) and total
p53
[64]
-no change in p53 expression [173]
-increased expression of p53-p(ser15)
-decreased or unchanged expression of mutated p53
[156, 205]
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Curcumin
Cancer model Described effects on TSG (p53/p73) References
-cell cycle arrest, senescence and autophagy independent of
p53 expression
-cytochrome c release independent of p53 expression
-increased expression of total p53
[206, 207]
Colitis-associated colorectal
cancer in mice
-no change in p53 expression [17]
Acute lymphoblastic leukemia
cells (B6p210, T315I)
-increased expression of total p53 [208]
Chondrosarcoma cells and
xenograft in nude mice (JJ012)
-increased expression of total p53 in vitro and in vivo
-p53-dependent apoptosis
[57]
Melanoma cells (MMRU, p53-
mutated PMWK, B16BL6)
-no change in p53 expression [209, 210]
Glioblastoma cells (C6,
U-87MG, p53-mutated
U138MG and U251, DBTRG,
T98G, T67)
-p53-independent cell death
-unchanged or increased expression of p53
[60, 71, 163, 211,
212]
Neuroblastoma cells (SK-N-AS,
NUB-7, p53-mutated SK-N-
BE(2))
-p53-independent cell death
-nuclear translocation of p53
[65, 94]
Cancer cell lines express wild-type p53 except where otherwise stated; ac(lys.)=acetylated lysine, p(ser.)=phosphorylated
serine
Table 2. p53 family-related anticancer properties of curcumin
Polyphenolic Compounds Targeting p53-Family Tumor Suppressors: Current Progress and Challenges
http://dx.doi.org/10.5772/56102
137
Epigallocatechin-3-gallate (EGCG)
Cancer model Described effects on TSG (p53/p73) References
Breast Cancer cells (MCF7, p53-
mutated MDA-MB-468)
-increased expression of p53-p(ser15) and total p53
-p53-independent cell death
[213, 214]
Prostate cancer cells (LNCaP, p53-
null PC-3, p53-expressing PC-3, PC3-
ML, p53-mutated DU-145)
-increased expression of p53-p(ser6), p53-p(ser15), p53-
p(ser20), p53-p(ser37), p53-p(ser392) , p53-ac(lys373), p53-
ac(lys382) and total p53
-p53-dependent and independent cell death
-increased expression of p73
[53, 66, 89,
139, 140,
170, 215]
PC3-ML cells (prostate cancer)
xenograft in mice
-increased expression of p53 and p73 (synergistic effect with
paclitaxel and docetaxel)
[170]
Cervical cancer cells (Hela) -increased expression of p53 [216]
Ovarian cancer cells (PA-1, p53-null
SKOV3, p53-mutated OVCAR-3)
-p53-independent cell death [217]
Hepatocellular carcinoma cells
(HepG2, p53-null Hep3B)
-increased expression of p53
-p53-independent cytotoxicity
[218, 219]
Colorectal cancer cells ( HCT116,
p53-mutated HT-29)
-increased expression of p53 [55, 155,
157]
Head and neck squamous
carcinoma cells (KB, Hep2, Tu686,
-increased expression of p53-p(ser15) and p53-p(ser37),
-decreased expression of p53-p(ser6), p53-p(ser392)
-unchanged or increased expression of p53
[101, 172,
220]
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Epigallocatechin-3-gallate (EGCG)
Cancer model Described effects on TSG (p53/p73) References
686NL, Tu212, Tu177, p53-null
M4e)
-p53-dependent cytotoxicity
Head and neck squamous cell
carcinoma syngenic mouse model
(SCC VII/SF cells xenograft)
-increased in vivo expression of p53-p(ser15) [101]
Lung cancer cells (A549) -increased expression of p53-p(ser15) and total p53
-absence of p73 expression
-p53-dependent activation of caspases 3/7
[221]
Fibrosarcoma cells (HT-1080) -increased expression of p53 [222]
Sarcoma xenograft (S180) -increased in vivo expression of p53 [90]
Multiple myeloma cells (INA6) -increased expression of p63 and 73, unchanged expression
of p73
[75]
T lymphocyte leukemic cells (p53-
mutated Jurkat, HuT-102, C91-PL,
p53-mutated CEM)
-increased expression of p73
-increased expression of p53
[76, 223]
Cancer cell lines express wild-type p53 except where otherwise stated; ac(lys.)=acetylated lysine, p(ser.)=phosphorylated
serine
Table 3. p53 family-related anticancer properties of EGCG
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Polyphenolic
source
Cancer model p53- and p73-related effects References
Grape-derived
products (red
wine, grape seed
extract)
C26 colorectal cancer cells xenograft
in mice
-increased expression of p53 and p73 [78]
Human colorectal cancer cells (LoVo,
p53-mutated HT29, P53-mutated
SW480)
-p53-independent apoptosis [224]
Oral squamous carcinoma cells
(SCC-25, p53-mutated OEC-MI)
-p53-independent cytotoxicity [225]
Leukemia cells (p53-mutated Jurkat) -increased expression of p73 [80]
Teratocarcinoma cells (P19) -increased expression of p53 [174]
Prostate cancer cells (LNCaP, p53-
mutated DU145)
-increased expression of p53-p(ser15)
and total p53
[226]
Black and green
tea
DMBA-induced mammary tumor in
rat
-increased expression of wild-type p53
and decreased expression of mutated-
p53
[227]
3,4-benzopyrene-induced lung
carcinoma in rat
-increased expression of p53 [228]
Ehrlich’s ascites carcinoma cell
xenograft in mice
-increased expression of p53 [229]
Oral cells from smoker and non-
smoker subjects
-increased expression of p53 [230]
Patients with high-risk oral
premalignant lesions
-no association between p53
expression and clinical response
[231]
Prostate cancer cells (LNCaP, p53-
null PC3)
-increased expression of p53-
ac(lys373), p53-ac(lys382) and total
p53
-p53-independent apoptosis
[139, 140]
Colorectal cancer cells (LoVo, p53-
mutated HT29)
-p53-independent cytotoxicity [232]
Berry-derived
products (aronia
juice, strawberry
extract)
Leukemia cells (p53-mutated Jurkat) -increased expression of p73 [79]
Breast cancer cells (p53-mutated
T47D)
-increased expression of p73 [81]
Cancer cell lines express wild-type p53 except where otherwise stated; ac(lys.)=acetylated lysine, p(ser.)=phosphorylated
serine
Table 4. p53 family-related anticancer properties of polyphenolic sources
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4. Polyphenols as regulator of p53 expression and localization
Under physiological conditions, the transcriptional activity of p53 is downregulated by three
different ways: i) ubiquitin-mediated proteasomal degradation mainly through the action of
mouse double minute protein (MDM2), ii) nuclear export leading to a decrease in nuclear level,
or iii) transcriptional repression of chromatin. MDM2 is an ubiquitin E3 ligase considered as
an oncoprotein because of its activity in promoting p53 ubiquitination and proteasomal
degradation. Moreover MDM2 binds to the NH2 terminus of p53 and blocks its transactiva‐
tional activities [27]. Interestingly, MDM2 promotes also cell cycle progression independently
of p53 for instance by modulating the activity of p21 [85]. Then MDM2 itself represents a
potential target for new drug with chemotherapeutic properties including polyphenolic
compounds [86]. Indeed, curcumin has been identified as an inhibitor of MDM2 expression
(Figure 1) in vitro and in vivo in p53-null and p53-wild-type human prostate cancer cells and
this inhibitory effect seems to be related to the inhibition of the PI3K/mTOR pathway [87]. In
addition, the curcumin analog EF24, which displays higher potency, increases phosphoryla‐
tion of p53 together with downregulation of MDM2, which likely leads to p53 overexpression
and cytotoxicity in hepatocellular carcinoma cells [88]. Similarly, EGCG reduces MDM2
expression in prostate cancer cells [89], but not in sarcoma cells [90]. Data concerning the effect
of resveratrol on MDM2 expression are more controversial since upregulation or downregu‐
lation have been observed in different cancer models [91, 92].
As mentioned previously, p53 activity depends upon its expression level but also its subcel‐
lular localization. Indeed, p53 displays direct pro-apoptotic effects related to mitochondrial
translocation and this pathway works in synergy with transcriptional activation function of
p53 dependent upon its nuclear translocation [24, 93]. Therefore, the control of p53 subcellular
localization might interfere with p53-mediated cell death. For instance, treatment of neuro‐
blasma cells by either curcumin or resveratrol transiently upregulated p53 expression and
induced nuclear translocation of p53, followed by induction of p21 and Bax expression
associated with apoptosis [94]. In addition curcumin increases p53 and Bax expression in
mitochondrial fraction under the control of the PI3K/Akt pathway in prostate cancer cells
followed by caspase-dependent apoptosis [95]. Altogether, these data indicate that polyphe‐
nols are able to control not only p53 expression, but also its localization and therefore its pro-
apoptotic activity in cancer cells. However, other post-translational regulatory effects of
polyphenols have been also described and related to phosphorylation and acetylation of the
tumor suppressor.
5. Polyphenols as regulator of p53 phosphorylation
Phosphorylation of serine/threonine residues are essential for stabilization and activation
of p53, the most extensively studied being serine 15 (Ser 15). These phosphorylation sites
are mainly concentrated in the N-terminal transactivation domain and in the C-terminal
regulatory  domain [96].  Recent  data  about  p53  phosphorylation induced by resveratrol,
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curcumin or EGCG, in vitro and in vivo, are summarized in Tables 1, 2 and 3 as well as in
Figure 1. The DNA damage is one of the main signals relayed to p53 subsequently activated
by phosphorylation at serine residues that are the target of ataxia-telangiectasia mutated
(ATM), ataxia telangiectasia and Rad3 related (ATR) and DNA-dependent protein kinase
(DNA-PK) [97]. The DNA damage response could be activated by chemotherapeutic drugs,
UV or  oxidative  stress  [98,  99],  but  activation  of  this  pathway by  polyphenols  remains
controversial.  Watson  et  al.  investigated  the  pro-apoptotic  effect  of  curcumin  which  is
similar  in  p53+/+  (wild-type)  and  p53-/-  (knockout)  HCT116  colorectal  cancer  cells.
Moreover, they demonstrated the ability of this polyphenol to induce up regulation of p53-
p(Ser 15) and total p53 without any change in the expression level of ATM, ATR or DNA-
PK. In contrast, curcumin enhances p38, JNK and ERK1/2 phosphorylation in both p53+/+
and  p53-/-  HCT116  cell  lines;  this  suggests  that  the  cytotoxic  effects  of  curcumin  are
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damage
p73
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Figure 1. Overview of p53- or p73-mediated pro-apoptotic effects of polyphenols in cancer cells. Polyphenols likely
induce intracellular oxidative stress and DNA damage with subsequent activation of kinases (MAPK, ATM, DNA-PK) re‐
sponsible for p53 phosphorylation. Simultaneously, and also in response to DNA damage, acetylation of p53 or p73 have
been described due to enhanced acetylase activity from p300 and/or to reduced deacetylase activity from SIRT1 or HDAC.
In addition, p53 expression has been shown to be under the control of MDM2 as well as MTA1/NuRD, both factors being
downregulated by polyphenols. Phosphorylation and acetylation, together with MDM2 inhibition result in p53, and to a
less extend, p73 stabilization and sustained expression which activate cell death cascade in cancer cells.
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independent  of  the  DNA-damage/ATM/ATR/DNA-PK  pathway  but  associated  with
Mitogen-Activated Protein Kinases (MAPKs) activities [64]. On the other hand, treatment
of LNCaP prostate cancer cells or HCT116 colorectal cancer cells with curcumin induces
the phosphorylation of ATM, histone H2AX (a marker of DNA damage) and p53 at Ser 15
together  with  increased  expression  of  p53,  suggesting  p53  activation  through the  DNA
damage/ATM pathway [52, 100]. The importance of ATM in polyphenols-induced cytotox‐
icity is also supported by recent data showing that EGCG lose the ability to trigger p53
phosphorylation  at  Ser  15  in  absence  of  ATM [101].  In  addition,  genistein  induced p53
phosphorylation at Ser 6, 9, 15, 20, 46 and 392 in the ATM-proficient human lymphoblas‐
tic  cell  lines,  but  not  in  ATM-deficient  cell  lines,  indicating  a  key  role  of  ATM  kinase
activity for polyphenol-induced p53 activation [102]. Moreover, stimulation of the ATM/p53
pathway  by  polyphenols  like  resveratrol  has  been  shown  to  also  participate  in  senes‐
cence  of  cancer  cells  [103].  On  the  other  hand,  quercetin  strongly  induced  DNA-PK
expression,  p53 phosphorylation and apoptosis  in melanoma cells,  suggesting that  other
kinases might be activated by polyphenols [77].
Alternatively, MAPKs such as ERK1/2, p38 or JNK have been involved in p53 activation and
phosphorylation [104, 105]. Therefore, the potential MAPKs/p53-dependent activation of
apoptosis by polyphenols has been investigated. As previously mentioned, curcumin induces
phospho-p38, phospho-ERK1/2 and phospho-JNK in colorectal as well as ovarian cancer cells
[64, 106, 107]. In addition, it has been shown that resveratrol- or luteolin-induced apoptosis
depends on the activities of ERK1/2, JNK and p38 kinase which target p53 phosphorylation at
Ser 15 [49, 108]. An alternative pathway which implicates cyclooxygenase (COX)-2 activity and
expression has been decribed by Lin et al. They have shown that resveratrol-induced apoptosis
of human head and neck squamous cancer cells or human ovarian carcinoma cells is associated
with p53 phosphorylation at Ser 15 and that both processes are downregulated by pERK1/2
and COX-2 specific inhibitors [109, 110]. Recent investigations indicate that ERK and p53
regulate each other and that ATM controls their interaction [104]. Therefore polyphenols might
likely trigger p53 activation through ATM and MAPKs complementary pathways.
6. Polyphenols as regulators of p53 and p73 acetylation
Functions of p53 and p73 are also regulated by acetylation on different lysine (Lys) residues.
These posttranslational covalent modifications occur in response to DNA damage in the close
vicinity of the oligomerization domain. The main Histone Acetyl Transferases (HATs)
responsible for these modifications include p300, CREB-Binding Protein (CBP), P300/CBP-
Associated Factor (PCAF) and Tat-Interactive Protein of 60 kDa (TIP60) [38]. As a consequence
of its acetylation, p53 is stabilized by excluding ubiquitination on the same site and acetylation
also promotes p53 transcriptional activity [96]. In comparison to p53, only few data are
available concerning p73 interaction with HAT and acetylation. It has been established that
p300 can acetylate p73 in response to DNA damage, but p300 can also behave as a co-activator
of p73 independently of its HAT activity [111]. Importantly, the level of p53 or p73 acetylation
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seems to be a major way of regulation for the tumor suppressors function since deacetylated
p53 and p73 are compromised in their ability to induce cell cycle arrest and apoptosis [91, 112].
The transcriptional coactivator p300 is a large multidomain protein that possesses histone
acetyl-transferase ability [113]. Together with its homolog CBP, p300 mediate transcription
through binding to transcriptional activators such as JUN, E1A, NF-κB, as well as to the p53
family members and they have been involved in human diseases including cancers [114].
Recent studies indicate that the transcriptional activity of p53 and p73 in response to genotoxic
stress is regulated by its interaction with p300 [115-117]. Indeed, it has been established that
interaction between p73 and p300 acetyl-transferase promotes first p73 stability and then its
transcriptional activity.
Narayanan et al., have suggested that resveratrol-induced apoptosis of prostate cancer cells is
mediated by transcriptional activation of p300 which subsequently acetylates and stabilizes
p53 [118]. Similarly in breast cancer cells, resveratrol enhanced p300 expression and interaction
with the phosphorylated form of p53 by a MAPK-dependent mechanism [119]. Interestingly,
p53-p300 interaction fails to occur in doxorubicin-resistant cells, but curcumin pre-treatment
could restore this interaction. Consistently, curcumin also restored drug-induced p53 acety‐
lation (lysine 373) and p53-dependent transcription of Bax, PUMA, and Noxa in resistant cells
leading to their apoptosis [120]. Therefore, polyphenols-induced acetylation of p53 by p300
might represent a key molecular mechanism for the cytotoxic properties of these natural
compounds in cancer cells including chemoresistant cells (Figure 1).
Acetylation level of tumor suppressors is dependent upon the balance between acetylation
and deacetylation reactions. Indeed, deacetylation of p53 or p73 by SIRT1 (silent information
regulator 1), a member of the sirtuin Histone DeACetylase (HDAC) class III family, prevents
p53-mediated transactivation of cell cycle inhibitor p21 and pro-apoptotic factor Bax, allowing
promotion of cell survival after DNA damage and ultimately tumorigenesis [121]. Members
of the Silent Information Regulator family (SIRT or sirtuins) are evolutionary conserved NAD-
dependent protein deacetylases and adenosine diphosphate (ADP)-ribosylases. There are
seven identified isoforms (SIRT1-7) that differ in their subcellular localization (cytoplasmic,
mitochondrial or nuclear), substrate specificities and functions [122]. The founding member
of this class of deacetylases, SIRT1 (homolog of yeast silent information regulator, Sir2), is the
most widely studied sirtuins. SIRT1 has been associated with aging processes as well as a
variety of human diseases such as metabolic syndrome, inflammation, neurodegeneration and
more recently cancer [123, 124]. SIRT1 can deacetylate a variety of histones as well as a number
of non-histone substrates, the first identified of these non-histone substrates being p53 (Lys
382-p53). The SIRT1 activity on p53 results in repression of p53-dependent apoptosis in
response to DNA damage and oxidative stress [125, 126]. SIRT1 deacetylates also other tumor
suppressors such as p73 [91]. Then SIRT1 has been considered as an oncogenic protein because
of its role in inactivating tumor suppressors such as p53, p73 but also PTEN [127], and/or
activating other oncogenic proteins like N-Myc [128]. Nevertheless, the oncogenic potential of
SIRT1 has been controversial and, depending on the context, SIRT1 might also act as a tumor
suppressor [122]. However, inhibition of the oncogenic potential of SIRT1 is likely able to
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induce apoptosis by counteracting the deacetylation of p53 or p73 and other key factors such
as FOXO3a [91, 125, 129].
In 2003, resveratrol was the top hit in a screen designed to identify activators of sirtuin enzymes
[130] and was subsequently shown to extend lifespan in yeast. However following experiments
led to confusing data suggesting that resveratrol might not be a direct activator of SIRT1 [131].
Regardless of the controversy about its mode of action, resveratrol has been confirmed to have
numerous health benefits, including anticancer properties. Nevertheless, the role of SIRT1 in
the anti-proliferative and pro-apoptotic effects of resveratrol on cancer cells is still unclear.
Indeed, in neuroblastoma cells, resveratrol-induced apoptosis was associated with a reduced
expression of SIRT1 as well as up-regulation of the acetylated and active form of p53, but the
pre-treatment of cancer cells with SIRT1 enzymatic inhibitors such as sirtinol or nicotinamide
has no cytotoxic effect suggesting that resveratrol-induced apoptosis is independent of SIRT1
activity [132]. In the opposite, siRNA-mediated downregulation of SIRT1 in lymphoma cells
decreased the resveratrol-induced apoptosis, indicating in this case a critical role of SIRT1 in
polyphenol-mediated cancer cell death [133]. Interestingly, Frazzi et al., have recently descri‐
bed anti-proliferative effect of resveratrol associated with downregulation of SIRT1 expression
and activity together with upregulation of acetylated-Lys 373-p53, the active form of p53, and
total p53 overexpression [129]. All together, these data suggest that, in the context of cancer
cells, resveratrol might be an inhibitor, instead of an activator, of SIRT1 functions (Figure 1).
However, only few data are available concerning potential regulation of SIRT1/p53 pathway
by other polyphenolic compounds [134]. Therefore additional investigations are needed to
further understand the role of SIRT1 in polyphenols-mediated anticancer effects.
On the other hand, resveratrol has been shown to enhance p53 acetylation and apoptosis
in  prostate  cancer  cells  through alternative  pathways.  Indeed,  resveratrol  caused down-
regulation  of  MTA1  protein,  leading  to  destabilization  of  MTA1/NuRD  complex  thus
allowing acetylation/activation of p53 [135]. Metastasis-associated protein 1 (MTA1) is part
of the nucleosome remodelling deacetylation (NuRD) complex involved in global and gene-
specific  histone  deacetylation,  alteration  of  chromatin  structure  and  transcriptional
repression [136,  137].  This  complex,  which also contains Histone DeACetylase (HDAC)1
and HDAC2, plays an essential role in governing deacetylation of histones but also non
histone proteins, such as p53 [138]. In addition, green tea polyphenols have been shown
to behave as HDAC class I  inhibitors which results in p21 and Bax expression irrespec‐
tive of p53 status in prostate cancer cells [139, 140]. Moreover HDAC inhibition by EGCG
is associated with p53 acetylation in p53-wild-type LNCAP prostate cancer cells suggest‐
ing  an  increase  of  p53  halftime  and  binding  to  p21  and  Bax  promoters  as  previously
described  [141].  The  mechanism  by  which  HDAC  inhibition  could  induce  apoptosis  in
absence  of  functional  p53  in  p53-null  PC3  prostate  cancer  cells  might  be  related  to
interaction with p73 pathway as previously suggested [142, 143] or direct regulation of p21
promoter  activation  [144].  Similar  HDAC inhibition  by  curcumin has  been  also  seen  in
prostate  cancer  cells  [145].  However  the  exact  role  of  HDAC  inhibition  in  polyphenol-
induced apoptosis of cancer cells remains to be elucidated especially in vivo.
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7. Role of oxidative stress and DNA damage in p53/p73 regulation by
polyphenols
Polyphenolic compounds have been extensively described as anti-oxidant molecules with the
capability to scavenge reactive oxygen species (ROS), which include radical oxygen and
nitrogen species such as O2- (superoxide anion), HO. (hydroxyl radical), NO. (nitric oxide
radical), ONOO-. (peroxinitrite anion) and H2O2 (hydrogen peroxide), as well as oxidatively
generated free radicals RO. and ROO. from biomolecules like lipids, proteins or nucleic acids
(DNA and RNA) [3, 146]. Polyphenols are not only able to quench the ROS but also to regulate
directly the oxidative stress-mediated enzyme activity, therefore reducing the formation of
ROS. These anti-oxidant properties have been linked to the polyphenol-mediated reduction
of chronic disease risk including cancer chemoprevention [13, 147]. Indeed, redox changes are
often reported as important inducer of neoplastic transformation as well as chemoresistance.
Cerutti et al. identified for the first time in 1985 the close relationship between pro-oxidant
conditions and cancer development [148]. More than twenty years later, accumulated eviden‐
ces indicate that the non-physiological alterations of the intracellular redox state could be
considered as a hallmark of tumor biology. Indeed, redox changes have been involved in
several key events of carcinogenesis such as self-sufficiency in growth signals [149, 150],
resistance to apoptosis [151, 152], sustained angiogenesis [153, 154], autophagy and invasive‐
ness. However, recent findings also suggest that this redox changes might be exploited as
therapeutic strategy to selectively kill tumor cells.
Recently and unexpectedly, it has been established that various and structurally different
(flavonoids or non-flavonoids) polyphenols are able to induce ROS (mainly superoxide anions
or hydrogen peroxide) formation in cancer cells and for some of them to activate the DNA-
damage response pathway [51, 79, 80, 95, 102, 103, 155-158]. Heiss et al. have also shown that
the resveratrol-induced senescence in colon cancer cells is dependent upon an increased
formation of ROS and the subsequent phosphorylation of p53 on the Ser15, suggesting a
relationship between polyphenol-induced oxidative stress and p53 activation [103]. On the
other hand, curcumin and wogonin induce ROS production and cause cytotoxicity in p53+/+
and p53-/- cancer cells [56, 64], indicating that ROS formation is an event independent of p53
and might be an earlier step in the cell death pathway. This hypothesis is supported by the
study showing ROS in cancer cells as earlier as 20 minutes after the beginning of wogonin
treatment. Moreover, in the same study, the subsequent up-regulation of p53 (maximal
activation at 16 hours) is significantly inhibited by anti-oxidants such as N-Acetyl-Cysteine.
Importantly, most of the studies did not investigate the possible alternative role of p73 in p53-
mutated cells, but we and others have shown that in p53-mutated or p53-deficient cells, a
polyphenolic compound (EGCG) or source (red wine polyphenolic extract, polyphenol-rich
aronia juice) strongly induced oxidative stress-mediated up-regulation of p73 and apoptosis
[79, 80, 84]. Further reports also supported that p53-family tumor suppressors regulation might
be related to oxidative stress [159].
Interestingly, the cytotoxic effects induced by curcumin or its analogue HO-3867 were reduced
in non-cancerous cells as well as the ROS formation in comparison to human ovarian cancer
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cells. This suggests that the specific pro-oxidant activity of polyphenols in cancer cells might
explain the selective anticancer properties of these compounds, sparing healthy normal cells
[107, 160]. Similarly, EGCG increased preferentially ROS formation, p53 and p21 expression
and cytotoxicity in colorectal cancer cells but not in human embryonic kidney cells and normal
human lung cell line [157].
Oxidative stress is one of the major conditions that damages DNA, acting as a mediator of
environmental stressors such as UV- and X-rays irradiation, drugs, and of metabolic imbalance
[161]. Since p53 might be regulated by the redox environment [162], especially by the
ROS/DNA damage pathway, it has been proposed that polyphenol-mediated anticancer
effects are related to a ROS/DNA damage/p53 pathway (Figure 1). Indeed polyphenol-induced
DNA damage and apoptosis have been demonstrated with various compounds such as
curcumin in glioblastoma and prostate cancer cells [100, 163], resveratrol in prostate cancer
cells [164, 165], EGCG in lung cancer cells and xenograft in mice [166], wogonin in glioblastoma
and prostate cancer cells [51, 56], and luteolin in lung and head and neck cancer cells [58].
Therefore the current molecular mechanism of the anticancer properties of polyphenols might
involve selective ROS formation together with DNA damage in cancer cells. Thus, this process
might lead to the regulation of several pathways (ATM/DNA-PK, MAPKs, p300, SIRT1,
HDAC, see Figure 1), and ultimately to the expression and stabilization of p53-family tumor
suppressors triggering programmed cell death.
8. Therapeutic perspectives
Recent investigations have demonstrated additional or synergistic effects when polyphenols
are combined with chemo- or radiotherapy. Indeed, resveratrol induces synergistic apoptosis
with 5-fluorouracile [167]. Similar observations have been made with curcumin associated
with doxorubicin, cisplatin, gemcitabine or radiation for cell death induction of glioblastoma
cells and prostate cancer cells [60, 87]. More importantly, curcumin and its analogue, HO-3867
sensitized doxorubicin-resistant ascite carcinoma cells and breast cancer cells as well as
cisplatin-resistant ovarian carcinoma cells together with enhanced p53 expression [107, 120,
168, 169]. Similarly, EGCG displayed synergistic upregulation of p53 and p73 as well as
anticancer properties with taxanes (paclitaxel and docetaxel) in vitro but also in vivo in prostate
cancer models [170, 171]. Because all of the previously mentioned drugs demonstrated the
ability to induce DNA damage, it is likely that polyphenols might amplify these damages
leading therefore to synergistic effects. Surprisingly, EGCG has also synergistic effects with
targeted therapy such as erlotinib (inhibitor of epidermal growth factor receptor) to induce
p53 phosphorylation on Ser15 and expression together with apoptosis [172].
Interestingly, curcumin also ameliorated oxaliplatin-induced chemoresistance in colorectal
cancer  cells  without  significant  effect  on  p53  expression  [173].  Similarly,  curcumin  and
EGCG sensitized glioma cells in vitro  and in vivo  to chemotherapeutic drugs and also to
radiation  in  a  p53-independent  manner  [163].  These  data  suggest  that  polyphenols  can
effectively circumvent resistance of cancer cells to chemotherapy, but likely through a p53-
independent pathway.
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Numerous in vitro studies have demonstrated the cytotoxic effects of polyphenols by using
micromolar concentrations which are much higher than current chemotherapeutic drugs
under development. However, polyphenols still keep their potential as chemotherapeutic
drug, firstly because of their activity on chemo- or radioresistant cancer cells and secondly
because of their very low toxicity on healthy tissues giving them a large therapeutic index.
Indeed, many recent in vitro studies have highlighted the selective pro-apoptotic properties of
polyphenols or analogues with no or low cytotoxic effect on non-cancer healthy cells, such as
endothelial cells, cardiomyocytes, lymphocytes, chondrocytes, ovarian cells, prostate and
mammary epithelial cells, astrocytes, or neurons [54, 57, 60, 79, 95, 107, 158, 163, 169, 174].
Interestingly, the selective pro-apoptotic effect of curcumin in breast cancer cells is associated
with an increased expression of p53, whereas p53 is only slightly upregulated in normal
mammary epithelial cells, suggesting a selective activation of p53 pathway in cancer cells
sparing normal cells [54]. Moreover, in vivo treatment with polyphenolic compounds or
products in tumor model such as cancer cells xenografts induced a significant inhibition of
tumor growth together with a very good tolerance for healthy tissues, including heart, liver,
kidney, lung and haematopoietic tissue [60, 78]. However, more animal studies and human
clinical trials are now necessary to clearly determine whether polyphenols or their natural
nutritional sources are safe and efficient to treat cancer.
9. Concluding remarks
The present literature review has summarized the results of recent studies focusing mainly on
the p53-related anticancer properties of three major polyphenolic compounds (resveratrol,
curcumin and EGCG). Despite highly active research in this area, the data are still controversial
concerning the possible key role of the tumor suppressor p53 in the polyphenol-mediated
apoptosis of tumor cells. However, according to the emerging evidences suggesting that
polyphenols might alternatively regulate also the structurally- and functionally-related tumor
suppressors such as p73, these natural compounds might be considered as general executors
of the p53 family-mediated programmed cell death in cancer cells. Importantly, the selective
anticancer properties of polyphenols are maintained even when p53 is mutated or absent, as
well as when cells are resistant to current therapies. However, further investigations are still
mandatory to better understand the underlying molecular mechanism in vitro as well as in
vivo before a potential clinical development.
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1. Introduction
The Rho family of GTPases belongs to the superfamily named “Ras-like” proteins, which
consists of over 150 varieties in mammals [1]. Significant progress has recently been made in
understanding the biological functions mediated by this family of small (~21 kDa) G proteins
(guanine nucleotide-binding proteins). Rho GTPases affect crucial biological processes such
as transcriptional regulation, cell cycle progression, apoptosis and membrane trafficking [2,
3]. Thus far, a total of 23 Rho proteins have been identified [4], among which RhoA, Rac1 and
Cdc42 are characterized in detail. Rho GTPases are also involved in the cytoskeleton formation
of the cell via the regulation of actin dynamics [5, 6]. RhoA induces stress fiber formation and
focal adhesion assembly, thereby regulating cell shape, attachment and motility, whereas Rac1
promotes extension of lamellipodia and membrane ruffling [7]. Cdc42 has been shown to play
a role in the formation of filopodia [8].
Like other small G proteins of the Ras-like protein family, Rho GTPases act by switching
between an inactive GDP-bound and an active GTP-bound form, with the latter form capable
of interacting with a myriad of downstream effectors (so far, more than 70 proteins have been
identified [4]) to be activated by them. The activation of Rho GTPases is stimulated by guanine
nucleotide exchange factors (GEFs) that exchange GDP for GTP and is inhibited by GTPase-
activating proteins (GAPs) that hydrolyze the GTP to GDP [9]. Rho GTPases are also negatively
regulated by guanine nucleotide dissociation inhibitors (GDIs), which bind to the GDP-bound
form and not only prevent nucleotide exchange, but also remove Rho GTPases from the plasma
membrane to the cytoplasm [4, 10, 11]. Taken together, cell morphology requires spatiotem‐
porally restricted regulation of Rho GTPases through these regulatory proteins. Nonetheless,
detailed insight into regulation of Rho GTPases has not been provided.
© 2013 Yagisawa; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
The effect on the wide spectrum of biological functions suggests the involvement of Rho
GTPases and their regulators in cancer progression. Findings from extensive in vitro and in
vivo studies shows that deregulated signaling of Rho GTPases may lead to tumorigenesis [12]
and thus Rho GTPases are taken as potential targeting candidates for cancer therapy [13]. Since
no constitutively active Rho mutants have been reported in human cancers, it is likely that
aberrant Rho GTPase signaling in malignancy is caused by the alterations of their regulators
[4, 12]. Extensive studies so far have revealed that regulators of Rho proteins are over- or
underexpressed in various types of human cancer cells [14-17]. The most common alteration
reported for Rho regulators in cancer is inactivation of RhoGAPs, especially of the START-
GAP/DLC family RhoGAPs [18]. “START” stands for “steroidogenic acute regulatory protein
(STAR)-related lipid transfer” and “DLC” stands for “Deleted in Liver Cancer (DLC),” a gene
(or its product) found to be commonly deleted in liver tumors. The START-GAP/DLC family
proteins have become the focus of attention on their roles in tumorigenesis. This type of genetic
loss was also found in a number of other cancers [17, 19-21].
START-GAP1/DLC1 was originally cloned from rat cDNA library as a binding partner of
phospholipase C-δ1 (PLCδ1) [22]. It has been shown that the C-terminal region of START-
GAP1/DLC1 and the PH domain of PLCδ1 are responsible for the interaction [23, 24]. START-
GAP1/DLC1 enhances the activity of PLCδ1, which generates two second-messengers, inositol
1,4,5-trisphospate (Ins(1,4,5)P3) and diacylglycerol via hydrolysis of phosphatidylinositol 4,5-
bisphosphate (PtdIns(4,5)P2). Ins(1,4,5)P3 is accepted by receptors on ER, resulting the eleva‐
tion of intracellular calcium concentration, whereas diacylglycerol acts as the activator for PKC
[25, 26]. Indeed, microinjection of START-GAP1/DLC1 into the cytosol elevated intracellular
calcium concentration [23].
As mentioned in detail in the following sections, each member of the START-GAP/DLC multi-
domain protein family contains one GAP domain for Rho GTPases. Overexpression of START-
GAP1/DLC1 in cultured cells was first to demonstrate induction of drastic morphological
changes accompanied by the disruption of actin stress fibers and elevation of intracellular
Ca2+ concentrations [23]. START-GAP1/DLC1 was therefore originally designated ARP
(adaptor for both Rho and PLC) [22], but later the name p122RhoGAP (or just p122) was used
to avoid confusion with another ARP (actin related proteins) [23, 24, 27, 28]. We have then
introduced the new name, START-GAP1, based on the characteristic domain structure of this
Rho GTPase family [29-32]. Meanwhile the antioncogenic properties of the protein family have
been revealed and the DLC nomenclature was introduced [21]. In this chapter, the combination
of both the structure- and function-based nomenclatures is used throughout, since the use of
either of them would not be appropriate to reflect the fundamental properties of the protein
family accurately.
In the following sections we will focus on the structure, localization and expression-function
relationship of the START-GAP/DLC family proteins in physiological conditions and in
human diseases.
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2. The START-GAP/DLC gene family
In mammalian genome, there are three genes encoding structurally-related RhoGAPs con‐
taining the START domain (Figure 1). There are three groups of START domain-containing
RhoGAP proteins in vertebrates, while a worm (Caenorhabditis elegans) or a fly (Drosophila
melanogaster) possesses only one START-containing RhoGAP.
Figure 1. A phylogenetic analysis of the START domain-containing RhoGAPs generated with a “Treeview” after CLUS‐
TAL W analysis (http://clustalw.ddbj.nig.ac.jp/). Modified from Kawai et al. [31].
2.1. Human START-GAP/DLC genes and their expression in various tumor cells
There are about 70 human genes encoding RhoGAPs that share a conserved GAP domain and
are capable of switching off the Rho signal [33]. The START-GAP1/DLC1 (also named as
STARD12 or ARHGAP7) gene is localized on chromosome 8p21-22 and encodes a 1,091-amino
acid protein with a molecular mass of 122 kDa. Using the quantitative RT-PCR method, Ko et
al. have reported that START-GAP1/DLC1 is widely expressed in normal tissues, with high
abundance in the lung and ovary, and moderately in the thyroid, spleen, intestine and kidney
[34]. START-GAP1/DLC1 has also been known as a tumor suppressor gene product. It is
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frequently underexpressed or not expressed in several tumor cells and inhibits cell growth,
invasion and metastasis [35, 36]. Studies have indicated that downexpression of START-GAP1/
DLC1 either by genomic deletion or DNA methylation [37] is associated with a variety of cancer
types including lung [38], breast, prostate, kidney, colon, uterus, ovary, and stomach [38] [39]
[40]. These phenotypes require the GAP activity of START-GAP1/DLC1 [35].
Negative regulation of the Rho/Rho-kinase (ROCK)/myosin light chain (MLC) pathway in
hepatocellular carcinoma (HCC) cell lines by START-GAP1/DLC1 was shown to be RhoGAP-
dependent [23, 41, 42]. The RhoGAP defective mutant failed to inhibit stress fiber formation
in HCC lines [41], whereas the overexpression of START-GAP1/DLC1 resulted in morpho‐
logical change with disruption of actin stress fibers [23, 42]. Using various cancer cell models,
START-GAP1/DLC1 was shown to inhibit cell proliferation, suppress cell migration and
invasion, and induce apoptosis [35, 36, 41, 43-45]. Restoration of START-GAP1/DLC1 expres‐
sion in metastatic cell lines has been shown to cause the inhibition of cell migration and
invasion as well as a significant reduction in metastases in nude mice [45].
Underexpression of START-GAP1/DLC1 was associated with either heterozygous deletions
of the START-GAP1/DLC1 gene or hypermethylation of the gene promoter region [17, 37,
46-49]. This protein is therefore thought to be under the epigenetic regulation for expression.
The START-GAP1/DLC1 gene is transcribed from two different promoters, resulting in
transcripts encoding three isoforms [47]. To date, most of studies on START-GAP1/DLC1 have
focused on the so-called isoform 2. Low et al. have recently identified a new isoform of START-
GAP1/DLC1, isoform 4 (DLC1-i4), using 5’-RACE method [50]. This novel isoform encodes a
1,125-amino acid protein with distinct N-terminus as compared with other three isoforms.
Similar to them, DLC1-i4 is expressed ubiquitously in normal tissues and immortalized normal
epithelial cells, suggesting a role as a major START-GAP1/DLC1 transcript. Differential
expression of the four START-GAP1/DLC1 isoforms, however, is found in tumor cell lines:
Isoform 1 (the longest isoform) and isoform 3 (short and probably nonfunctional) share a
promoter and are silenced in almost all cancer and immortalized cell lines, whereas isoform 2
and isoform 4 utilize different promoters and are frequently downregulated. Isoform 4 is
significantly downregulated in multiple carcinoma cell lines, including nasopharyngeal,
esophageal, gastric, breast, colorectal, cervical and lung carcinomas. Ectopic expression of
DLC1-i4 suppresses tumor cell colony formation. Differential expression of the isoforms
suggests interplay in modulating the complex activities of START-GAP1/DLC1 during
carcinogenesis.
There are two additional members of the START-GAP/DLC family. START-GAP2/DLC2 (or
STARD13) gene is located on chromosome 13q12 [51] and START-GAP3/DLC3 (or STARD8/
KIAA0189) gene is located on the X chromosome at q13 band [31, 52]. The START-GAP2/
DLC2 encodes a 1,113-amino acid protein with a molecular mass of 125 kDa, whereas the
protein product of the START-GAP3/DLC3 transcript has 1,103 amino acids with a molecular
mass of 121 kDa. START-GAP2/DLC2 has a broad tissue distribution, with the highest levels
in the brain, heart and liver [15, 53]. Human START-GAP2/DLC2 protein shares 51% identity
and 64% similarity to human START-GAP1/DLC1 at the level of the amino acid sequence [51].
Introduction of human START-GAP2/DLC2 into mouse fibroblasts suppress Ras signaling and
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cell transformation in a GAP dependent manner, suggesting the role of START-GAP2/DLC2
for growth suppression and carcinogenesis [51].
START-GAP3/DLC3 is also detected in a variety of human tissues with high abundance in the
lung, kidney and placenta [53].
Following the findings of dysregulation of the START-GAP1/DLC1 gene function in a variety
of solid tumors, downregulation of START-GAP2/DLC2 and START-GAP3/DLC3 genes was
also shown to be involved in human cancer development.
START-GAP2/DLC2 was found to be downregulated in breast, lung, ovarian, renal, uterine,
gastric, colon, rectal, and liver tumors [15, 52, 54]. The comparison of START-GAP1/DLC1 and
START-GAP2/DLC2 gene expression in the same cell lines revealed that START-GAP2/DLC2
is more frequently downregulated than START-GAP1/DLC1 in HCC cell lines [15]. Moreover,
the overexpression of START-GAP2/DLC2 suppresses cell proliferation, motility and anchor‐
age-independent growth in the human hepatoma cell line, HepG2 [55]. START-GAP2/DLC2
was also reported to have an inhibitory effect on the growth of breast cancer cells in vitro [56].
Decreased START-GAP3/DLC3 expression in primary tumors from kidney, lung, uterine,
ovary and breast has been reported [52]. Kawai et al. have demonstrated that START-GAP3/
DLC3 serves as a GAP for both RhoA and Cdc42 in in vitro assays. Furthermore, the overex‐
pression of START-GAP3/DLC3 in HeLa cells disrupts actin stress fibers and changes cell
morphology in a GAP-dependent manner [31]. Ectopic expression of START-GAP3/DLC3 in
human breast and prostate cancer cell lines inhibits cell proliferation, colony formation and
growth in soft agar [52].
The structures of the three human START-GAP/DLC transcripts are depicted in Figure 2.
Figure 2. Schematic representation of the START-GAP/DLC family proteins. Each member of the family comprises of
three distinct domains, namely the sterile α motif (SAM), RhoGAP (GAP) domain and START (steroidogenic acute regu‐
latory protein (STAR)-related lipid transfer) domain.
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2.2. Gene knockout studies of START-GAP/DLC proteins
Using a mouse model a gene knockout study of START-GAP1/DLC1 has been carried out [57].
The mouse START-GAP1/DLC1 gene was inactivated by homologous recombination. Mice
heterozygous for the targeted allele were phenotypically normal, but homozygous mutant
embryos did not survive beyond 10.5 days postcoitum. Cultured fibroblasts from START-
GAP1/DLC1-deficient embryos displayed alterations in the organization of actin filaments and
focal adhesions [57]. In addition, a gene knockdown of START-GAP1/DLC1 in the background
of c-myc overexpression promotes the formation of liver tumors [58].
Although the START-GAP1/DLC1 gene deficient mice were embryonic lethal, deletion of the
START-GAP2/DLC2 gene from mice resulted in survival to adulthood, indicating that the gene,
unlike the START-GAP1/DLC1 gene, was dispensable for embryonic development [59].
Neither did the authors observe a higher incidence of liver tumor formation in the START-
GAP2/DLC2 gene knockout mice. Nevertheless, they reported smaller phenotype with less
formation of adipose tissue [59].
To the best of our knowledge, no reports describing the gene knockout study of the START-
GAP3/DLC3 gene are currently available.
2.3. Homologs of the START-GAP/DLC family
As mentioned earlier, there are homologs of the mammalian START-GAP/DLC family proteins
in invertebrates in the BLAST database. A Drosophila ortholog of START-GAP1/DLC1,
Crossveinless-c (Cv-c or RhoGAP88C), was identified in search for genes that regulate Drosophi‐
la morphogenesis [60]. The function of Cv-c has been revealed to be a key regulator for
unidirectional growth of dendritic branches of the fly via downregulating the activity of Rho1,
the Drosophila Rho GTPase [61]. In the Cv-c mutant, two subclass of multidendritic sensory
neurons formed dorsally directed branches; however, dendritic branches had a difficulty in
growing along the anterior–posterior (A–P) body axis, suggesting that Cv-c contributes to
sprouting and subsequent growth of the A–P-oriented branches through negative regulation
of Rho1 [61]. Thus Cv-c plays a key role in directional dendritic growth presumably via its
RhoGAP activity, localizing the GAP activity to sites undergoing cytoskeleton rearrangements
during morphogenesis.
3. Structure and function of the domains
The START-GAP/DLC family proteins are composed of multi-domain structures. START-
GAP/DLC proteins have three distinct domains: The sterile α motif (SAM) localized at its N-
terminus, a conserved RhoGAP (GAP) domain in the middle and the steroidogenic acute
regulatory (StAR)-related lipid transfer (START) domain at the C-terminus [51-53]. (Figure 2)
Although the START-GAP/DLC family proteins contain a potential lipid-binding START
domain, the proteins are produced in soluble forms. The intracellular localization of these
proteins, therefore, is determined by their specific interactions with target proteins resided at
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various cellular structures. Each domain of the START-GAP/DLC family proteins may
contribute to different subcellular localization patterns.
3.1. The GAP domain
The biological activity of START-GAP1/DLC1 is mainly executed by the GAP domain
(~150-200 amino acid), which promotes the hydrolysis of GTP bound to the Rho GTPases. This
catalytic activity is mediated by the ‘arginine-finger’ present in the GAP domain [62]. START-
GAP1/DLC1 and START-GAP3/DLC3 contain a conserved ‘arginine-finger’ at position 677
and 688, respectively [52, 53]. In in vitro assays both the full-length START-GAP1/DLC1 and
the isolated GAP domain reveal activity on RhoA, RhoB and RhoC, to a lesser extent on Cdc42,
and no activity on Rac1 [17, 32, 63]. By inactivating these small GTPases, START-GAP1/DLC1
affects cell morphology and control actin cytoskeletal remodeling [22, 23]. Similar to START-
GAP1/DLC1, both START-GAP2/DLC2 and START-GAP3/DLC3 contain a RhoGAP domain
and exhibit the GAP activity for RhoA and Cdc42 but not Rac1 in vitro [31, 32, 51].
3.2. The sterile α motif (SAM)
The SAM domain (~70 amino acids) has been found in signaling proteins (e.g., p53 related
proteins p73 and p63, Eph-related tyrosine kinases and Ets transcription factors) [64, 65]. The
SAM domain is thought to act as a protein interaction module via homo- or hetero-oligome‐
rization with other SAM domains [64]. As an example, the EphA2 receptor that plays key roles
in many physiological and pathological events including cancer has the SAM domain.
Recently, a structural study of the EphA2 receptor SAM domain has validated structural
elements relevant for the heterotypic SAM-SAM interactions: two SAM domains interact with
a head-to-tail topology characteristic of several SAM-SAM complexes [66]. The SAM domain
even interacts with RNA [67].
Structural studies of the SAM domain of START-GAP2/DLC2 have suggested that it binds to
lipids such as phosphatidylglycerol [68]. Nevertheless, we know little about exact roles of the
SAM domain in START-GAP/DLC function. Kim et al. have shown that the expression of the
amino-terminal domain of START-GAP1/DLC1 acts as a dominant negative and profoundly
inhibits cell migration by displacing endogenous START-GAP1/DLC1 from focal adhesions
[69]. The SAM domain of START-GAP1/DLC1 may serve as an autoinhibitory domain for
intrinsic RhoGAP catalytic activity. Eukaryotic elongation factor-1A1 (EF1A1) was found to
be a target of the SAM domain of START-GAP1/DLC1 [70]. EF1A1 is involved in protein
synthesis [71] and also in transporting β-actin mRNA [72]. EF1A1 is a regulator of cell growth
and the cytoskeletal network controlling the actin network through its G-actin-binding activity
[73], F-actin-bundling activity [74] and by stabilizing microtubules [75]. EF1A1 is overex‐
pressed in various human cancers, including pancreas, lung, prostate, breast and colon cancers
[71]. The SAM domain of START-GAP1/DLC1 adopts a four-helix fold similarly to the SAM
domain of START-GAP2/DLC2, but it utilizes a unique motif on a hydrophobic surface to bind
directly to EF1A1 [70]. Importantly, the SAM domain is necessary for START-GAP1/DLC1 to
translocate EF1A1 to the membrane periphery and ruffles upon fibroblast growth factor
stimulation, acting as an auxiliary oncogenic switch to the GAP domain [70].
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3.3. The START domain
The START domain (~210 amino acids) is a well-conserved lipid binding domain, which is
primarily found in proteins that transfer lipids between organelles and are involved in lipid
metabolism as well as in modulation of signaling events involved in lipid processing [76, 77].
The mammalian START domain protein family is well characterized and is composed of 15
members that are classified into 6 subfamilies based on the sequence and ligand specificity:
STARD1/3 and STARD4/5/6 subfamilies bind cholesterol and oxysterols, STARD2 (PCTP:
phosphatidylcholine transfer protein)/7/10/11(CERT: ceramide transfer protein) subfamily
binds phospholipids and ceramides/sphingolipids, STARD14 binds possibly fatty acids. They
all may have roles in non-vesicular lipid transport. STARD14/15 subfamily consists of proteins
with the thioesterase activity such as the Acyl-CoA thioesterase (ACOT) family proteins. The
START-GAP/DLC family proteins fall into the STARD8/12/13 subfamily [76, 77]. Lipid binding
properties of START-GAP1/DLC1 (STARD12), START-GAP2/DLC2 (STARD13) and START-
GAP3/DLC3 (STARD8) have not well characterized yet.
Among these proteins, STARD1 (or steroidogenic acute regulatory protein, StAR) and STARD3
(or metastatic lymph node 64 kDa protein, MLN64) appear to be the most well characterized
[78]. Both STARD1 and STARD3 bind cholesterol [79], and are also known to play a role in
lipid transport into mitochondria [80, 81]. In particular, STARD1 localizes to the mitochondria
and stimulates the translocation of cholesterol from the outer to the inner mitochondrial
membranes [79]. It has been suggested that STARD1 is an essential component in steroid
hormone production in steroidogenic cell [82, 83]. It is noteworthy, therefore, that START-
GAP2/DLC2 has been found to localize in mitochondria and was found in proximity to the
lipid droplets through the START domain [84]. Future research is required in order to establish
the lipid ligand of the START domain of START-GAP2/DLC2 and clarify whether the START
domain plays a role in mitochondrial lipid transport. START-GAP2/DLC2 also mediates
ceramide activation of phosphatidylglycerolphosphate (PGP) synthase and drug response in
Chinese hamster ovary cells [85].
The  crystal  structures  for  the  START  domains  of  human  STARD3/MLN64  (PDB  entry:
IEM2)  [86]  and murine  STARD4 (PDB entry:  1JSS)  [87]  were  the  first  to  be  solved and
showed  an  α-β  helix-grip  fold  with  a  nine-stranded  anti-parallel  β-sheet  forming  a  U-
shaped hydrophobic  cleft  that  binds  the  ligand and is  flanked by N-  and C-terminal  α
helices. The C-terminal α helix is proposed to serve as a ‘cap’ to the ligand-binding site,
with lipid access to the binding pocket requiring a conformational change in the START
domain and movement of the C-terminal helix. To date, the crystal structures for a limited
number of the START domain-containing proteins were solved: human STARD1/StAR (PDB
entry:  3P0L)  [88],  human STARD5 (PDB entry:  2R55)  [88],  human STARD2/PCTP (PDB
entry: 1LN1) [87], STARD11/CERT (PDB entry: 2E3R) [89], human STARD13/START-GAP2/
DLC2  (PDB  entry:  2PSO)  [88]  and  human  STARD14  (PDB  entry:  3FO5)  [88].  The  data
confirm  the  basic  helix-grip  fold  structure  across  the  five  mammalian  subfamilies  that
defines this family of proteins [88].
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3.4. The FAT region
Between the SAM and GAP domains there is a long unstructured region (~190 amino acids)
termed the FAT (focal adhesion targeting) region, due to the fact that its presence deter‐
mines of focal adhesion localization of the START-GAP/DLC proteins [27]. START-GAP1/
DLC1, START-GAP2/DLC2 and START-GAP3/DLC3 are recruited to focal adhesion sites
via their FAT sequence, which binds to the Src homology 2 (SH2) domains of focal adhesion
proteins and interacts with tensins [32,  43,  90].  The same region of START-GAP1/DLC1,
however, has been found to possess the ability to interact with the PTB domain of tensin2
[30,  91,  92]  and  tensin1  [43].  The  role  of  the  interaction  with  the  PTB  domain  in  the
localization of START-GAP1/DLC1 to focal adhesions remains controversial and requires
further  investigation.  Using  pull-down  assay,  Kawai  et  al.  reported  the  interaction  be‐
tween the other members of the START-GAP/DLC family, START-GAP2/DLC2 and START-
GAP3/DLC3, and tensin2 PTB [30].
Since the START-GAP/DLC family proteins are rich in serine residues, especially in their
FAT regions, it is natural to propose that these proteins could be phosphorylated by the
AGC (protein kinases A, G, and C) family protein kinases. Indeed, a numerous potential
phosphorylation  motifs  by  these  kinases  can  be  found  in  the  START-GAP/DLC  family
proteins. Protein kinase B (PKB or Akt) is among the member of the kinase family. Since
PKB/Akt plays an essential role in the actions of growth factors as well as the regulation
of many other cellular processes, such as apoptosis and anoikis, neuronal development and
degeneration, and the cell cycle [93], its involvement in function of the START-GAP/DLC
family proteins is argued [94].
Hers et al. have demonstrated that Ser322 in the FAT region of rat START-GAP1/DLC1 is
phosphorylated upon insulin stimulation of intact cells and that this site is directly phos‐
phorylated in vitro by PKB/Akt and ribosomal S6 kinase (RSK1), another member of the AGC
family of protein kinases [95], suggesting the phosphorylation via both the PKB/Akt and
MAPK kinase (MEK)/extracellular signal-regulated kinase (ERK)/RSK pathways by growth
factors. In other words, this site has the potential to integrate the activities of two different
signal transduction pathways in a manner dependent on the cellular context. As Ser322 falls
within the FAT region, its phosphorylation may be involved in regulating the targeting of
STASRT-GAP1/DLC1 to focal adhesions. However, despite the profound morphological
changes, both S322A and S322D mutants showed similar localizations to focal adhesions as the
wild-type STASRT-GAP1/DLC1. The function of the phosphorylation in signaling events
downstream of PKB/Akt, such as GLUT4 translocation, the activation of RhoA effectors and
cellular transformation, therefore awaits further studies.
A recent report by Ko et al. [96] has also postulated a central role of PKB/Akt phosphorylation
of human START-GAP1/DLC1 in the regulation of its tumor suppressive activity, but it argues
against the results obtained from the previously-mentioned study on rodent STASRT-GAP1/
DLC1. Although human START-GAP1/DLC1 has three characteristic phospho-PKB/Akt
substrate motifs, the authors showed that only Ser567 was phosphorylated by PKB/Akt. Only
active PKB/Akt was able to interact with STASRT-GAP1/DLC1. Since phosphorylated START-
GAP1/DLC1 forms a more stable interaction with PKB/Akt, there seems to be a cooperative
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increase in binding. Furthermore, Ko et al. showed that unphosphorylated START-GAP1/
DLC1 is sufficient to suppress proliferation and anchorage-independent cell growth. Using a
ras transformed, p53-deficient murine hepatoma line, the authors demonstrated that only wild-
type START-GAP1/DLC1 or a phosphorylation-dead mutant (S567A) was able to inhibit tumor
formation in nude mice, whereas the S567D mutant, simulating constitutive phosphorylation,
did not inhibit tumor growth. PKB/Akt, suggesting that all START-GAP/DLC family members
may share common mechanisms of post-translational regulation, also phosphorylated human
START-GAP2/DLC2 in the corresponding motif.
The central region of START-GAP1/DLC1 containing the FAT region was reported to target
caveolae by interacting with caveolin-1 [28, 92].
4. Regulation of intracellular localization
Generally, members of the START-GAP family, START-GAP1/DLC1, START-GAP2/DLC2
and START-GAP3/DLC3, START-GAP/DLCs do not localize evenly in the cytoplasm. Rather,
they are localized in the specialized place in intracellular spaces. All three members are
localized to focal adhesions of attached cells. A conserved region among them (the FAT region),
responsible for targeting to focal adhesions, has now been identified. It is now established that
the tensin family, which is the major component of the focal adhesion complex, is responsible
for recruiting the START-GAP/DLC family proteins to focal adhesions. Nevertheless, many
proteins are now revealed to interact with START-GAP/DLCs. Vinculin, another member in
the focal adhesion complex, can also interacts with the START-GAP/DLC family proteins. In
addition, PLCδ1 interacts with all three isoforms of START-GAP/DLCs and make a molecular
complex in lipid rafts upon stimulation with extracellular stimuli. Moreover, 14-3-3 binds to
START-GAP1/DLC1. Binding of 14-3-3 proteins often sequesters the target protein in a
particular subcellular compartment and the release of 14-3-3 proteins then allows the target to
be relocated. Since START-GAP1/DLC1 has a nuclear localization signal (NLS) sequence and
found in the nucleus, it is suggested that it also interacts with importins.
Thus expected function of the START-GAP/DLC family proteins varies from one cell type to
next, depending on the spatiotemporal regulation according to the binding proteins. Never‐
theless, as a whole, they regulate cell shapes and motility via remodeling of actin cytoskeleton.
4.1. Focal adhesion targeting via interaction with tensin and vinculin
START-GAP1/DLC1 is localized in focal adhesions via the FAT region located in its N-terminal
half and interacts with tensin family proteins, that constitutes focal adhesion components.
Evidences that the interaction between START-GAP1/DLC1 and tensin2 occurs in a PTB
domain-dependent manner have been provided. It was revealed that FAT3, the third subre‐
gion of the FAT region divided into five (39 amino acids), binds directly to the PTB domain of
tensin2 [30]. This interaction does not require protein phosphorylation, since the interaction
was detected with proteins expressed in bacterial expression system.
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START-GAP2/DLC2 and START-GAP3/DLC3, as well as STRT-GAP1/DLC1, bind to the PTB
domain of tensin2, presumably due to the presence of highly conserved residues in the center
of FAT3. Deletion of this sub-region abrogates the interaction with the tensin PTB domain. The
tensin2 PTB domain seems to determine the subcellular localization of FAT3. Nevertheless,
our study with deletion mutants revealed that FAT3 is essential but not sufficient for the focal
adhesion localization of START-GAP1/DLC1. These results suggest that the interaction
between the tensin PTB domain and FAT3 contributes to START-GAP1/DLC1 localization but
only partially. Other factors could affect the START-GAP1/DLC1 localization.
Figure 3. START-GAP1/DLC1 contributes to at least two signaling pathways. START-GAP1/DLC1 consists of about 11
hundred amino acids (for rat: 1,083 and for human: 1, 093) and contain the sterile α motif at the N-terminus, which is
known to function in protein-protein interaction. In the C-terminal half there are “GAP domain” followed by the
START domain, which is generally thought as a lipid binding or transfer domain. The GAP domain shows a GTPase-
activating function, specific for Rho family GTPases, RhoA and Cdc42 but not Rac1 [31], converting “the active, GTP-
bound form” to “the inactive, GDP-bound form.” The GAP activity of START-GAP1/DLC1 therefore may be implicated
in control of the cytoskeleton, cell polarity and cell migration. As for phosphoinositide signaling, one of the down‐
stream effectors of RhoA is PIP5K that generates PtdIns(4,5)P2. So by inhibition of activated Rho, PtdIns(4,5)P2 genera‐
tion is expected to be reduced. The C-terminal half of START-GAP1 is responsible for stimulation of PLCδ1 and breaks
down PtdIns(4,5)P2. This not only causes the generation of two second messengers, Ins(1,4,5)P3 and diacylgrycerol, but
also alters the activity of several PtdIns(4,5)P2-dependent actin-regulating proteins. As a whole, in microenvironment
surrounding active START-GAP1/DLC1, RhoA and Cdc42 are inacitvated and a loss of PtdIns(4,5)P2 is expected. The
region between the SAM and GAP domains is rich in serine residues and does not fall on any known protein domains
and has been thought to form disordered conformation.
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Amino acid sequence of START-GAP3/DLC3 contains a segment similar to the START-GAP1/
DLC1 tensin binding site (353STYDNL358) and full-length START-GAP3/DLC3 was shown to
bind the SH2 and PTB domains of tensin1 [43].
We noticed that tensin2 does not always colocalize with START-GAP1/DLC1 and that this
interaction was insufficient for targeting START-GAP1/DLC1 to focal adhesions. We thereby
explored if there is another molecule that interacts with START-GAP1/DLC1 by the GST pull-
down assay using GST-START-GAP1/DLC1 transfected HeLa cells. As a result, we found that
START-GAP1/DLC2 can bind with the C-terminus (730-1066) of vinculin. Moreover, START-
GAP1/DLC1 and vinculin were found colocalized in foal adhesions. The domain in START-
GAP1/DLC1 required for interaction with vinculin was narrowed down to residues 460-470
including an LD motif, a motif in paxillin required for interaction with vinculin. A deletion
mutant and point mutants of this motif were fully localized to focal adhesions, although they
lost binding ability to vinculin. It is likely that when START-GAP1, vinculin and tensin2 form
a stable complex, they are localized to focal adhesions.
PtdIns(4,5)P2 has an important role in regulating cytoskeleton assembly by inducing confor‐
mational changes in actin binding proteins such as vinculin and talin [97]. Thus, START-GAP1/
DLC1 could influence cytoskeletal dynamics by altering local PtdIns(4,5)P2 levels by activating
PLCδ1 in the vicinity of focal adhesions as well as by regulating Rho GTPase activity there.
4.2. Raft localization via interaction with PLCδ1
The C-terminal region of START-GAP1/DLC1 covering the GAP and START domain is known
to interact with PLCδ1, enhancing its activity [22]. Although START-GAP1/DLC1 binds with
PLCδ1, it is not usually localized at the plasma membrane where PLCδ1 targets itself through
its PH domain under unstimulated conditions.
Caveolae are plasma membrane domains that appear as flask-shaped invaginations at the cell
surface and are enriched in cholesterol and sphingolipids. Yamaga et al. have shown that
endogenous START-GAP1/DLC1 was found to sediment with caveolin-1 in low density
cholesterol-rich membrane fractions [28], and both endogenous and exogenous START-GAP1/
DLC1 were co-immunoprecipitated with caveolin-1 [28, 92]. Since multiple functions have
been proposed for caveolae [98] and caveolin-1 has been found in membrane subdomains other
than caveolae, including focal adhesions [98] the physiological significance of the interaction
between START-GAP1/DLC1 and caveolin-1 requires further investigation.
In their previous study [28], Yamaga et al. provided supportive evidences for START-GAP1/
DLC1 localization in caveola, which is cholesterol-enriched membrane microdomain, using an
expression system of GFP-tagged proteins, an immunoprecipitation assay and a sucrose
density gradient centrifugation analysis of cell lysates. GFP-tagged START-GAP1/DLC1 was
observed as patch-like structures at the cell surface and in the cytoplasm of attached cells. The
patches were dependent on the levels of the membrane cholesterol and co-localized with
caveolin-1. START-GAP1/DLC1 interacts with caveolin-1 in vivo and is fractionated into low-
density caveolin-enriched membrane fractions. These results support the idea that START-
GAP1/DLC1 is targeted to caveolae via binding to caveolin-1. Yamaga et al. also found the C-
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terminal half of START-GAP1/DLC1 was responsible for its patch-like distribution. The
authors found amino acid sequences that resemble putative caveolin-binding motifs
(ΦXΦXXXXΦ, ΦXXXXΦXXΦ or ΦXΦXXXXΦXXΦ), where Φ is an aromatic residue and X is
any amino acid [99] in the N-terminal region (14WLRVTGFPQY23 and
93WTFQRDSKRWSRLEEFDVF111) and in the GAP domain (690YVNYEGQSAY699 and
725FLQIYQY731) of START-GAP1/DLC1. Since GFP-tagged START-GAP1/DLC1–534ΔC does
not seem to reside in caveolin-1-containing membranes, the sequences in the N-terminal region
may not function as caveolin-binding motifs. Either (or both) the sequence(s) in the GAP
domain, however, could be important for caveolin-1 binding and therefore responsible for the
distribution of START-GAP1/DLC1. It is therefore possible that the RhoGAP domain of
START-GAP1/DLC1 contributes not only to the catalytic activity but also to the intracellular
localization of START-GAP1/DLC1. The exact roles of the N-terminal region have to be
clarified. GFP-tagged START domain was also observed as patches, but unlike GFP-tagged
full-length protein or GFP-tagged GAP domain, it was just partially co-localized with caveo‐
lin-1. The patch-like localization of GFP-tagged START domain was similar to the distribution
of cholesterol visualized by filipin, a fluorescent molecule that specifically binds to free
cholesterol. The result suggests that the START domain can associate with cholesterol but it is
not sufficient to recruit START-GAP1/DLC1 to caveolin-1-enriched membrane microdomains.
Recruitment and activation of PLCδ1 in lipid rafts by a muscarinic agonist was examined using
PC12 cells [24]. Sucrose density gradient centrifugation analyses of cell lysates revealed that
only a small amount of PLCδ1 was recovered in low-density membrane fractions. The amount,
however, significantly increased when cells were treated with a muscarinic agonist carbachol.
Immunoprecipitation studies demonstrated that carbachol also enhanced the interaction
between PLCδ1 and START-GAP1/DLC1, which is constitutively localized in lipid rafts. The
PH domain of PLCδ1 is likely responsible for the interaction. Since carbachol elevates intra‐
cellular Ca2+levels in PC12 cells, Yamaga et al. next examined whether a rise of intracellular
Ca2+ levels participates in the carbachol-induced raft recruitment of PLCδ1. After treatment
with a Ca2+ ionophore ionomycin PLCδ1 was also translocated to lipid rafts in PC12 cells.
Chelating extracellular Ca2+ by EGTA did not inhibit the carbachol-induced translocation of
PLCδ1 to lipid rafts, whereas treatment of cells with thapsigargin to block the intracellular
Ca2+ mobilization inhibited its translocation. These results suggest that PLCδ1 is recruited to
lipid rafts and binds to preexisting START-GAP1/DLC1 in Ca2+ dependent manner, and this
process can be triggered by external stimuli activating GPCRs (Figure 4).
Although the physiological function and significance of START-GAP1/DLC1 in caveolar
localization remain unclear, it appears that caveolae are one of the compartments whereby
START-GAP1/DLC1 may exhibit its tumor-suppressive role and possibly vasoregulatory role
which will be mentioned in Section 7, and affect the cytoskeletal reorganization by its RhoGAP
activity.
4.3. START-GAP2/DLC2 localization in mitochondria
Apart from focal adhesion localization, START-GAP/DLCs could be localized in mitochondria.
Ng et al. has disclosed that START-GAP2/DLC2 is targeted to mitochondria through the
START-GAP/DLC Family Proteins: Molecular Mechanisms for Anti-Tumor Activities
http://dx.doi.org/10.5772/55268
181
START domain using Huh-7 hepatoma cells [84]. They could observe the expression of ectopic
START-GAP2/DLC2 in the cytoplasm especially in a punctate structure, suggesting that
START-GAP2/DLC2 was concentrated in cytoplasmic speckles. It is noteworthy that the
localization patterns of full-length START-GAP2/DLC2, START-GAP2/DLC2-ΔSAM lacking
the N-terminal SAM domain and START-GAP2/DLC2-START, that consists of only from the
START domain were very similar, indicating that the START domain is responsible for the
intracellular localization. Analysis of the amino acid sequence has revealed that no noticeable
localization signal in the START domain. START-GAP2/DLC2-START was in dot-like
structure throughout the cytosol, although some cells showed aggregates in the perinuclear
region, while START-GAP2/DLC2-ΔSTART, a mutant lacking the START domain, was found
to distribute homogenously in the cytoplasm. Notably, almost all START-GAP2/DLC2 signals
overlapped those of mitochondria, but not all mitochondria were targeted by START-GAP2/
DLC2. They also biochemically fractionated mitochondrial fraction from myc-tagged START-
GAP2/DLC2 expressed Huh-7 cells and found that it was found in both the cytoplasmic and
mitochondrial fraction. Taken together, the START domain plays a pivotal role in intracellular
localization and function of START-GAP2/DLC2. Whether these results could also apply for
endogenous START-GAP1/DLC1 or START-GAP3/DLC3 in other cell types awaits future
experiments.
4.4. START-GAP2/DLC2 localization around lipid droplets
In addition to demonstrate the mitochondrial localization of START-GAP2/DLC2, Ng et al.
also examined whether START-GAP2/DLC2 and/or the START domain of START-GAP2/
DLC2 can interact with intracellular lipids [84]. Since localization pattern of START-GAP2/
DLC2 and its START domain are very similar, they examined whether lipophilic dyes such as
Nile red and Sudan III overlap with signal of the START domain of START-GAP2/DLC2. The
speckles containing the START domain were localized around the lipid droplets stained by
Nile red. Nevertheless, the two signals did not overlap substantially with each other, despite
that a major portion of the START domain was found to be in proximity to the lipid droplets.
The authors suggested that the START domain of START-GAP2/DLC2 likely serves a lipid
related function in the cell and it targets START-GAP2/DLC2 to areas proximal to the lipid
droplets [84].
4.5. START-GAP1/DLC1 localization in the nucleus
Recently, using lung carcinoma cells Yuan et al. showed that START-GAP1/DLC1 harbors a
functional bipartite nuclear localization signal (NLS) in serine-rich domain in the FAT region,
which works together with the GAP domain to mediate START-GAP1/DLC1 nuclear import
and subsequent apoptosis [38]. The potential NLS sequence was found as amino acids
415RRENSSDSPKELKRRNS431 including a pat7 NLS spanning residues 423PKELKRR429 [100]. A
deletion mutant START-GAP1/DLC1-Δ372 lacking the N-terminus 372 amino acids accumu‐
lates in the nucleus, suggesting the presence of nuclear export signal (NES) in this region,
whereas mutants with disruption of this NLS sequence could only localize in the cytosol.
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The function of START-GAP1/DLC1 in the nucleus remains to be defined. Some Rho GTPases
have C-terminal polybasic region that could be function as an NLS [101]. Therefore these
GTPases may serve as substrates for START-GAP1/DLC1 in the nucleus. In the nucleus
START-GAP1/DLC1 may also interact with non-GTPase substrates such as PLCδ1 [22], which
is under nuclear import-export equilibrium and accumulate in the nucleus under specific
phases of the cell cycle [102, 103] or extracellular stimuli that causes aberrant increase in
intracellular Ca2+ [103-106]. Nuclear translocation of START-GAP1/DLC1 was proposed to be
associated with apoptosis by a yet unknown mechanism [38].
START-GAP1/DLC1 interacts with 14-3-3 proteins, resulting inhibition of the GAP activity and
block nucleo-cytoplasmic shuttling [100]. In GST pull-down assays, START-GAP1/DLC1
interacted with all 14-3-3 isoforms except 14-3-3σ. The other six 14-3-3 isoforms are ubiqui‐
tously expressed, readily form homo- and heterodimers, and could therefore potentially
participate in the regulation of START-GAP1/DLC1 function. 14-3-3 proteins often regulate
cellular processes by modulating target protein localization. The pat7 NLS spanning residues
of START-GAP1/DLC1, 423PKELKRR429, was demonstrated to be masked by phorbolester-
induced phosphorylation and the 14-3-3 interaction. Inactivation of this NLS by exchange of
critical arginine residues impaired but did not prevent nuclear import of START-GAP1/DLC1.
This suggests the presence of another NLS that contributes to START-GAP1/DLC1 nuclear
shuttling.
Taken together, it was suggested that START-GAP1/DLC1 functions both as a cytoplasmic and
nuclear tumor suppressor.
5. Negative regulation of carcinogenesis not dependent on the RhoGAP
activity
5.1. RhoGAP activity-dependent pathway
As mentioned earlier, the START-GAP/DLC family proteins may exert their suppressive
function by decreasing the levels of active, GTP-bound Rho proteins or inhibiting the GDP-
GTP cycling process, affecting cytoskeletal remodeling, cell shape, motility, proliferation and
apoptosis. Nevertheless, molecular mechanisms through which START-GAP/DLC family
proteins are capable of suppressing cell motility and cell growth are still unclear.
Holeiter et al. have shown that enhanced migration of cells lacking START-GAP1/DLC1 is
dependent on the Rho effector, Dia1, and does not require the activity of ROCK [107]. Leung
et al. provide evidence for a key mechanism through which the START-GAP/DLC family
proteins act as tumor suppressors [108]. In this study, the authors demonstrated that the
expression of START-GAP2/DLC2 is involved in the inactivation of the Raf/MEK/ERK/RSK
pathway, which is crucial for cell proliferation. This inhibitory activity of START-GAP2/DLC2
is attributed to RhoGAP function [108].
By binding to PLCδ1, START-GAP1/DLC1 enhances the hydrolysis of PtdIns(4,5)P2, which
interacts with a variety of actin regulatory proteins that affect the actin cytoskeleton [22, 23,
START-GAP/DLC Family Proteins: Molecular Mechanisms for Anti-Tumor Activities
http://dx.doi.org/10.5772/55268
183
28]. In addition to the PLCδ1 activation and the modulation of RhoGAP activities, proper focal
adhesion localization and interaction with tensins have been demonstrated to be essential for
the growth-suppression function of START-GAP1/DLC1 [43, 90, 92, 109].
START-GAP1/DLC1 overexpression induces a significant reduction of stress fibers and
filopodia, as well as membrane blabbing and cellular decomposition, nuclear condensation or
fragmentation in NCI-H358 cells known as highly sensitive cells to tumor suppression
functions of START-GAP1/DLC1 [110]. These effects were due to the collapse of actin cytos‐
keleton during apoptosis [111].
To overcome the embryonic lethality of homozygous START-GAP1/DLC1 knockdown [57],
Zender et al. combined in vivo RNAi and a ‘mosaic’ mouse model of HCC to address the
impact of the loss of START-GAP1/DLC1 on liver carcinogenesis [112]. Genetically modified
liver  progenitors  (p53−/−  cells  infected  with  a  retrovirus  expressing  c-myc  and  another
expressing a START-GAP1/DLC1 shRNA) were transplanted into the liver of syngenic mice
to assess their  ability to generate tumors in situ.  In contrast  to  control  shRNA, START-
GAP1/DLC1 shRNA accelerates  the formation of  liver  tumors,  which mimics  aggressive
HCC. Conversely,  reintroduction of START-GAP1/DLC1 in hepatoma cells co-expressing
oncogenic Ras results in a dramatic reduction of tumor growth in situ. This study demon‐
strates  that  START-GAP1/DLC1  loss,  when  combined  with  other  oncogenic  lesions,
efficiently promotes the development of HCC.
Activation of RhoA, and thereby of its downstream effector ROCK, is both necessary and
sufficient to promote HCC in vivo. Therefore, START-GAP1/DLC1, due to its RhoGAP activity,
is capable to antagonize the activities of RhoA and its downstream effectors in HCC [58, 113,
114]. Moreover, RhoA is required for tumorigenesis induced by the loss of START-GAP1/DLC1
and constitutively active RhoA mimics loss of START-GAP1/DLC1 in promoting HCC in the
‘mosaic’ mouse model [58].
START-GAP1/DLC1 was also implicated in tumor metastasis. The expression levels of START-
GAP1/DLC1 mRNA are significantly lower in highly invasive tumors than in less invasive
ones [115]. Restoration of START-GAP1/DLC1 expression in vitro reduces the migration and
the invasiveness of HCC cells [35, 41, 113]. This mechanism also seems to be dependent on
RhoGAP activity and its downstream effectors ROCK and MLC [42].
Finally, reexpression of START-GAP1/DLC1 in HCC cells downregulated the expression of
osteopontin and matrix metalloproteinase-9, which are found overexpressed in most primary
metastatic liver tumors [114]. START-GAP1/DLC1 restoration also suppresses the distant
dissemination of cells from subcutaneous tumors developing after inoculation of HCC cell
lines in mice. This process is also dependent on the RhoA activity and reorganization of actin
cytoskeleton in tumor cells [114].
5.2. RhoGAP activity-independent pathway
Angiogenesis is another form of cancer development. In addition to its direct effect via
activation of Rho pathway, START-GAP1/DLC1 is responsible for regulation of angiogenesis
in an indirect manner [116]. START-GAP1/DLC1 negatively regulates angiogenesis in a
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paracrine fashion. START-GAP1/DLC1 silencing promoted pro-angiogenic responses through
vascular endothelial growth factor upregulation, accompanied by the accumulation of
hypoxia-inducible factor 1 and its nuclear localization.
6. Stability of START-GAP/DLCs
Stability of proteins may also contribute to the expression levels of the START-GAP/DLC
family proteins. Generally, degradation of proteins is controlled by ubiquitination-dependent
and independent proteolysis. START-GAP1/DLC1 seems to be ubiqutinylated and processed
at least partly by ubiquitinylation-dependent proteasomal degradation [117]. Nevertheless,
the sites and the mode of ubiquitinylation (mono- or poly-) on the molecule are unclear. In
addition, a proinflammatory protein S100A10, a key cell surface receptor for plasminogen and
a regulator of proteolysis, was found to be a novel binding partner of START-GAP1/DLC1
[118]. S100A10 colocalizes with START-GAP1/DLC1 in the cytoplasm via interaction between
the C-terminus of S100A10 and the central domain of START-GAP1/DLC1, regulating tumor
cell invasion [118]. These results strongly suggest that proteolysis dependent on post-tran‐
scriptional modification of START-GAP1/DLC1 plays an important role in the regulation of
its tumor suppressive activity.
7. Possible roles of START-GAP1/DLC1 in the development of vascular
diseases
Recently, another potential role of START-GAP1/DLC1 in the pathogenesis of a human disease
has emerged. It has been known that the PLC activity with its effect on the regulation of
intracellular Ca2+ levels has potential roles in cardiac regulation. PLCδ1 activity has shown to
be enhanced in patients with coronary artery spasm, CSA (coronary spastic angina) [119,
120]. In this context, a new finding that START-GAP1/DLC1 protein levels and mRNA levels
in fibroblasts from Japanese patients with CSA were enhanced compared with levels in control
subjects is noteworthy [121]. The authors also found in the START-GAP1/DLC1 promoter
analysis, the -228G/A and -1466C/T variants found associated with CSA patients using 5’-
RACE method revealed the increase in luciferase activity [121]. The incidence of -228G-A was
more frequent in male patients with CSA than in male control subjects, suggesting that this
variant is a possible candidate responsible for upregulation of START-GAP1/DLC1 protein in
CSA. Thus, it was postulated that START-GAP1/DLC1 is up-regulated in patients with
coronary spasm, possibly by mutations in the promoter region, causing increased [Ca2+]i to
acetylcholine, and thereby seems to be related to enhanced coronary vasomotility.
As stated in the earlier section, START-GAP1/DLC1 plays two important roles in signaling
pathways: One of the dual functions is the ability to enhance the PtdIns(4,5)P2-hydrolyzing
activity of PLCδ1 and the other is the GAP activity specific for RhoA and Cdc42. The former
leads to both the protein kinase C-mediated pathway and Ca2+-dependent pathway, resulting
START-GAP/DLC Family Proteins: Molecular Mechanisms for Anti-Tumor Activities
http://dx.doi.org/10.5772/55268
185
in enhanced myosin light chain phosphorylation that plays an important role in the constrictor
response of the coronary artery smooth muscle to transmitters such as serotonin and histamine.
Homma and Emori showed that recombinant PLCδ1 catalyzes the hydrolysis of PtdIns(4,5)P2
in a Ca2+-dependent manner; in the presence of START-GAP1/DLC1, its activity is 5- to 10-fold
increased in the range of physiological Ca2+ concentration [22]. Thus, it is conceivable that
upregulation of START-GAP1/DLC1 protein observed in patients with CSA is responsible for
the high activity of PLCδ1. These results are consistent with the previous finding of the H257R
variant of PLCδ1, in which the conformational change is associated with upregulation of
PLCδ1 activity [120]. These characteristics seem to explain the pathogenesis of CSA in which
both the basal vascular tone and the vasoconstrictor response to the diverse stimuli were
enhanced. Previously, PLC activity was shown to positively correlate not only with basal
coronary artery tone but also with the maximal and averaged constrictor responses of the
coronary artery to acetylcholine [119]. This finding also suggests a critical role of START-GAP1/
DLC1 protein in the genesis of coronary spasm.
The START-GAP1/DLC1 protein has another function, a GAP activity for Rho GTPases.
Alterations in RhoA/ROCK pathway have been implicated in the development of a variety of
cardiovascular diseases, including hypertension, atherosclerosis, and cerebral and coronary
vasospasm [122, 123].
It was reported that the ROCK inhibitor fasudil attenuated the constrictor response of the
coronary artery to ACh and prevented the occurrence of chest pain in patients with CSA [124].
By its GAP activity, START-GAP1/DLC1 may antagonize the development of coronary spasm
like the ROCK inhibitor. On the other hand, Ca2+ mobilization induced by PLCδ1 activation
may upregulate Rho and ROCK in the vascular smooth muscle [125]. Thus, the role of START-
GAP1/DLC1 in the regulation of Rho is complicated, and the relation of START-GAP1/DLC1
to the genesis of coronary spasm via Rho activity remains to be determined.
The mechanisms of enhancement of START-GAP1/DLC1 promoter activity by the -228G/A
variant may be related to transcription factor SP because this variance causes loss of binding
to SP1 in its region [121]. Upregulation of START-GAP1/DLC1 protein in the coronary arteries
of CSA patients should be confirmed. It remains unclear whether upregulation of START-
GAP2/DLC2 or START-GAP3/DLC3 is associated with CSA.
Regarding the caveola localization of START-GAP1/DLC1, the recent report by Nuno et al.
that RhoA colocalization with caveolin-1 in caveolae regulates vascular contractions to
serotonin is of interest [126]. Caveolins are not only structural components of caveola micro‐
domains, but also regulate assembly and activation of a variety of receptors and signaling
molecules such as PtdIns(4,5)P2, glucose transporter 4 (GLUT4), epidermal growth factor
receptors (EGFR) and endothelial nitric oxide synthase (eNOS). Localization of RhoA to
caveolae versus noncaveolar lipid rafts differentially regulates its activation and contractions
to RhoA-dependent agonists with greater activation associated with its localization to
noncaveolar rafts. Presumably, translocalization of START-GAP1/DLC1 to caveolae by
agonists reported by Yamaga et al. [24, 28] may also contribute to modulate the activity of
RhoA/ROCK pathway in vascular cells.
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Figure 4. Roles of START-GAP1/DLC1 in a lipid raft/caveola and its possible involvement in the pathogenesis of coro‐
nary vasospasm. When G protein coupled receptors (GPCRs) such as muscarinic receptors are activated by agonists
they initially stimulate β-type PLC resulting in the production of Ins(1,4,5)P3 from PtdIns(4,5)P2. Ins(1,4,5)P3 binds to the
receptors (IP3R or ER Ca2+ pump) at the intracellular Ca2+ stores such as ER and mobilizes Ca2+ from the stores. PLCδ1 is
localized at the plasma membrane and in the cytosol in unstimulated cells, whereas START-GAP1/DLC1 is localized in
lipid rafts via binding with cholesterol (or with caveolin if the lipid rafts are caveolae). The agonist-induced primary
increase in Ca2+ recruits PLCδ1 into lipid rafts from other parts of the plasma membrane or from the cytosol by un‐
known mechanisms. PLCδ1 in the lipid rafts then binds START-GAP1/DLC1 to be activated in the presence of Ca2+, re‐
sulting in a robust hydrolysis of PtdIns(4,5)P2 that forms clusters in lipid rafts. Released Ins(1,4,5)P3 then empties the
internal Ca2+ stores via activation of IP3R followed by stimulation of TRP channels, a component of store-operated
channels (SOCs) to increase Ca2+ influx (secondary Ca2+). Thus the recruitment of PLCδ1 to rafts confers a general posi‐
tive feedback mechanism for phosphoinositide/Ca2+ signaling in the cells. START-GAP1/DLC1 also modulates the
RhoA/ROCK signaling pathway. Modified from [24].
8. Conclusion
The START-GAP/DLC family proteins are a group of Rho GTPases whose aberrant function
suggests dysregulation of numerous cell processes that can develop diseases such as cancers
and vascular spasm. Both in vitro and in vivo studies have provided strong evidence that
START-GAP/DLCs have roles in regulating actin cytoskeleton organization. Binding to tensins
and other molecules may target the RhoGAP activity of the START-GAP/DLCs to particular
subcellular domains. Accumulating reports indicate that the START-GAP/DLC proteins are
regulated in various ways at a genetic level by gene deletion, at an epigenetic level by the
aberrant promoter methylation, or at a cellular level by the regulation of localization and
stability. More information is required on the mechanisms responsible for these regulations,
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including post-translational modifications such as phosphorylation and ubiquitination. In
addition, dissection of the interacting partners of START-GAP/DLCs by proteomic analyses
will reveal detailed signaling pathways that regulate cell shape, motility and proliferation.
Future studies on the difference among START-GAP/DLCs may reveal which member of this
family plays a key role in individual types of cancer or in vascular abnormality and whether
restoration of the proper function of the START-GAP/DLCs is capable of restraining cell
transformation or abnormal signaling. These efforts would result in identification of the
member that becomes the subject of future studies as a potential drug target for therapy.
Nomenclature
CSA: cardiac spastic angina, DLC: deleted in liver cancer, GAP: GTPase activating protein,
HCC: hepatocellular carcinoma, Ins(1,4,5)P3: inositol 1,4,5-trisphospate (IP3), NLS: nuclear
localization signal, PLC: phosphoinositide-specific phospholipase C, PKB: protein kinase B,
PtdIns(4,5)P2: phosphatidylinositol 4,5-bisphosphate (PIP2), ROCK: Rho-kinase, START:
steroidogenic acute regulatory protein (STAR)-related lipid transfer
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1. Introduction
Tumor suppressor genes (TSGs) function in concert with diverse parts of the cellular machi‐
nery and integrate the signaling networks in a cell [1]. TSGs act to safeguard the networks,
to fine-tune signaling outputs, and to maintain tissue homeostasis. The loss of tumor sup‐
pressor activity or inactivation of a TSG is often due to genetic alterations such as a loss-of-
function mutation or a deletion in the gene; alternatively, epigenetic silencing can result
from methylation or histone modification in the TSG’s promoter regulatory elements [1-3].
Cells with a loss or a significant reduction of a particular tumor suppressor’s activity are
prone to develop neoplasia in the tissues/organs where the TSG is expressed [1, 2].
The properties and modes of action of TSGs can be very distinct from one class to another.
Most TSGs encode proteins that participate in controlling cell cycle progression, inducing
apoptosis, repairing damaged DNAs, or performing other important functions [1]. TSGs can
also be a source of microRNAs, a class of small hairpin RNAs that are transcribed in many
cells and may act as tumor suppressors by regulating the expression of their targeted genes
[4]. In this chapter, we will focus on one class of the TSGs, represented by the mitogen-indu‐
cible gene 6 (MIG-6) and Sprouty 2 (SPRY2), whose activities are crucial in regulating recep‐
tor tyrosine kinases signaling through negative feedback loops.
Receptor tyrosine kinases (RTKs) are important cellular components, and there are nearly 60
members encoded in the genome [5, 6]. They all possess a single transmembrane domain
linking their extracellular ligand-binding region to the cytoplasmic region in which the cata‐
lytic kinase domain and the domain for docking of downstream signaling molecules reside.
Upon binding of the ligand to its physiologic RTK partner, the receptors dimerize, resulting
© 2013 Zhang and Woude; licensee InTech. This is an open access article distributed under the terms of the
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in autophosphorylation of key tyrosine residues in the kinase domain. This leads to a con‐
formational change in the receptor and the recruitment of downstream signaling molecules
to its docking domain or in close proximity for phosphorylation and activation. In this cellu‐
lar process, the RTK plays a central role by relaying external stimuli (ligands) to internal sig‐
naling cascades such as the RAS-MAPK or PI3K-AKT pathways, translating the signal input
into biological actions ranging from mitogenesis, to motility, morphogenesis, metabolism,
and many others [5, 6].
RTK signaling is essential in many developmental processes and in normal physiology, and
the actions of RTKs must be controlled temporally and spatially [5, 6]. Their actions are
tightly regulated at several molecular levels to ensure appropriate cellular responses.
Among the mechanisms that keep RTK signaling in “check and balance” are receptor endo‐
cytosis/degradation, dephosphorylation by protein tyrosine phosphatases (PTPs), and nega‐
tive feedback regulation. Signal overactivity caused by inappropriate RTK activation can
lead to serious pathological outcomes, particularly cancer. Thus, many RTKs such as epider‐
mal growth factor receptor (EGFR) and the N-methyl-N’-nitroso-guanidine human osteosar‐
coma (MNNG HOS) transforming gene (MET) have been classified as oncogenes, because
activating mutations, amplifications or other anomalies in these receptors have been identi‐
fied in various human cancers, and their roles in the development and progression of tumor
malignancy have been well documented [7, 8]. For example, aberrant activation of MET can
result in deregulated cell proliferation, transformation, and promotion of tumor cell inva‐
sion and metastasis [8].
Unlike the rapid attenuation resulting from receptor endocytosis/degradation or PTP-medi‐
ated dephosphorylation, negative feedback regulation of RTK signaling by MIG-6 and
SPRY2 is a delayed event because it requires de novo mRNA and protein syntheses. The ex‐
pression of both MIG-6 and SPRY2 can be induced by ligands of many RTKs including epi‐
dermal growth factor (EGF), hepatocyte growth factor (HGF), and fibroblast growth factor
(FGF) [9, 10]. In turn, MIG-6 and SPRY2 exerts their inhibitory activities on RTK signaling by
either directly affecting the receptor itself or by modulating the signaling molecules down‐
stream of the RTK. In this review, we will highlight the current understanding of how
MIG-6 and SPRY2 regulates RTK signaling via negative feedback loops, and shed lights on
why the loss of their tumor suppressor activities may affect RTK signaling in cancer cells, as
well as their impact on cancer therapy.
2. The features and functions of MIG-6 and SPRY2
2.1. MIG-6
MIG-6  (also  known  as  gene  33,  ERRFI1  or  RALT)  is  a  unique  and  immediate  early  re‐
sponse gene that is not present in relatively simple organisms like Drosophila  and C. ele‐
gans.  It  emerges  in  the  more  complex,  higher-order  species  [9,  11],  underlying  its
importance in evolution. It  encodes a 58 kDa nonkinase protein that resides in the cyto‐
plasm and functions as  a  scaffolding adaptor for  modulating signal  transduction.  Struc‐
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turally, MIG-6 has several functional motifs/domains that are crucial for interaction with
other signaling molecules [9,  12].  The Cdc42/Rac-interaction and binding (CRIB) domain
of MIG-6 (Figure 1A) shares consensus sequences with many other proteins that associate
with Cdc42 or  Rac small  GTPases,  which are important  regulators  of  actin cytoskeleton
remodeling and signal transduction [11, 13]. CRIB domain mediates the binding of MIG-6
to  active  (GTP-bound)  Cdc42  and  negatively  regulates  HGF-induced  Cdc42  activation
and cell migration [12, 14]. This domain has also been shown to play a role in regulating
transactivation of  nuclear  factor  κB (NFκB)  by  sequestering the  inhibitor  of  κBα (IκBα)
[15, 16]. Within its middle region, MIG-6 has several proline-rich motifs that likely medi‐
ate  its  binding  to  various  Src  homology-3  (SH3]  domain-containing  proteins  such  as
GRB2, Src, PI3K p85 and PLC-γ [14, 17]. MIG-6 interacts with 14-3-3ζ via the 14-3-3 pro‐
tein  binding  motif  [12].  MIG-6  also  possesses  two  PEST  sequences,  and  is  targeted  by
ubiquitination and proteasome degradation [18].  The ErbB-binding region (EBR),  a large
portion of the carboxyl terminus in MIG-6, is required for physical interaction with EGFR
family receptors, which resulted in attenuation of EGFR/ErbBs signaling [17, 19, 20]. The
EBR  domain  shares  a  high  homology  with  the  activated  Cdc42-associated  kinase  1
(ACK1), a non-receptor tyrosine kinase that also interacts with and regulates EGFR [21].
Figure 1. MIG-6 and SPRY2 structures. A. MIG-6 protein structural features and its interacting partners. The CRIB do‐
main (amino acids 1-38) interacts with Cdc42 and IκBα. The orange box indicates the SH3-domain binding motif that
likely mediates interactions with SH3-domain-containing proteins such as GRB2 and PI3Kp85. The cyan box (amino
acids 246-253) marks the 14-3-3 binding motif in which serine residue 251 can be phosphorylated by Chk1 kinase. The
EBR domain (amino acids 337-412) binds to EGFR and other ErbB members. The red bar (ED) indicates the MIG-6 en‐
docytic domain (amino acids 143-323); the blue bar indicates the Ack homology (AH) region (amino acids 264-424). B.
Structural features of SPRY2 and its partner molecules. The red box shows the SH2-domain binding motif (amino acids
50-60) that binds to CBL and GRB2; the key tyrosine residue Y55 is also indicated. The conserved cysteine-rich SPRY
domain (amino acids 178-293) is crucial for its ability to interact with signaling molecules such as FRS2 and SHP2. The
SPRY domain is also responsible for membrane translocation (MTD). There is an SH3-domain binding motif (amino
acids 303-309) shown in blue at the C-terminal end of SPRY2 that also binds to GRB2.
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MIG-6 is expressed in many tissues/organs, with high expression in liver and kidney and
low to moderate expression in brain, lung, heart, and other tissues [22, 23]. Its expression
can be induced by diverse factors ranging from hormones and growth factors, to chemical
agents, to stress stimuli [9]. The induction of MIG-6 expression by growth factors is mainly
mediated by the RAS-MEK-MAPK/ERK pathway, while other inducers may involve other
pathways such as PI3K [9]. MIG-6 has also been reported to be a G-actin-regulated target
gene, because the actin-MAL-serum response factor (SRF) cascade mediates MIG-6 induc‐
tion by serum or lipid agonists such as lysophosphatidic acid (LPA) or sphingosine 1-phos‐
phate (S1P) [24]. MIG-6 may play a crucial role in patho-physiological conditions such as
myocardial ischemic injury and infarction [25], liver regeneration [26-28], joint mechanical
injury [29], and diabetic nephropathy and hypertension [12]. Its activity is required for skin
morphogenesis [30, 31] and lung development in mice [32], and it plays an important role in
the maintenance of tissue homeostasis in joints, the lungs and the uterus [32-35].
2.2. SPRY2
In term of evolution, the Spry gene emerged far earlier than Mig-6. SPRY2 is the mammalian
homolog of Drosophila melanogaster Spry (dSpry), and is one of the four SPRY genes in the
human genome [10]. The dSpry protein is 63 kDa, while its mammalian counterparts are 32–
34 kDa, but they all contain a functional cysteine-rich region in their C-terminus (designated
the SPRY domain) and an SH2-binding motif carrying a conserved tyrosine at the N-termi‐
nus (Tyr55 residue in human SPRY2) (Figure 1B). These conserved regions are essential for
SPRY2 to fully execute its inhibitory function in the regulation of RTK signaling [10, 36, 37].
The SPRY domain is also found in the SPRED (Sprouty-related EVH1 domain-containing
protein) family, which like SPRY proteins inhibits RTK signaling upon stimulation by
growth factors [10, 38]. The SPRY domain mediates the binding of SPRY2 to many signaling
molecules including GAP1, FRS2, SHP2, RAF, PKCδ, TESK1 and caveolin1 [10, 39]. The
SPRY domain is also required for translocation of SPRY2 to the membrane during its activa‐
tion. The Tyr55 residue is essential for the SPRY2 protein’s interaction with CBL, PP2A and
GRB2 [10, 39]. A cryptic SH3-binding motif (PxxPxR) in the C-terminal end of SPRY2 (but
not present in other SPRY members) has been shown to mediate GRB2 interaction as well
[39-41]. The dual-specificity tyrosine phosphorylation–regulated kinase (DYRK1A) interacts
with and phosphorylates Thr75 on SPRY2 [42]. SPRY2 is targeted for ubiquitination and
proteasome degradation by at least two ubiquitin E3 ligases: CBL-mediated Tyr55 phos‐
phorylation-dependent ubiquitination and SIAH2-mediated Tyr55 phosphorylation-inde‐
pendent ubiquitination [43, 44]. On the other hand, SPRY2 protein can be stabilized by
phosphorylation of its serines 112 and 121 residues by the mitogen-activated protein kinase-
interacting kinase 1 (Mnk1], thereby decreasing growth factor–induced degradation [45].
In Drosophila, dSpry expression is detected at the tips of branching lung buds and is induced
by branchless, the Drosophila Fgf. Losing dSpry leads to excessive tracheal branching as a re‐
sult of increased Fgf signaling activity [46]. The Xenopus homolog, xSpry2, is expressed in a
pattern resembling that of Xenopus Fgf8 and inhibits Fgf-mediated gastrulation [47]. During
mammalian embryogenesis, Spry2 expression tends to localize closest to the sites where Fgf
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activity is needed for organ/tissue development, underlying the importance of this molecule
as an intrinsic Fgf signaling regulator in organogenesis [48-50]. Mouse Spry2 is highly ex‐
pressed in the terminal buds of peripheral mesenchyme in the embryonic lung, adjacent to
that of Fgf10, a key mouse lung-branching morphogen [50]. Ectopic expression of Spry2 in
the mouse pulmonary epithelium results in decreased branching; exogenous Fgf10 produces
greater lung branching and higher Spry2 expression [50]. Spry2 also plays a role in mouse
kidney development; its ectopic expression in the ureteric bud leads to postnatal kidney fail‐
ure due to deficiency in ureteric branching [51]. Moreover, Spry2 deficiency in mice results
in defects of the auditory sensory epithelium development in the inner ear, and leads to en‐
teric neuronal hyperplasia and esophageal achalasia [52, 53]. The lack of phenotypes in oth‐
er Spry2-deficient tissues is likely due to compensatory roles of other Spry family members,
because there are overlapping expressions of Spry1, 2 and 4 in many tissues during the de‐
velopment [54]. In adult mice, Spry2 expression is abundant in the brain, lung, heart, kid‐
ney, skeletal muscle and mammary glands [48, 55].
Beyond being an intrinsic inhibitor for Fgf signaling, Spry also regulates signaling driven by
other RTKs like Egfr. The dSpry gene is required for eye and wing development in Drosophi‐
la, antagonizing Egfr signaling for neuronal induction in the retina and for vein formation in
the wings [56, 57]. Loss of dSpry results in excess photoreceptors, cone cells and pigment
cells in the retina, while its overexpression leads to phenotypes that mimic loss of Egfr sig‐
naling [56, 57].
3. Negative feedback regulation of RTK signaling by MIG-6 and SPRY2
3.1. Regulation of RTK pathways by MIG-6
Many growth factors can induce MIG-6 expression, including EGF, FGF, and HGF [9]. Upon
induction, MIG-6 proteins rapidly and transiently accumulate in the cytoplasm, where they
feed back to inhibit the activated RTK signaling (Figure 2]. The inhibition of EGFR/ErbB sig‐
naling by MIG-6 can occur at two molecular levels: one on the receptor itself, and another on
the signaling molecules downstream of the receptor (Figure 2). Through its C-terminal EBR
domain, MIG-6 directly binds to EGFR and other ErbB members [17, 19, 20, 58]. The interac‐
tion involves the kinase domain of EGFR or ErbB2 and requires their catalytic activities, but
does not involve their C-terminal regions in which there are tyrosine residues essential for
activating downstream signaling [20, 58]. Crystal structures reveal that the MIG-6 EBR do‐
main binds to the distal surface of the carboxy-terminal lobe (C-lobe) in the kinase domain
of EGFR [59]. The C-lobe is crucial in asymmetric EGFR dimer formation [60]; binding of
MIG-6 to the C-lobe blocks the dimer interface thereby preventing EGFR activation [59].
MIG-6 coupling also promotes clathrin-mediated endocytosis of EGFR [61], an important
mechanism for timely attenuation of ligand-induced EGFR activation [62, 63]. The region re‐
sponsible for promoting EGFR endocytosis has been mapped to the endocytic domain (ED)
of MIG-6 (see Figure 1A) [61], which mediates the binding of MIG-6 to the AP2 adaptor
complex, a key component in forming clathrin-coated pits during endocytosis [63]. Interest‐
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ingly, the non-receptor tyrosine kinase ACK1 also binds to EGFR upon EGF stimulation
through a region sharing high homology with the MIG-6 EBR domain [21]. This interaction
also regulates clathrin-mediated EGFR endocytosis and degradation [21, 64]. However, it is
not clear whether MIG-6 and ACK1 cooperate in regulating EGFR turnover or whether they
bind to EGFR in a mutually exclusive way to accomplish individual inhibitory roles under
different circumstances. The internalized EGFR is guided to late endosome through the
binding of MIG-6 to the endosomal SNARE complex component STX8, en route to degrada‐
tion in the lysosome [61, 65].
Figure 2. MIG-6 regulates EGFR and MET signaling via a negative feedback loop. Upon ligand stimulation, EGFR and
MET activate the RAS-RAF-MEK-ERK pathway and induce MIG-6 expression. In turn, MIG-6 exerts its inhibitory activity
by interacting with signaling molecules to fine-tune RTK signaling and its timely attenuation. The direct MIG-6–EGFR
interaction facilitates receptor endocytosis and degradation. This inhibitory activity is unique to the EGFR family and
does not extend to other RTKs like MET. The interaction of MIG-6 with signaling molecules such as GRB2 and PI3Kp85
indistinguishably influences the RTK signaling in general, resulting in the inhibition of downstream pathways like RAS-
MAPK/ERK and PI3K-AKT.
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The magnitude of MIG-6-mediated inhibition of EGFR signaling is likely maximized and in‐
tegrated by the second level of molecular regulation, that is, direct inhibition of downstream
signaling molecules (Figure 2). MIG-6 binds to the SH3 domain-containing protein GRB2
[14, 17], the key molecule in linking activated RTK to the intracellular signaling cascade;
GRB2 brings RAS together with SOS to the phosphorylated receptor for activation [66].
Binding of MIG-6 may block GRB2’s interaction with activated EGFR and other RTKs or dis‐
rupt GRB2-SOS-RAS complex formation, thereby preventing activation of the RAS-MEK-
MAPK pathway. MIG-6 also interacts with Src, the PI3K p85 subunit, PLCγ, and Fyn [17],
although those interactions were demonstrated in an artificial system and their biological
meaning remains to be determined. More complexity is likely in the dynamics of MIG-6-
mediated RTK signaling regulation due to the interaction of MIG-6 with 14-3-3 proteins [12,
67], an adaptor family that may interact with diverse signaling molecules and regulate many
biological activities [68]. Nonetheless, most of these direct downstream signaling regulations
by MIG-6 remain largely speculation and require further investigation.
Assessing  the  effect  of  MIG-6  on  RTK pathways  other  than  those  of  the  EGFR family,
however,  may provide insightful  answers to  such speculation,  because direct  regulation
of  the  RTK  itself  by  MIG-6  appears  to  be  unique  to  the  EGFR  family.  For  instance,
MIG-6 can be induced by HGF and function as negative feedback regulator of the MET
pathway by inhibiting HGF-induced cell migration and proliferation [14], yet no physical
interaction  between  MIG-6  and  MET  has  been  observed.  Through  its  CRIB  domain,
MIG-6 can bind to and inhibit  the activity of the Cdc42 small  GTPase [12,  14],  and this
inhibitory activity is required for blocking of HGF-induced cell migration [14]. The CRIB
domain  also  interacts  with  IκBα,  thereby  activating  NFκB for  transcriptional  regulation
of its target gene expression [15, 16].  Whether the inhibition of HGF-induced cell  prolif‐
eration by MIG-6 is  mediated by its  ability to bind GRB2 or to bind other downstream
molecules  is  still  unknown.  Negative  feedback  inhibition  of  other  RTKs  (such  as  FGFR
and  IGFR)  by  MIG-6  is  also  likely  to  be  mediated  by  its  inhibitory  activities  on  the
downstream signaling molecules rather than on the receptor itself.
The inhibitory activity of MIG-6 on RTK signaling seems to be modulated by phosphoryla‐
tion; Liu et al. recently reported that MIG-6 can be phosphorylated by Chk1 upon EGF stim‐
ulation [67]. EGF activates Chk1 via the PI3K-AKT-S6K pathway, which in turn
phosphorylates Ser251 of MIG-6 and results in inhibition of MIG-6 [67]. Thus, Chk1 counter-
balances the EGFR inhibition of MIG-6, positively regulating EGFR signaling. Interestingly,
Ser251 resides in the 14-3-3 binding motif of MIG-6 and its phosphorylation is likely in‐
volved in the MIG-6 and 14-3-3ζ interaction, because that interaction is abolished by Chk1
depletion [67]. In addition, two tyrosine residues (Tyr394 and Tyr458) in MIG-6 are phos‐
phorylated by EGFR activation [69-71], but the underlying mechanism and the biological
significance remain unclear.
3.2. Regulation of RTK pathways by SPRY2
SPRY2 renders another layer of modulation on RTK signaling via a negative feedback loop
[10, 36, 37, 72]; its expression is induced by many activated RTKs including EGFR, FGFR,
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MET, and VEGFR [10, 72]. As with MIG-6, SPRY2-mediated regulation can occur on two
levels: on the RTK itself and on the downstream signaling molecules (Figure 3). However
unlike MIG-6, the most prominent inhibitory activity of SPRY2 is derived from its abilities to
interact with downstream signaling molecules centering on the RAS-RAF-MAPK pathway,
while its effect on the RTK itself seems to be indirect and may provide some signaling spe‐
cificity for different RTKs [10, 36, 37].
Figure 3. Feedback regulation of EGFR and FGFR signaling by SPRY2. SPRY2, upon induction, translocates to the mem‐
brane by binding to PtdIns(4,5)P2, and is phosphorylated on its Y55 residue. This modification is essential for SPRY2’s
inhibitory activity, which is mediated by interaction with many signaling proteins including FRS2, SHP2, GRB2, RAF and
PLCδ. On the other hand, its interaction with CBL E3 ubiquitin ligase may positively regulate EGFR signaling, because
such interaction sequesters CBL and prevents CBL-mediated EGFR degradation.
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Upon growth factor stimulation, SPRY2 translocates from the cytosol to the plasma mem‐
brane where it binds to phosphatidylinositol-4,5-bisphosphate [PtdIns(4,5)P2] via the con‐
served  SPRY  domain  [73-75].  Membrane  translocation  appears  to  be  triggered  by  the
activated  Rac  small  GTPase  and is  essential  for  SPRY2 function  [76].  The  phosphoryla‐
tion  of  the  Tyr55  residue  in  SPRY2  is  likely  regulated  by  a  SRC  family  kinase,  which
upon  FGF  stimulation  is  recruited  to  activated  FGFR  by  FRS2  [77].  While  Tyr55  phos‐
phorylation enables the binding of SPRY2 to GRB2 via the SH2-binding motif  in the N-
terminus  [78],  the  SH3-binding  motif  in  its  C-terminus  may  also  play  a  role  in  the
SPRY2-GRB2 interaction [39-41] (Figure 1B).  The latter is  likely regulated by the protein
phosphatase 2A (PP2A), a serine/threonine phosphatase that interacts with Tyr55 and de‐
phosphorylates  certain  serine  residues  in  SPRY2  for  permitting  access  of  GRB2  to  the
SH3-binding motif on SPRY2 [41, 45]. Consequently, the binding of SPRY2 to GRB2 pre‐
vents the recruitment of the GRB2-SOS complex to the FRS2 adaptor or SHP2 phospha‐
tase  proximal  to  the  activated  RTK,  thereby  inhibiting  the  activation  of  RAS  and  its
downstream molecules [10,  36,  39,  77,  78].  The RTK-RAS-RAF-MAPK/ERK pathway can
also  be  inhibited  by  direct  binding  of  SPRY2  to  RAF  [75,  79,  80].  On  the  other  hand,
TESK1 negatively  regulates  SPRY2 inhibitory  activity  by interfering with  the  SPRY2 in‐
teraction with GRB2 and PP2A [81], while DYRK1A binding results in Thr75 phosphory‐
lation  on SPRY2 and suppression of  SPRY2 inhibitory  activity,  thereby enhancing FGF-
induced ERK activation [42].
The regulation of EGFR signaling by SPRY2 appears to be more complicated than that of
FGFR signaling, because SPRY2 can indirectly influence the turnover of EGFR through its
interaction with CBL (Figure 3) [10, 36, 37]. This regulation is mediated by the SH2-binding
motif, which includes Tyr55 in the N-terminus of SPRY2. When Tyr55 is phosphorylated,
SPRY2 interacts with the SH2-domain on CBL, and prevents CBL from binding to the acti‐
vated EGFR, thereby interfering with CBL-mediated EGFR endocytosis and degradation [43,
82-84]. This action can prolong the activation of EGFR and the downstream RAS-RAF-
MAPK pathway, contrary to the direct inhibitory activity of SPRY2 on the downstream sig‐
naling molecules. These two opposite activities render SPRY2 a delicate role in fine-tuning
EGFR signaling, negative in some situations and positive in others, depending on the
threshold and balance of these two activities.
It is conceivable that RTKs such as MET and PDGFR that are also substrates of CBL might
also be affected by SPRY2 like that of EGFR [8, 85], while non-CBL-substrate RTKs like
FGFR appears unaffected by SPRY2-CBL interaction [36]. However, it is known that MET
protein level is not affected by SPRY2 overexpression that inhibits HGF-induced ERK and
AKT activation, indicating that the effect of SPRY2-CBL interaction on EGFR and on MET
might not be the same [72, 86]. The sequestration of CBL by SPRY2 can also affect down‐
stream signaling molecules, as it may free proteins like GRB2 from CBL-mediated ubiquiti‐
nation and degradation [85]. Furthermore, SPRY2 itself can be ubiquitinylated and degraded
by the CBL binding, thereby influencing the RTK signaling [83].
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4. Tumor suppressor role of MIG-6 and SPRY2 in cancer
4.1. MIG-6 as a tumor suppressor gene
Human  chromosome  1p36,  a  locus  frequently  associated  with  many  human  cancers
[87-92],  harbors the MIG-6  gene. In fact,  loss or reduction of MIG-6  expression has been
observed  in  non-small  cell  lung  cancer  (NSCLC)  [35,  93-95],  breast  carcinoma  [30,  96],
melanoma and skin cancer [30, 94], ovarian carcinoma [30], pancreatic cancer [30], endo‐
metrial cancer [34], thyroid cancer [97, 98], hepatocellular carcinoma [28], and glioblasto‐
ma [91]. Prognostically, low MIG-6  expression is often associated with poor prognosis or
poor patient survival [93, 96, 97].
Unlike many other tumor suppressor genes whose expression is directly regulated by epige‐
netic modification of their promoter regulatory elements [3], the silencing of MIG-6 expres‐
sion seems otherwise [94]. Although high in CpG contents, the MIG-6 promoter appears
hypomethylated and is not directly affected by either the DNA methyltransferase inhibitor
5-aza-2’-deoxycytidine [5-aza-dC) or the histone deacetylase inhibitor trichostatin A (TSA),
indicating indirect regulation [94]. Interestingly, MIG-6 expression seems to be differently
induced by 5-aza-dC and TSA in different cancer types: it is induced by 5-aza-dC in melano‐
ma but not in NSCLC and neuroblastoma, and by TSA in NSCLC and neuroblastoma but
not in melanoma, suggesting a possible tissue-specific transcriptional regulation for this
gene [90, 94, 96]. However in some papillary thyroid cancer, it is reported that the MIG-6
promoter is hypermethylated as determined by methylation-specific PCR [98]. It is unclear
at this point what cause such differences.
Besides loss or reduction of expression, MIG-6 can also be inactivated by genetic mutation,
even though this occurs rarely [35, 90, 96]. To date, two homozygous mutations (Asp109 to
Asn, and Glu83 to a stop codon) in MIG-6 were identified in human lung cancer cell lines,
while heterozygous germline mutations were found in a primary lung cancer (Ala373 to
Val) and a neuroblastoma patient (Asn343 to Ser) [35, 90]. Evidence that MIG-6 is a bona fide
tumor suppressor gene also arises from mouse studies. Mice with targeted disruption of
Mig-6 are prone to neoplastic development ranging from epithelial hyperplasia to carcinoma
at multiple sites including the lung, gallbladder, bile duct, uterus, gastrointestinal tract and
skin [30, 34, 35]. The carcinogen-induced skin cancer seen in Mig-6-deficient mice is likely
mediated by EGFR-ERK/MAPK pathway, because inhibiting EGFR kinase activity with gefi‐
tinib or replacing it with a kinase-defective EGFR rescues the phenotype [30].
4.2. SPRY2 as a tumor suppressor gene
There is compelling evidence supporting SPRY2 as a tumor suppressor [99]. The SPRY2
gene is located on human chromosome 13q31, where loss of heterozygosity (LOH) is ob‐
served in prostate cancer and hepatocellular carcinoma [86, 100]. Down-regulation of SPRY2
expression has been reported in breast cancer [55, 101], hepatocellular carcinoma [86, 102,
103], NSCLC [104], prostate cancer [100, 105, 106], endometrial carcinoma [107], gliomas
[108], and B-cell lymphomas [109, 110]. However in colon cancer, both downregulation and
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upregulation of SPRY2 have been reported [111, 112]. Low (or no) SPRY2 expression is asso‐
ciated with advanced tumor stages and poor survival, and it may be a significant prognostic
factor in breast cancer [101], hepatocellular carcinoma [86, 103], prostate cancer [100, 105],
gliomas [108], and colon cancer [111]. Further, SPRY2 expression is inversely correlated with
the level of miR-21 microRNA expression in gliomas and colon cancer, indicating that
SPRY2 is a target of miR-21[108, 111].
Downregulation of SPRY2 expression may be attributed to DNA methylation; hypermethy‐
lation of its promoter has been observed in prostate cancer [100], hepatocellular carcinoma
[86], endometrial carcinoma [107] and B-cell lymphomas [109, 110]. However, controversial
results have also been reported, since no methylation in SPRY2 promoter was found in other
studies involving different cancer types [55, 102, 106, 111], indicating that other epigenetic
mechanisms might as well be responsible for SPRY2 down-regulation. Thus far, no mutation
has been identified in the SPRY2 gene in any human cancers, and no neoplastic phenotypes
have been observed in any Spry2-deficient mice. This may be due to compensatory roles
played by other family members such as SPRY1 or SPRY4.
5. The impacts of MIG-6 or SPRY2 activity on RTK signaling in cancer
The loss of MIG-6 and SPRY2 feedback regulation leads to prolonged RTK signaling activa‐
tion and may contribute to hallmark activities of cancer [113]. Ectopic expression of MIG-6
results in decreased phosphorylation of EGFR/ErbBs and downstream ERK/MAPK and
AKT, and it inhibits cell proliferation in several cancer types [19, 20, 65, 96, 114]. In contrast,
down-regulation of MIG-6 expression by small interference RNA (siRNA)-mediated knock‐
down leads to prolonged activation of the EGFR or ErbB2 pathway and increases ligand-in‐
duced proliferation, cell cycle progression, and cell migration [28, 30, 65, 96, 114]. Likewise,
MIG-6 overexpression inhibits HGF-induced cell migration and proliferation, whereas
MIG-6 knockdown by siRNA enhances those activities [14]. Intriguingly, it has been shown
that in thyroid cancer, MIG-6 overexpression suppresses MET phosphorylation along with
the inhibition of EGFR, ErbB2, and SRC, while its knockdown does the opposite and enhan‐
ces cell proliferation and invasion [98]. However, it is unclear how MIG-6 affects MET tyro‐
sine phosphorylation given that no physical interaction between the two is observed [14].
The activity of MIG-6 on apoptosis is unsettled: one group showed that MIG-6 inhibits
apoptosis of breast cancer cells [115], while another showed that it promotes the death of
cardiomyocytes [25]. This discrepancy might be due to the differences in cellular states (can‐
cer cells versus normal cells) or in tissue types (breast versus cardiac).
Nonetheless, a study of NCI-60 cell lines, which cover a broad spectrum of cancer types, re‐
vealed that MIG-6 expression correlated with EGFR expression, indicating an intrinsic activ‐
ity for MIG-6 in regulating EGFR signaling [116]. MIG-6 expression has been shown to have
a significant effect on ErbB-targeted cancer therapy [96, 116, 117]. MIG-6 synergizes with the
EGFR inhibitor gefitinib to suppress the growth of NSCLC cells carrying gefitinib-sensitive
EGFR mutations [116, 117]. Further, the loss of MIG-6 expression renders ErbB2-amplified
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breast cancer cells more resistant to Herceptin (trastuzumab), a neutralizing antibody
against ErbB2/HER2 [96]. It will be interesting to see the influence of MIG-6 expression on
cancer therapies targeting other RTKs such as MET as well.
SPRY2  overexpression inhibits MET-mediated ERK and AKT activation in leiomyosarco‐
ma and hepatocellular carcinoma cells, and it suppresses cell proliferation, migration and
invasion induced by HGF [72, 86, 102].  In NSCLC, SPRY2 suppresses ERK but not AKT
activation, and it inhibits the migration of the cells expressing wild-type but not constitu‐
tively  activated  K-RAS;  however,  proliferation  and  tumorigenesis  of  cells  with  either
wild-type or mutant K-RAS can be inhibited by SPRY2  overexpression [104].  SPRY2 has
different effects on wild-type and V599E mutant B-RAF in melanoma cells: its downregu‐
lation enhances ERK phosphorylation only in melanoma cells carrying wild-type B-RAF,
likely  because  of  its  ability  to  interact  with  wild-type,  but  not  mutant,  B-RAF  [118].
Overexpression of SPRY2  suppresses ERK activation in osteosarcoma and B-cell lympho‐
ma, and it  inhibits tumor growth and metastasis in vivo  [109, 119],  while suppression of
SPRY2 activity by its dominant negative mutant SPRY2Y55F enhances the proliferation and
tumorigenesis  of  breast  cancer  cells  [55].  Surprisingly,  SPRY2 has  also  been reported to
enhance cell  proliferation and HGF-induced ERK and AKT activation, migration and in‐
vasion of  colon cancer  cells  [112],  quite  opposite  to  another  report  showing that  in  the
same cell  line,  SPRY2 negatively  regulates  ERK and AKT phosphorylation  and inhibits
proliferation,  migration and tumorigenesis  [111].  The discrepancy is  quite  puzzling,  and
it  is  unclear whether it  is  due to differences in the experimental  approaches or to other
factors such as clonal effects originating from tumor cell heterogeneity. Using an induci‐
ble system in the same cell line might be able to solve the puzzle of whether the effects
in those two reports were truly the results of SPRY2 overexpression.
There is limited evidence that SPRY2 expression, like that of MIG-6, influences ErbB-target‐
ed therapy in human cancers [101, 120]. Breast cancer patients with low SPRY2 expression
show poorer response to trastuzumab treatment, and have a significant lower survival rate
relative to those with high SPRY2 expression [101]. Low SPRY2 expression is usually associ‐
ated with high ErbB2/HER2 in breast cancer, while reconstituting SPRY2 may enhance the
sensitivity of breast cancer cells in vitro to trastuzumab treatment [101]. In colon cancer cells,
low SPRY2 expression is associated with less sensitivity to gefitinib, whereas its ectopic
overexpression can enhance gefitinib responsiveness [120].
6. Conclusion and perspective
The negative feedback loops to receptor tyrosine kinases of MIG-6 and of SPRY2 provide
crucial  intersecting  points  for  tumor  suppressor  genes  and  oncogenes,  placing  them  in
the same signaling networks  for  regulating physiologic  and oncogenic  activity.  This  so‐
phisticated  regulatory  mechanism  allows  timely  attenuation  of  RTK  signaling  by  those
TSGs, and ensures a proper cellular response following growth factor stimulation. MIG-6
and SPRY2 are no more than the representatives for the class of TSGs involved in RTK
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signaling regulation, and we believe there are more such TSGs in the human genome ei‐
ther remain to be discovered or have already been revealed (such as other SPRY family
members).  To date,  most of  the studies on MIG-6 and SPRY2 have focused on their  ac‐
tivity in regulating selected RTKs such as EGFR, MET and FGFR. Their roles in regulat‐
ing  most  other  RTKs  and  the  clinical  relevance  of  such  regulation  remain  largely
unknown. Also, there are conflicting results on how MIG-6 and SPRY2 may regulate the
RTK  signaling,  on  both  the  receptor  and  the  downstream  signaling  levels,  and  further
studies are required to address those issues.  Although EGFR and other  RTKs like MET
appear to be regulated slightly differently by MIG-6 and SPRY2, it  remains to be deter‐
mined to what extent these TSGs may provide signaling specificity to different RTKs. Be‐
yond all aforementioned issues, a broader question might be why an RTK network needs
multiple  negative  feedback  regulators  to  fine-tune  its  signaling;  might  the  regulators
function differently for each RTK in a temporal and spatial manner i.e. at right place, on
right time and for right target?
While conventional mechanisms such as mutation or promoter methylation may contribute
to the inactivation of MIG-6 or SPRY2 tumor suppressor roles, their activities are also likely
silenced by unconventional means in cancer. For example, in most cancer types investigated
so far, MIG-6 expression is not down-regulated by direct methylation or histone deacetyla‐
tion in its promoter, but rather by an indirect mechanism involving other unidentified tran‐
scriptional factor(s) or transcriptional co-regulator(s). It is also striking to see that different
promoter methylation status in MIG-6 or SPRY2 gene is observed in different cancer types:
methylated in some cancers, but unmethylated in others. The cause of such difference is a
curiosity, but if only for TSG down-modulation, genome instability in the cancer cell envi‐
ronment could provide many mechanisms.
Clinically, it is important to understand how tumor suppressor genes may affect the thera‐
peutic outcome of RTK-targeted therapies, which can be effective in treating certain human
cancers. In a limited number of studies, low expression of MIG-6 or SPRY2 is associated
with poorer patient responses to ErbB-targeted therapies (i.e., the EGFR inhibitor gefitinib
and the ErbB2/HER2 inhibitor Herceptin). The question is, can MIG-6 or SPRY2 expression
be used in conjunction with RTK status to select patients for RTK-targeted “personalized”
cancer therapy? The approach sounds plausible, given that those TSGs negatively regulate
the RTK signaling activities, but extensive studies will certainly be required before imple‐
menting such measures.
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